WO2025240536A1 - Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway - Google Patents

Abstract

The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) and/or Cyclin-dependent kinase 4 (CDK4) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2 and/or CDK4. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Description

BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 AND/OR CYCLIN-DEPENDENT KINASE 4 VIA UBIQUITIN PROTEASOME PATHWAY

Cross-reference to Related Applications

This international application claims the benefit of U.S. Provisional Application No. 63/648,144, filed on May 15, 2024; the entire contents of which are incorporated by reference.

Field of the Disclosure

The present disclosure provides certain bifunctional compounds containing 2, 5 -substituted pyrimidine derivatives that cause degradation of Cyclin-dependent kinase 2 (CDK2) and/or Cyclin-dependent kinase 4 (CDK4) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2 and/or CDK4. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Background

Cyclin-dependent kinases (CDKs) are essential cellular serine/threonine kinases that play an important role in orchestrating signaling events, such as DNA replication and protein synthesis, to ensure faithful eukaryotic cell division and proliferation. The regulation of CDK activity is tightly controlled by the fluctuating levels of various cyclins, which form heterodimeric complexes with CDKs to activate them. Out of the 21 identified CDKs, CDKl/Cyclin B, CDK2/Cyclin E, CDK2/Cyclin A, CDK4/Cyclin D, CDK6/Cyclin D complexes are well known to be vital regulators of cell cycle progression. Other CDKs are involved in regulating gene transcription, DNA repair, differentiation, and apoptosis (see Morgan, D. O. Annu. Rev. Cell. Dev. Biol. (1997) 13: 261-291).

In the canonical model of cell cycle, mitogenic signaling upregulat.es D-type cyclins, which directly bind and activate CDK4/6. Active CDK4/6-cyclin D complexes partially phosphorylate Rb, disrupting the Rb/E2F interaction and de-repressing E2F activity, leading to upregulation of cyclin E, a CDK2 activator. Cdk2-cyclin E further hyper-phosphorylates Rb, releasing E2F to transcribe genes required for S-phase entry. During S-phase, cyclin E is degraded and CDK2 forms a complex with cyclin A to promote phosphorylation of substrates essential for DNA replication and inactivation of E2F, completing S-phase (Asghar et al. Nat. Rev. Drug. Discov. (2015) 14: 130-146). CDK 1 -Cyclin A and CDK 1 -Cyclin B complexes are activated in late S and G2 phases to drive the transition into and completion of mitosis, respectively (Katsuno et al., 2009; Lindqvist et al., 2009; Lohka et al., 1988).

Due to their crucial roles in regulating cell cycle and other essential cellular processes, increased activity or temporally abnormal activation of CDKs has been shown to promote tumorigenesis and disease progression (Cordon-Cardo C. Am. J. Pathol. (1995) 147:545-560; Karp JE, Broder S. Nat. Med. (1995) 1 :309-320; Hall M, Peters G. Adv. Cancer Res. (1996) 68:67-108). Genetic changes in CDK-cyclin complexes and the proteins that regulate them are widespread in various cancers and are often associated with poor clinical outcomes. Common alterations include amplifications/overexpression of cyclin D, cyclin E, CDK4 and CDK6; loss of Rb; deficiency in CDK inhibitory regulators such as pl 6, p21, p27, and loss-of-function mutations in FBXW7, a component of SCF^Fbw7ubiquitin E3 ligase responsible for cyclin E degradation. (Smalley et al. Cancer Res. (2008) 68: 5743-52).

Over the last two decades, there has been significant interest in developing CDK inhibitors for therapeutic purposes. In combination with endocrine therapies, selective reversible inhibitors of CDK4 and CDK6 e.g., palbociclib, riboci clib, and abemaciclib have revolutionized the therapeutic management for hormone receptor-positive (HR+) metastatic breast cancer (MBC). Ongoing clinical trials are also investigating these CDK4/6 inhibitors as single agents or in combination with other therapeutics for various cancers. (O'Leary et al. Nature Reviews (2016) 13:417-430).

Despite their significant clinical efficacy in ER-positive metastatic breast cancer, CDK4/6 inhibitors have some limitations. One major drawback is the development of primary or acquired resistance over time. An important mechanism of resistance involves the abnormal activation of CDK2. This can occur due to an overactivated CDK2/Cyclin E complex caused by elevated Cyclin E expression (Asghar, U. et al. Clin. Cancer Res. (2017) 23:5561) or formation of the noncanonical CDK2/cyclin DI complex in response to CDK4/6 inhibition (Herrera- Abreu MT et al, Cancer Res. (2006) 15: 2301), which bypasses the need for CDK4/6 for cell cycle reentry. Additionally, CDK4/6 inhibitors palbociclib and ribociclib exhibit relatively high hematological toxicity, primarily neutropenia. CDK6 is highly expressed in the blood system and plays a role in regulating the growth of hematopoietic cells. Therefore, it is generally believed that the inhibition of CDK6 leads to neutropenia, while breast cancer cells mainly depend on CDK4 for proliferation. Abemaciclib exhibits weaker inhibition of CDK6 than CDK4, resulting in lower hematological toxicity.

Currently, multiple CDK2 inhibitors are under clinical development in solid tumors, including PF-07104091 (NCT04553133), BLU-222 (NCT05252416), INCB123667 (NCT05238922), INX-315 (NCT05735080), ARTS-021 (NCT05867251), AZD8421

(NCT06188520) and BG-68501 (NCT06257264). Thus far, PF-07104091 and BLU-222 have demonstrated single agent activities in CDK4/6 inhibitor refractory breast cancer patients. In addition, a CDK4 specific inhibitor PF-07220060 (NCT04557449), in combination with endocrine therapy, has demonstrated clinical responses and lower neutropenia adverse events in CDK4/6 inhibitor refractory breast cancer patients. Thus, a molecule blocking both CDK2 and CDK4 as single agent or in combination with endocrine therapy, may address the primary and acquired resistance to CDK4/6 inhibitors, leading to enhanced antitumor activities and reduced adverse effects to achieve greater therapeutic efficacy in HR+ HER2- breast cancer.

Considering these factors, developing a small molecule inhibitor or a proteolysis-targeting chimeric molecule (PROTAC) that specifically targets CDK4 and/or CDK2 could represent a therapeutic opportunity with reduced toxicity and improved overall therapeutic efficacy.

PROTACs are bifunctional molecules comprised of target protein-recruitment moiety and a ligand for E3 ligase, connected by a biocompatible linker. PROTACs bring the protein of interest and the E3 ligase into close proximity and induce ubiquitination and subsequent degradation of the target protein by proteasome.

Compared to small molecule drugs that typically bind disease-relevant proteins and inhibit their function, PROTACs display several unique and attractive features that make them desirable drug candidates. For example, PROTACs have been shown to be more selective than their inhibitor counterparts, potentially reducing off-target toxicity. Moreover, PROTACs can perform multiple rounds of target ubiquitination and degradation. Due to this catalytic mode of action, PROTACs can function at sub-stoichiometric receptor occupancies. The E3 ligases used in PROTACs mainly include cereblon (CRBN), Von Hippel-Lindau-containing complex (VHL), inhibitor of apoptosis protein (LAP), and mouse double minute 2 (MDM2).

Therefore, PROTACs that could recruit CDK2 and/or CDK4 to a ubiquitin ligase, and thereby causing ubiquitylation and proteasomal degradation of CDK2 and/or CDK4 are desirable. The present disclosure fulfills this and related needs. Summary

In a first aspect, provided is a compound of Formula (I): wherein:

R¹ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyloxy (wherein cycloalkyl, either alone or as part of cycloalkoxy, is substituted with one to three halo), halo, haloalkyl, haloalkoxy, alkoxy, aryloxy, or cyano;

R² and R^2a are independently hydrogen or deuterium;

Hy is cycloalkylene, arylene, heteroarylene, heterocyclylene, bicyclic heterocyclylene, spiro heterocyclylene, bridged heterocyclylene, or fused heterocyclylene, where each of the aforementioned rings is substituted with R^a, R^b, and R^c independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano;

Degron is an E3 ubiquitin ligase ligand selected from:

(a) a group of formula (i):

(b) a group of formula (ii):

(ii);

Y^a is CH or N;

Z^a is a bond, -CH2-, -NH-, -O-, or -NHC(O)- where NH of -NHC(O)- is attached to Y^a; ring A is a group of formula (a) or (b): where:

R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano;

R⁴ and R⁵ are independently hydrogen or alkyl; or R⁴ and R⁵ together with the carbon to which they are attached form >C=O;

M is -O- or -NR⁶-; and

R⁶ is hydrogen or alkyl; ring B is phenylene, cyclylaminylene, a 5- or 6-membered monocyclic heteroarylene, or a 9- or 10-membered fused bicyclic heteroarylene, wherein in each heteroarylene one to three ring atoms are heteroatoms independently selected from nitrogen, oxygen, and sulfur and further wherein the phenylene, cyclylaminylene, and each heteroarylene are independently substituted with R^ee and R^ff independently selected from hydrogen, alkyl, cycloalkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano; and

Z is -O-, -NR³- (where R³ is hydrogen or alkyl), cycloalkylene, phenylene, monocyclic heteroarylene, unsaturated heterocyclylene, heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene and where each of the aforementioned rings is substituted with R^d and R^e independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano; alk is C3 to Ce alkenylene substituted with R^f selected from hydrogen, fluoro, and cyano; C3 to Ce alkylene or C3 to Ce heteroalkylene (wherein the C3 to Ce alkylene and C3 to Ce heteroalkylene are substituted with R^g, R^h, and R¹ where R^g is hydrogen, deuterium or halo, R^h is hydrogen, deuterium, cycloalkyl, cycloalkyloxy, bridged cycloalkyl, halo, haloalkoxy, alkoxy, hydroxy, cyano, cyanoalkyl, cyanoalkyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, phenyl, heteroaryl, heterocyclyl, heterocyclyloxy, heterocyclylcarbonyl, or bridged heterocyclyl (where cycloalkyl, either by itself or as part of cycloalkyloxy, bridged cycloalkyl, phenyl, heteroaryl, heterocyclyl, either by itself or as part of heterocyclyloxy or heterocyclylcarbonyl, and bridged heterocyclyl are substituted with R⁷ and R⁸ independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, alkyl carbonyl, alkyloxycarbonyl, amino, alkylamino, dialkylamino, and cyano) and R¹ is hydrogen or halo; or when R^h and R¹ are attached to the same carbon atom or to adjacent carbon atoms of the linear portion of the C3 to Ce alkylene or C3 to Ce heteroalkylene, R^h and R¹ together with the carbon atom(s) to which they are attached can form cycloalkylene or heterocyclylene (where the cycloalkylene and heterocyclylene formed by R^h and R¹ are substituted with R⁹ and R¹⁰ independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, alkyl carbonyl, alkyloxycarbonyl, amino, alkylamino, dialkylamino, and cyano)); or C3 to Ce alkynylene substituted with R¹ and R^k independently selected from hydrogen, halo, haloalkyl, alkoxy, hydroxy, and cyano; or when R> and R^k are attached to the same carbon atom of the alkynylene, they can combine with the carbon atom to which they are attached to form cycloalkylene or heterocyclylene wherein the cycloalkylene and heterocyclylene are substituted with R¹¹ and R¹² independently selected from hydrogen, alkyl, and halo; and the linear portion of C3 to Ce alkenylene, C3 to Ce alkylene, C3 to Ce heteroalkylene, and C3 to Ce alkynylene attaching -SO2- and Z, contains at least three atoms; or a pharmaceutically acceptable salt thereof.

In a second aspect, provided is a pharmaceutical composition comprising a compound of Formula (I) of the first aspect (or any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

In a third aspect, provided is a method of treating a disease mediated by CDK2 and/or CDK4 in a patient, (in one embodiment the patient is in need of such treatment), which method comprises administering to the patient a therapeutically effective amount of a compound of Formula (I) of the first aspect (and any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition thereof disclosed in the second aspect (or any embodiments thereof described herein). In a first embodiment of the third aspect, the disease is cancer. In a second embodiment of the third aspect the disease is cancer selected from lung cancer (e.g., adenocarcinoma, small cell lung cancer, non-small cell lung carcinomas, parvicellular and non-parvicellular carcinoma, bronchial carcinoma, bronchial adenoma, and/or pleuropulmonary blastoma), skin cancer (e.g., melanoma, squamous cell carcinoma, Kaposi sarcoma, and/or Merkel cell skin cancer), bladder cancer, breast cancer, cervical cancer, colorectal cancer, cancer of the small intestine, colon cancer, rectal cancer, cancer of the anus, endometrial cancer, gastric cancer, head and neck cancer (e.g., cancers of the larynx, hypopharynx, nasopharynx, oropharynx, lips, and/or mouth), liver cancer (e.g., hepatocellular carcinoma and/or cholangiocellular carcinoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, esophageal cancer, gall bladder cancer, pancreatic cancer (e.g., exocrine pancreatic carcinoma), stomach cancer, thyroid cancer, parathyroid cancer, bone cancer, biliary tract cancer, vaginal cancer, astrocytoma, liposarcomas, glioblastoma, neuroblastoma and/or kidney cancer. In a third embodiment of the third aspect, the cancers are those that are resistant to CDK4/6 inhibitors through CDK2-mediated mechanisms e.g., breast cancer. In a fourth embodiment of the third aspect, the disease is an autoimmune disease or a condition associated with an autoimmune disease. In some embodiments of the third aspect, the autoimmune disease or condition associated with an autoimmune disease is selected from rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary Sjogren’s syndrome (pSS), multiple sclerosis (MS), Crohn’s disease (CD), uveitis, pemphigus vulgaris, and sepsis. In a fifth embodiment of the third aspect, the disease is gout.

In a fourth aspect, provided is a method of treating noise-induced, chemotherapy-induced (cisplatin-induced), antibiotic-induced, or age-related hearing loss, which method comprises administering to a patient, (in one embodiment a patient in need of such treatment), a therapeutically effective amount of a compound of Formula (I) of the first aspect (and any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition thereof as disclosed in the second aspect (or any embodiments thereof described herein). In some embodiments of the fourth aspect, the amount of hearing loss is reduced when compared to an age-matched control. In some embodiments of the fourth aspect, the hearing loss is prevented when compared to an age-matched control.

In a fifth aspect, provided is a compound of Formula (I) of the first aspect (or any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the second aspect (or any embodiments thereof described herein) for use in therapy. In one embodiment of the fifth aspect, the compound of Formula (I) of the first aspect (or any embodiments thereof disclosed herein), or a pharmaceutically acceptable salt thereof is for use in the treatment of one or more of diseases disclosed in the third and fourth aspects above.

In a sixth aspect, provided is the use of a compound of Formula (I) of the first aspect (and any of the embodiments thereof described herein), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease in a patient in which the activity of CDK2 and/or CDK4 contributes to the pathology and/or symptoms of the disease. In one embodiment of the sixth aspect, the disease is one or more diseases disclosed in the third and fourth aspects above.

In a seventh aspect, provided is a method of degrading CDK2 and/or CDK4 in a cell via ubiquitin proteasome pathway which method comprises contacting the cell with a compound of Formula (I) of the first aspect (or embodiments thereof as disclosed herein). In one embodiment of the seventh aspect, the CDK2 and/or CDK4 are degraded in vitro. In another embodiment of the seventh aspect, the CDK2 and/or CDK4 are degraded in vivo. In yet another embodiment of the seventh aspect, the CDK2 and/or CDK4 are degraded in a cell of a patient.

In an embodiment of any one of above aspects, CDK2 is selectively degraded over CDK1. In another embodiment of any one of above aspects, CDK2 is selectively degraded over CDK1 and CDK4 or CDK4 is selectively degraded over CDK1 and CDK2. In some embodiments, both CDK2 and CDK4 are degraded by a compound of Formula (I), including CDK2 and CDK4 are selectively degraded over CDK1.

The ability of compounds of Formula (I) to degrade CDK2 and CDK4 selectively over CDK1 was measured by determining potency of the compounds in inhibiting retinoblastoma protein (Rb) phosphorylation in 0VCAR3 (CDK2 dependent cell line), T47D (CDK4 dependent cell line) and KYSE520 (CDK1 dependent cell line) as described in Biological Example 1 below, and then determining the ratio of Rb IC50 from 0VCAR3 and KYSE520 and T47D and KYSE520, respectively. Additionally, although the compounds of Formula (I) degrade both CDK2 and CDK4, they can, however, cause degradation of CDK2 to a greater extent than CDK4 or visa-versa. The degree of degradation of CDK2 and CDK4 can be determined by determining the ratio of phosphorylation of Rb IC50 from 0VCAR3 and T47D.

In the aforementioned aspects involving the treatment of cancer, further embodiments are provided comprising administering the compound of Formula (I) of the first aspect (and embodiments thereof as disclosed herein), or a pharmaceutically acceptable salt thereof (or any embodiments thereof disclosed herein) or the pharmaceutical composition of the second aspect, in combination with at least one additional anticancer agent. When combination therapy is used, the agents can be administered simultaneously or sequentially.

Detailed Description

Definitions:

Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this Application and have the following meaning:

“Alkyl” means a linear or branched saturated monovalent hydrocarbon radical of one to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, butyl, pentyl, and the like.

“Alkenyl” means a linear or branched monovalent hydrocarbon radical of two to six carbon atoms containing a double bond e.g., ethenyl, propenyl, 2-propenyl, butenyl, pentenyl, and the like. “Alkynyl” means a linear or branched monovalent hydrocarbon radical of two to six carbon atoms containing a triple bond e.g., ethynyl, propynyl, 2-propynyl, butynyl, and the like.

“Alkylene” means a linear or branched saturated divalent hydrocarbon radical of one to six carbon atoms unless otherwise stated. When alkylene contains three to six carbon atoms it is also referred to herein as C3 to C6 alkylene. Examples include, but are not limited to, methylene, ethylene, propylene, 1 -methylpropylene, 2-methylpropylene, butylene, pentylene, and the like.

“Alkenylene” means a linear or branched unsaturated divalent hydrocarbon radical of two to six carbon atoms containing a double bond. When alkenylene contains three to six carbon atoms it is also referred to herein as C3 to C6 alkenylene. Examples include, but are not limited to, ethen-diyl, propen-diyl, 2-propen-diyl, buten-diyl, penten-diyl, and the like.

“Alkynylene” means a linear or branched divalent unsaturated hydrocarbon radical of two to six carbon atoms containing a triple bond. When alkynylene contains three to six carbon atoms it is also referred to herein as C3 to C6 alkynylene. Examples include, but are not limited to, the like.

“Alkoxy” means a -OR^P radical where R^p is alkyl as defined above, e.g., methoxy, ethoxy, propoxy, or 2-propoxy, n-, iso-, or /c/V-butoxy, and the like.

“Alkoxycarbonyl” or “alkyloxycarbonyl” means a -C(O)OR^P radical where R^p is alkyl as defined above, e.g., methoxy carbonyl, ethoxy carbonyl, and the like.

“Alkylcarbonyl” means a -C(O)R^P radical where R^p is as defined herein, e.g., methylcarbonyl, ethylcarbonyland the like.

“Amino” means -NH2.

“Aminocarbonyl” means -C(0)NH2.

“Alkylaminocarbonyl” means -C(O)NHR^P radical where R^p is alkyl as defined above e.g., methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, and the like.

“Alkylcarbonylamino” means -NHC(O)R^P radical where R^p is alkyl as defined above e.g., methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, and the like.

“Alkyl sulfonyl” means -S(O)2R^P radical where R^p is alkyl as defined above e.g., methylsulfonyl, ethylsulfonyl, and the like.

“Dialkylaminocarbonyl” means -C(O)NR^plR^p radical where R^p and R^pl are independently alkyl as defined above e.g., dimethylaminocarbonyl, diethylaminocarbonyl, dipropylaminocarbonyl, and the like.

“Alkylamino” means -NHR^P radical where R^p is alkyl as defined above e.g., methylamino, ethylamino, propylamino, and the like. “Aryl” means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical of 6 to 10 ring atoms e.g., phenyl or naphthyl.

“Arylene” means a divalent aryl (as defined above) radical e.g., phenylene or naphthylene.

“Aryloxy” means a -O-R^E radical where R^p is aryl as defined above e.g., phenyloxy (or phenoxy), or naphthyl oxy.

“Bicyclic heterocyclylene” means a saturated divalent fused bicyclic group of 8 to 12 ring atoms in which one, two, or three ring atoms are heteroatoms independently selected from N, O, and S(O)_n, where n is an integer selected from 0 to 2, the remaining ring atoms being carbon, unless stated otherwise. Additionally, one or two ring carbon atoms of the bicyclic heterocyclylene ring can optionally be replaced by a -CO- group. More specifically the term bicyclic heterocyclylene includes, but is not limited to, isoindolin-diyl, decahydro-2, 6- naphthyridin-diyl, octahydrocyclopenta[c]pyrrol-diyl, octahydro-lH-pyrrolo[3,4-c]pyridin-diyl, hexahydrofuro[3,2-b]furan-3,6-diyl, and the like.

“Bridged cycloalkyl” means a saturated monovalent bicyclic ring having 5 to 8 ring carbon ring atoms in which two non-adjacent ring atoms are linked by a (CR^pR^p’)_n group where n is an integer selected from 1 to 3 and R^p and R^p’ are independently H or methyl (also may be referred to herein as “bridging” group). Examples include, but are not limited to, bicyclo[l. l.l]pent-l-yl, bicyclo[2.2.1]heptyl, (in one subembodiment bicy clo[2.2. l]hept-2-yl), and the like.

“Bridged heterocyclyl” means a saturated monovalent bicyclic ring having 5 to 9 ring carbon ring atoms in which two non-adjacent ring atoms are linked by a (CR^pR^p’)_n group where n is an integer selected from 1 to 3 and R^p and R^p’ are independently H or methyl (also may be referred to herein as “bridging” group) and further wherein one or two ring carbon atoms, including an atom in the bridging group, is replaced by a heteroatom selected from N, NH, O, and S(O)_n, where n is an integer selected from 0 to 2. Bridged heterocyclyl is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano unless stated otherwise. Examples include, but are not limited to, 3,8-diazabicyclo[3.2.1]octanyl,

7-oxabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo-[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.2]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 6-azabicyclo[3.1.1]heptanyl,

8-azabicyclo[3.2.1]octanyl, and the like.

“Bridged heterocyclylene” means a saturated divalent bicyclic ring having 5 to 9 ring carbon ring atoms in which two non-adjacent ring atoms are linked by a (CR^pR^p’)_n group where n is an integer selected from 1 to 3 and R^p and R^p’ are independently H or methyl (also may be referred to herein as “bridging” group) and further wherein one or two ring carbon atoms, including an atom in the bridging group, is replaced by a heteroatom selected from N, NH, O, and S(O)_n, where n is an integer selected from 0 to 2. Bridged heterocyclylene is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano unless stated otherwise. Examples include, but are not limited to, 3,8-diazabicyclo[3.2.1]octa-3,8- diyl, 7-oxabicyclo[2.2.1]heptan-diyl, 2,5-diazabicyclo[2.2.1]heptan-diyl, 3,6-diazabicyclo- [3.1.1]heptan-diyl, 2,5-diazabicyclo[2.2.2]octan-diyl, 3,8-diazabicyclo[3.2.1]octan-diyl, 6-azabicyclo[3.1.1]heptan-diyl, 8-azabicyclo[3.2.1]octan-diyl, and the like.

“Cycloalkyl” means a monocyclic saturated monovalent hydrocarbon radical of three to ten carbon atoms. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

“Cycloalkyloxy” and “cycloalkoxy” mean an -OR^P radical where R^p is cycloalkyl as defined above. Examples include, but are not limited to, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.

“Cycloalkylene” means a divalent monocyclic saturated hydrocarbon radical of three to six carbon atoms, unless stated otherwise e.g., 1,1 -cyclopropylene, 1,1 -cyclobutylene, 1,4- cyclohexylene, 1,2-cyclobutylene, and the like.

“Carbonyl” means -C(O)-.

“Carboxy” means -COOH.

“Cyclylaminylene” means a saturated divalent monocyclic ring of 4 to 8 ring atoms in which one or two ring atoms are nitrogen, the remaining ring atoms being carbon. More specifically, the term cyclylaminylene includes, but is not limited to, pyrrolidinylene, piperidinylene, homopiperidinylene, piperazinylene, and the like.

“Cyanoalkyl” means alkyl as defined above that is substituted with a cyano e.g., cyanomethyl, cyanoethyl, and the like.

“Cyanoalkyloxy” means an -OR^P radical where R^p is cyanoalkyl as defined above, e.g., cyanomethyloxy, cyanoethyloxy, and the like.

“Deuterium” means refers to ²H or D.

“Dialkylamino” means a -NR^PR^P radical where each R^p is alkyl as defined above and are independently selected, e.g., dimethylamino, methylethylamino, n-propylmethylamino, 2-propylmethylamino, n-, iso-, or /c/V-butylmethylamino, and the like.

“Fused heterocyclylene” means a divalent bicyclic ring in which two adjacent ring atoms of a saturated monocyclic ring of 4 to 7 ring atoms having one or two heteroatoms independently selected from N, NH, O, and S(O)n (where n is 0, 1, or 2) and the remaining ring atoms being carbon, are fused to two adjacent ring members of a phenyl, or a five or six membered heteroaryl, each as defined herein, unless stated otherwise. The nitrogen atom is optionally oxidized and further wherein one of the carbon ring atoms of the saturated monocyclic ring is optionally replaced by a -C(=O)- group. The fused heterocyclylene can be attached at any two atoms of the ring. Representative examples include, but are not limited to, l,2,3,4-tetrahydroquinolin-l,4-diyl, 3,4-dihydro-2H-benzo[b][l,4]oxazin-5,8-diyl, 3,4-dihydro-2H-pyrido[3,2-b][l,4]oxazin-diyl, 4,5,6,7-tetrahydropyrazolo[l,5-a]pyrazin-diyl, and the like.

“Halo” means fluoro, chloro, bromo, or iodo, in one embodiment, fluoro or chloro.

“Haloalkyl” means alkyl radical as defined above, which is substituted with one or more halogen atoms, e.g., one to five halogen atoms, such as fluorine or chlorine, including those substituted with different halogens, e.g., -CH2CI, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH₃)₂, and the like. When the alkyl is substituted with only fluoro, it can be referred to in this Application as fluoroalkyl.

“Haloalkoxy” means an -OR^P radical where R^p is haloalkyl as defined above e.g., -OCF3, -OCHF2, and the like. When R^p is haloalkyl where the alkyl is substituted with only fluoro (in some examples, one or more fluoro), it is referred to in this Application as fluoroalkoxy.

“Heteroaryl” means a monovalent monocyclic or fused bicyclic aromatic radical of 5 to 10 ring atoms where one or more, (in one embodiment, one, two, or three), ring atoms are heteroatom selected from N, NH, O, and S, the remaining ring atoms being carbon, unless otherwise stated. Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, indazolyl, imidazo[l,2-a]pyridinyl, imidazo[l,2-a]pyrazinyl, oxazolyl, isoxazolyl, oxadiazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, and the like. As defined herein, the terms “heteroaryl” and “aryl” are mutually exclusive. When the heteroaryl ring contains 5- or 6 ring atoms and is a monocyclic ring, it is also referred to herein as 5- or 6- membered monocyclic heteroaryl. When the heteroaryl ring contains 9- or 10-ring atoms, it is also referred to herein as 9- or 10-membered fused bicyclic heteroaryl.

“Heteroarylene” means a divalent heteroaryl radical as defined above, unless stated otherwise. Representative examples include, but are not limited to, benzimidazoldiyl e.g., benzimidazole-l,5-diyl, and the like. When the heteroarylene ring contains 5- or 6 ring atoms and is a monocyclic ring, it is also referred to herein as monocyclic heteroarylene or as 5-or 6-membered monocyclic heteroarylene e.g., pyrazolyl-diyl (pyrazolyl-1.3-diyl, pyrazolyl-1.4- diyl, pyrazolyl-1.5-diyl and the like) and imidazol-diyl (imidazol-l,2-diyl, imidazol-l,4-diyl, imidazol-l,5-diyl). When the heteroarylene ring contains 9- or 10 ring atoms and is a fused bicyclic ring, it is also referred to herein as 9-or 10-membered fused bicyclic heteroarylene. “Heterocyclyl” means a saturated, monovalent, monocyclic group of 4 to 8 ring atoms in which one or two ring atoms are heteroatom independently selected from N, NH, O, and S(O)_n, where n is an integer selected from 0 to 2, the remaining ring atoms being C, unless stated otherwise. Additionally, one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a -C(=O)- group. More specifically, the term heterocyclyl includes, but is not limited to, oxetanyl, piperidinyl, piperazinyl, pyrrolidinyl, azetidinyl, and the like.

“Heterocyclylcarbonyl” means a -C(O)R group where R is heterocyclyl as defined herein. More specifically, the term heterocyclyl includes, but is not limited to, piperidinylcarbonyl, piperazinylcarbonyl, pyrrolidinylcarbonyl, azetidinyl carbonyl, and the like.

“Heterocyclyloxy” means an -OR group where R is heterocyclyl as defined herein. More specifically, the term heterocyclyl includes, but is not limited to, piperidinyloxy, piperazinyloxy, pyrrolidinyloxy, azetidinyloxy, and the like.

“Heterocyclylene” means a saturated, divalent, monocyclic group of 4 to 8 ring atoms in which one or two ring atoms are heteroatom independently selected from N, NH, O, and S(O)_n, where n is an integer selected from 0 to 2, the remaining ring atoms being C, unless stated otherwise. Additionally, one or two ring carbon atoms in the heterocyclylene ring can optionally be replaced by a -C(=O)- group. More specifically, the term heterocyclylene includes, but is not limited to, , piperidin-l,4-diyl, azeti din- 1,3 -diyl, and the like.

“C3 to Ce heteroalkylene” means is a linear or branched saturated divalent hydrocarbon radical of three to six carbon atoms where (a) one carbon atom of the linear portion of the divalent hydrocarbon radical is replaced by X^a where X^a is -O-, -CO-, or -NR^q- or (b) two adjacent carbon atoms of the linear portion of the divalent hydrocarbon radical are replaced by X^al where X^al is -NR^qCO-, -CONR^q-, -NR^qSO-, -SONR^q-, -NR^qSO₂-, or -SO₂NR^q- (where each R^q is hydrogen, alkyl, alkylcarbonyl, or alkylsulfonyl), provided that the linear portion of C3 to Ce heteroalkylene attaching Z and the -SO₂- depicted in the structure of Formula (I) contains at least three atoms. For the sake of clarity, as used in this definition, the linear portion of the C3 to Ce heteroalkylene means the consecutive atoms of the C3 to Ce heteroalkylene connecting Z and the -SO₂- depicted in the structure of Formula (I) e.g., in the structure , the atoms with * form the linear portion of C5 heteroalkylene. When the heteroalkylene contains only -O-, it can be referred to herein as “oxoalkylene.” When the heteroalkylene contains only -NR^q-, it can be referred to herein as “aminylalkylene.” Representative examples, of heteroalkylene include, e.g., -CH2CH2-NH-, -CH₂CH2-N(CH₃)-, -CH2CH2-O-, and the like.

“Phenylene” means divalent phenyl.

The phrase “optionally” or “optional” as used herein means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, the phrase “alkylene optionally substituted with halo” is intended to cover alkylene that is unsubstituted and alkylene that is substituted with halo.

“Spiro heterocyclylene" means a saturated bicyclic divalent ring having 6 to 10 ring atoms in which one, two, or three ring atoms are heteroatom selected from NH, N, O, and S(O)_n, where n is an integer selected from 0 to 2, the remaining ring atoms being C and the rings are connected through only one atom, the connecting atom is also called the spiroatom, most often a quaternary carbon (“spiro carbon”). Spiro heterocyclylene is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, and cyano, unless stated otherwise. Representative examples include, but are not limited to, 2-azaspiro[3.3]heptan-diyl, 2,6-diazaspiro[3.3]heptan-diyl, l,7-diazaspiro[3.5]nonan-diyl, 2,7-diazaspiro[3.5]nonan-diyl, 3,9-diazaspiro[5.5]undecan-diyl, and the like.

“Unsaturated heterocyclylene” means a non-aromatic divalent, monocyclic group of 5 to 8 ring atoms containing one, two, or three double bonds and in which one or two ring atoms are heteroatom independently selected from N, NH, O, and S(O)_n, where n is an integer selected from 0 to 2, the remaining ring atoms being C, unless stated otherwise. Additionally, one or two ring carbon atoms in the heterocyclylene ring can optionally be replaced by a -C(=O)- group. More specifically, the term heterocyclylene includes, but is not limited to, , piperidin-l,4-diyl, azetidin-l,3-diyl, and the like.

The present disclosure also includes protected derivatives of compounds of Formula (I) of the first aspect (or any embodiments thereof disclosed herein), or a pharmaceutically acceptable salt thereof. For example, when compounds of Formula (I) contain groups such as hydroxy, carboxy, or any group containing a nitrogen atom(s), these groups can be protected with suitable protecting groups. A comprehensive list of suitable protective groups can be found in T.W. Greene, Protective Groups in Organic Synthesis, 5^th Ed., John Wiley & Sons, Inc. (2014), the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of compounds of the present disclosure can be prepared by methods well known in the art. The present disclosure also includes polymorphic forms and deuterated forms of the compound of Formula (I) of the first aspect and (or any embodiments thereof disclosed herein), or a pharmaceutically acceptable salt thereof.

Certain compounds of the present disclosure can exist as tautomers and/or geometric isomers. All possible tautomers and cis and trans isomers, as individual forms and mixtures thereof are within the scope of this disclosure. For example, a compound of Formula (I) having a hydroxy substituted pyridyl ring can exist as a tautomer as shown below:

The term “prodrug” refers to a compound that is made more active in vivo. Certain compounds Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the active compound. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.

A “pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxy ethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptonic acid, 4,4’-methylenebis-(3-hydroxy- 2-ene-l -carboxylic acid), 3 -phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, A-methylglucamine, and the like. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington ’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, which is incorporated herein by reference in its entirety.

The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may have asymmetric centers. Compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art. All chiral, diastereomeric, all mixtures of chiral or diastereomeric forms, and racemic forms are within the scope of this disclosure, unless the specific stereochemistry or isomeric form is specifically indicated. It will also be understood by a person of ordinary skill in the art that when a compound is denoted as (R) stereoisomer, it may contain the corresponding (S) stereoisomer as an impurity and vice versa.

Certain compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) can exist as tautomers and/or geometric isomers. All possible tautomers and cis and trans isomers, as individual forms and mixtures thereof are within the scope of this disclosure. Additionally, as used herein the term alkyl includes all the possible isomeric forms of said alkyl group albeit only a few examples are set forth. Furthermore, when the cyclic groups such as aryl is substituted, it includes all the positional isomers albeit only a few examples are set forth. Furthermore, all hydrates of a compound of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) are within the scope of this disclosure.

The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may also contain unnatural amounts of isotopes at one or more of the atoms that constitute such compounds. Unnatural amounts of an isotope may be defined as ranging from the amount found in nature to an amount 100% of the atom in question, that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into compounds of the present disclosure, such as a compound of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as ²H, ³H, ⁿC, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵0, ¹⁷O, ¹⁸O, ³²P, ³³P, ³⁵S, ¹⁸F, ³⁶C1, ¹²³I, and ¹²⁵1, respectively. Isotopically labeled compounds (e.g., those labeled with ³H and ¹⁴C) can be useful in compound or substrate tissue distribution assays. Tritiated (i.e., ³H) and carbon-14 (i.e., ¹⁴C) isotopes can be useful for their ease of preparation and detectability. Further, substitution with (or isotopically enriched for) heavier isotopes such as deuterium (i.e., ²H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, in compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds, including in Table 1 below, one or more hydrogen atoms are replaced by ²H or ³H, or one or more carbon atoms are replaced by ¹³C- or ¹⁴C-enriched carbon. Positron emitting isotopes such as ¹⁵O, ¹³N, ⁿC, and ¹⁵F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed in the Schemes or in the Examples herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.

A “pharmaceutically acceptable carrier or excipient” means a carrier or an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes a carrier or an excipient that is acceptable for veterinary use as well as human pharmaceutical use.

“A pharmaceutically acceptable carrier/excipienf ’ as used in the specification and claims includes both one and more than one such excipient. The term “about,” as used herein, is intended to qualify the numerical values which it modifies, denoting such a value as variable within a margin of error. When no particular margin of error, such as a standard deviation to a mean value given in a chart or table of data, is recited, the term “about” should be understood to mean that range which would encompass ± 10%, (in one subembodiment, the range for “about” encompasses ± 5%), the recited value and the range is included.

Certain structures provided herein are drawn with one or more floating substituents i.e., the substituent is not attached to a specific atom of the structure. Unless provided otherwise or otherwise clear from the context, the substituent(s) may be present on any atom of the ring to which it is attached, where chemically feasible and valency rules permitting. For example, in the structure: , the R^aa substituent, and similarly the R^bb substituent, is a floating substituent, and can replace hydrogen of any CH that is part of the benzo portion of the bicyclic ring that is not already substituted with R^bb (in the case of R^aa), and similarly with R^aa (in the case ofR^bb).

Additionally, as used throughout the application, including in the embodiments, when a group is drawn out as divalent, the left bond of the divalent group is attached to the group which is to its left in the remainder of the molecule, and the right bond of the divalent group is attached to the group which is to its right in the remainder of the molecule. For example, in Formula (I), in the following divalent groups: the bond on the left of (a) and (b) is attached to the following ring: and the on the right side of (a) and (b) is attached to Z of the Formula (I) structure: Similarly, for -Z-alk-, the bond on left side (i.e., Z) is attached to the group on its left side i.e., ring A of formula (i) or ring B of formula (ii) in Degron and the bond on right side (i.e., alk) is attached to -SO2- that is attached to an atom of Hy. For example, when -Z-alk- is a group of formula: and ring A of Degron of formula (i) is a group of formula , the ⁱ bond of the piperidinyl (of Z) is attached to the benzo portion of ring (a) and the * bond of 2-methylpropylene is attached to -SO2- that is attached to Hy.

The term “disease” as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.

The term “combination therapy” means the administration of two or more therapeutic agents to treat a disease or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.

The term “patient” is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. In one embodiment, the patient is a human.

“Treating” or “treatment” of a disease includes:

(1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease;

(2) inhibiting the disease, i.e., delaying, arresting (stabilizing), or reducing the development or severity of the disease or its clinical symptoms; or

(3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.

In one embodiment, treating or treatment of a disease includes inhibiting the disease, i.e., delaying, arresting or reducing the development or severity of the disease or its clinical symptoms; or relieving the disease, i.e., causing regression of the disease or its clinical symptoms.

A “therapeutically effective amount” means the amount of a compound of the present disclosure and/or a pharmaceutically acceptable salt thereof that, when administered to a patient for treating a disease, is sufficient to affect such treatment for the disease. The “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, etc., of the mammal to be treated.

A “condition associated with an autoimmune disease” means a condition that a patient with an autoimmune disease is susceptible to, e.g., sepsis, or a condition that is caused by the autoimmune disease, e.g., uveitis.

The compounds of Formula (I) can also inhibit CDK2 and/or CDK4. The term “inhibiting” and “reducing,” or any variation of these terms in relation to CDK2 and/or CDK4, includes any measurable decrease or complete inhibition of enzymatic activity of CDK2 and/or CDK4, respectively, to achieve a desired result. For example, the compound of Formula (I) may independently decrease about, at most about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, of CDK2 and/or CDK4 activities, compared to their/its normal activity. In some embodiments, the CDK2 and/or CDK4 activity is reduced by at least 40% in the presence of a compound disclosed herein in the Summary, Embodiments, and Compound Table 1 disclosed herein as compared to an equivalent sample comprising CDK2 and/or CDK4, respectively, in the absence of said compound. The inhibitory activity of a compound of Formula (I) can be measure using Biological Example 1, by converting a compound of Formula (I) to a corresponding compound of Formula (I) that cannot be degraded by the ubiquitin proteosome pathway e.g., by H O^N^O methylating the nitrogen atom in ' group of ligase ligand (i) or (ii) present in the compound of Formula (I).

The term “degrading” and “degrade,” or any variation of these terms in relation to CDK2, CDK4, and CDK1, means any measurable decrease in the concentration of CDK2, CDK4, and CDK1, respectively, over time in a sample containing a compound of Formula (I). For example, there may be a decrease of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or more, or any range derivable therein, in CDK2 and/or CDK4 concentration in a sample containing CDK2 and/or CDK4, respectively and a compound disclosed herein in the Summary, Embodiments, and Compound Table 1 disclosed herein as compared to an equivalent sample comprising CDK2 or CDK4, in the absence of said compound. The % degradation can be determined as described in Biological Example 2 below. In one embodiment, the decrease in the concentration of CDK2 and/or CDK4 is > 20%. In another embodiment, the decrease in the concentration of CDK2 and/or CDK4 is > 40%. In another embodiment, the decrease in the concentration of CDK2 and/or CDK4 is > 50%. In another embodiment, the decrease in the concentration of CDK2 and/or CDK4 is > 60%. In another embodiment, the decrease in the concentration of CDK2 and/or CDK4 > 70%. In another embodiment, the decrease in the concentration of CDK2 and/or CDK4 is > 80%.

Embodiments:

In embodiments Al to Al 78, the present disclosure includes:

Al. In embodiment Al, provided is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as described in the first aspect of the Summary.

A2. In embodiment A2, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is halo.

A3. In embodiment A3, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is haloalkyl or haloalkoxy.

A4. In embodiment A4, the compound of embodiment Al or A3, or a pharmaceutically acceptable salt thereof, is wherein R¹ is haloalkyl.

A5. In embodiment A5, the compound of embodiment Al or A3, or a pharmaceutically acceptable salt thereof, is wherein R¹ is haloalkoxy.

A6. In embodiment A6, the compound of any one of embodiments Al to A5, or a pharmaceutically acceptable salt thereof, is wherein R¹ is chloro, bromo, fluoro, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, difluoromethoxy, trifluoromethoxy, difluoroethoxy, or trifluoroethoxy unless stated otherwise.

A7. In embodiment A7, the compound of any one of embodiments Al to A6, or a pharmaceutically acceptable salt thereof, is wherein R¹ is chloro, bromo, difluoromethyl, trifluoromethyl, difluoromethoxy, or trifluoromethoxy unless stated otherwise.

A8. In embodiment A8, the compound of any one of embodiments Al, A2, and A6 and A7, or a pharmaceutically acceptable salt thereof, is wherein R¹ is chloro.

A9. In embodiment A9, the compound of any one of embodiments Al, A3, A4, A6, and A7, or a pharmaceutically acceptable salt thereof, is wherein R¹ is difluoromethyl or trifluoromethyl.

A10. In embodiment A10, the compound of any one of embodiments Al, A3, A4, A6, A7, and A9, or a pharmaceutically acceptable salt thereof, is wherein R¹ is trifluoromethyl.

Al l. In embodiment Al l, the compound of any one of embodiments Al, A3, and A5 to A7, or a pharmaceutically acceptable salt thereof, is wherein R¹ is trifluoromethoxy.

A12. In embodiment A12, the compound of any one of embodiments Al, A3, and A5 to A7, or a pharmaceutically acceptable salt thereof, is wherein R¹ is difluoromethoxy.

A13. In embodiment A13, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is alkyl, alkenyl, or alkynyl.

A14. In embodiment A14, the compound of embodiment Al or A13, or a pharmaceutically acceptable salt thereof, is wherein R¹ is methyl, ethyl, propyl, vinyl, propenyl, ethynyl, or propynyl.

A15. In embodiment A15, the compound of embodiment Al, A13, or A14, or a pharmaceutically acceptable salt thereof, is wherein R¹ is methyl, ethyl, or propyl.

A16. In embodiment A16, the compound of embodiment Al, A13, or A14, or a pharmaceutically acceptable salt thereof, is wherein R¹ is vinyl, propenyl, ethynyl, or propynyl.

A17. In embodiment A17, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is alkoxy.

A18. In embodiment A18, the compound of embodiment Al or A17, or a pharmaceutically acceptable salt thereof, is wherein R¹ is methoxy, ethoxy, or propoxy.

A19. In embodiment A19, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is aryloxy, In one subembodiment R¹ is phenoxy.

A20. In embodiment A20, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is cyano. A21. In embodiment A21, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is cycloalkyl. In one subembodiment, R¹ is cyclopropyl.

A22. In embodiment A22, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is cycloalkyl substituted with one to three halo. In one sub embodiment, R¹ is fluorocyclopropyl or difluorocyclopropyl.

A22a. In embodiment A22a, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is cycloalkyloxy. In one subembodiment, R¹ is cyclopropyloxy.

A22b. In embodiment A22b, the compound of embodiment Al, or a pharmaceutically acceptable salt thereof, is wherein R¹ is cycloalkyloxy substituted with one to three halo. In one sub embodiment, R¹ is fluorocyclopropyloxy or difluorocyclopropyloxy.

A23. In embodiment A23, the compound of any one of embodiments Al to A22b, or a pharmaceutically acceptable salt thereof, is wherein R² and R^2a are hydrogen.

A24. In embodiment A24, the compound of any one of embodiments Al to A22b, or a pharmaceutically acceptable salt thereof, is wherein one of R² and R^2a is deuterium and the other of R² and R^2a is hydrogen or both R² and R^2a are deuterium.

A25. In embodiment A25, the compound of any one of embodiments Al to A24, or a pharmaceutically acceptable salt thereof, is wherein Hy is heterocyclylene, arylene, spiro heterocyclylene, bridged heterocyclylene, or cycloalkylene, wherein each of the aforementioned rings is substituted with R^a, R^b, and R^c where R^a and R^b are independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano, and R^c is hydrogen.

A26. In embodiment A26, the compound of any one of embodiments Al to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is heterocyclylene substituted with R^a, R^b, and R^c where R^a and R^b are independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano, and R^c is hydrogen.

A27. In embodiment A27 , the compound of any one of embodiments Al to A26, or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene of Hy is pyrrolidin-1,3- diyl or piperidin-l,4-diyl, where each ring of Hy is substituted with R^a, R^b, and R^c where R^a and R^b are independently hydrogen, deuterium, methyl, fluoro, methoxy, or hydroxy, and R^c is hydrogen; and -SO2- is attached to the nitrogen atom of the piperidin-l,4-diyl or pyrrolidin-1,3- diyl ring of Hy.

A28. In embodiment A28, the compound of any one of embodiments Al to K 1 or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene of Hy is: where the N atom of the pyrrolidin- 1,3 -diyl or piperidin-l,4-diyl rings is attached to -SO2- A29. In embodiment A29, the compound of any one of embodiments Al to A28, or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene of Hy is: where the N atom of the pyrrolidin- 1,3 -diyl or piperidin-l,4-diyl rings is attached to -SO2-.

A29a. In embodiment A29a, the compound of any one of embodiments Al to A29, or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene of Hy is: where the N atom of the piperidin-l,4-diyl ring is attached to -SO2-.

A30. In embodiment A30, the compound of any one of embodiments Al to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is bridged heterocyclylene substituted with R^a, R^b, and R^c where R^c is hydrogen.

A31. In embodiment A31, the compound of any one of embodiments Al to A25 and A30, or a pharmaceutically acceptable salt thereof, is wherein the bridged heterocyclylene of Hy is a ring of formula: where each ring is substituted with R^a, R^b, and R^c where R^c is hydrogen, and the nitrogen atom of each ring is attached to -SO2-.

A32. In embodiment A32, the compound of embodiment A30 or A31, or a pharmaceutically acceptable salt thereof, is wherein R^a and R^b are independently hydrogen, deuterium, methyl, fluoro, methoxy, or hydroxy.

A33. In embodiment A33, the compound of embodiment A30, A31, or A32, or a pharmaceutically acceptable salt thereof, is wherein R^b is hydrogen. A34. In embodiment A34, the compound of any one of embodiments Al to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is cycloalkylene substituted with R^a, R^b, and R^c where R^a is deuterium, methyl, fluoro, methoxy, or hydroxy and R^b and R^c are hydrogen.

A35. In embodiment A35, the compound of any one of embodiments Al to A25 and A34, or a pharmaceutically acceptable salt thereof, is wherein the cycloalkylene of Hy is cyclohexylene.

A36. In embodiment A36, the compound of any one of embodiments Al to A25, A34, and A35, or a pharmaceutically acceptable salt thereof, is wherein the cycloalkylene of Hy is 9 . where denotes bond to NH and denotes bond of -SO2-.

A37. In embodiment A37, the compound of any one of embodiments Al to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is arylene wherein the arylene is phenylene substituted with R^a, R^b, and R^c where R^a and R^b are independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano, and R^c is hydrogen.

A38. In embodiment A38, the compound of any one of embodiments Al to A25, or a pharmaceutically acceptable salt thereof, is wherein Hy is spiro heterocyclylene (in one subembodiment 2-azaspiro[3.3]heptan-2-yl) substituted with R^a, R^b, and R^c where R^a and R^b are independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano and R^c is hydrogen.

A39. In embodiment A39, the compound of embodiment A37, or a pharmaceutically acceptable salt thereof, is wherein the phenylene of Hy is 1,4-phenylene according to structure denotes the bond to -SO2- where R^a is hydrogen, fluoro, methyl or methoxy and where R^b is hydrogen.

A39a. In embodiment A39a, the compound of any one of embodiments Al to A24, or a pharmaceutically acceptable salt thereof, is wherein Hy is fused heterocyclylene substituted with R^a, R^b, and R^c where R^a and R^b are independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano and R^c is hydrogen.

A39b. In embodiment A39b, the compound of any one of embodiments Al to A24, or a pharmaceutically acceptable salt thereof, is wherein Hy is bicyclic heterocyclylene substituted with R^a, R^b, and R^c where R^a and R^b are independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano and R^c is hydrogen.

A40. In embodiment A40, the compound of any one of embodiments Al to A39b, or a pharmaceutically acceptable salt thereof, is wherein the Degron is an E3 ubiquitin ligase ligand of formula (i):

A41. In embodiment A41, the compound of any one of embodiments Al to A40, or a pharmaceutically acceptable salt thereof, is wherein the ring A of the E3 ubiquitin ligase ligand of formula (i) is a group of formula (a):

A42. In embodiment A42, the compound of any one of embodiments Al to A41, or a pharmaceutically acceptable salt thereof, is wherein R⁴ and R⁵ are independently hydrogen or alkyl.

A43. In embodiment A43, the compound of any one of embodiments Al to A42, or a pharmaceutically acceptable salt thereof, is wherein R⁴ and R⁵ are hydrogen.

A44. In embodiment A44, the compound of any one of embodiments Al to A42, or a pharmaceutically acceptable salt thereof, is wherein R⁴ is hydrogen and R⁵ is methyl.

A45. In embodiment A45, the compound of any one of embodiments Al to A41, or a pharmaceutically acceptable salt thereof, is wherein R⁴ and R⁵ together with the carbon to which they are attached form >C =0.

A46. In embodiment A46, the compound of any one of embodiments Al to A40, or a pharmaceutically acceptable salt thereof, is wherein the ring A of the E3 ubiquitin ligase ligand of formula (i) is a group of formula (b):

A47. In embodiment A47, the compound of any one of embodiments Al to A40 and A42 to A46, or a pharmaceutically acceptable salt thereof, is wherein R⁶ is hydrogen.

A48. In embodiment A48, the compound of any one of embodiments Al to A40 and A42 to A46, or a pharmaceutically acceptable salt thereof, wherein R⁶ is alkyl. In one sub embodiment, R⁶ is methyl.

A49. In embodiment A49, the compound of any one of embodiments Al to A48, or a pharmaceutically acceptable salt thereof, is wherein the ring A of the E3 ubiquitin ligase ligand of formula (i) is:

A50. In embodiment A50, the compound of any one of embodiments Al to A49, or a pharmaceutically acceptable salt thereof, is wherein the ring A of the E3 ubiquitin ligase ligand of formula (i) is: A51. In embodiment A51, the compound of any one of embodiments Al to A50, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

A52. In embodiment A52, the compound of any one of embodiments Al to A51, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is: i.e., where R^aa is hydrogen (when R^aa is not drawn out in above rings) and R^bb, R^cc, and R^dd are hydrogen.

A52a. In embodiment A52a, the compound of any one of embodiments Al to A41, A45, and A49 to A52, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is:

A53. In embodiment A53, the compound of any one of embodiments Al to A41, A45, and A49 to A52, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is: i.e., where R^bb, R^cc, and R^dd are hydrogen.

A54. In embodiment A54, the compound of any one of embodiments Al to A43, and A49 to A52, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is: i.e., where R^bb, R^cc, and R^dd are hydrogen.

A55. In embodiment A55, the compound of any one of embodiments Al to A43, A49 to A52, and A54, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is: i.e., where R^aa, R^bb, R^cc, and R^dd are hydrogen.

A56. In embodiment A56, the compound of any one of embodiments Al to A40, A42 to A46, and A48 to A52, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is: i.e., where R^aa, R^bb, R^cc, and R^dd are hydrogen.

A57. In embodiment A57, the compound of any one of embodiments Al to A40, A42 to A46, and A48 to A52, or a pharmaceutically acceptable salt thereof, is wherein ring A of the E3 ubiquitin ligase ligand of formula (i) is: i.e., where R^aa, R^bb, R^cc, and R^dd are hydrogen. A58. In embodiment A58, the compound of any one of embodiments Al to A54, or a pharmaceutically acceptable salt thereof, is wherein R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy, unless stated otherwise i.e., in embodiments A52 to A54, where R^bb, R^cc, and R^dd are hydrogen.

A59. In embodiment A59, the compound of any one of embodiments Al to A54, or a pharmaceutically acceptable salt thereof, is wherein R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, and cyano, unless stated otherwise.

A60. In embodiment A60, the compound of any one of embodiments Al to A54, A58, and A59, or a pharmaceutically acceptable salt thereof, is wherein R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen, methyl, methoxy, ethoxy, fluoro, trifluoromethyl, difluoromethyl, and trifluoromethoxy, unless stated otherwise.

A61. In embodiment A61, the compound of any one of embodiments Al to A54, and A58 to A60, or a pharmaceutically acceptable salt thereof, is wherein R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen and methyl, unless stated otherwise.

A62. In embodiment A62, the compound of any one of embodiments Al to A54, and A58 to A60, or a pharmaceutically acceptable salt thereof, is wherein R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen and methoxy, unless stated otherwise.

A63. In embodiment A63, the compound of any one of embodiments Al to A54, and A58 to A60, or a pharmaceutically acceptable salt thereof, is wherein R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen and fluoro, unless stated otherwise.

A64. In embodiment A64, the compound of any one of embodiments Al to A54, and A58 to A60, or a pharmaceutically acceptable salt thereof, is wherein R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen, trifluoromethyl, and difluoromethyl, unless stated otherwise.

A65. In embodiment A65, the compound of any one of embodiments Al to A54, A58, and A60, or a pharmaceutically acceptable salt thereof, is wherein R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen and trifluoromethoxy, unless stated otherwise.

A66. In embodiment A66, the compound of any one of embodiments Al to A54, and A58 to A60, or a pharmaceutically acceptable salt thereof, is wherein R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen, fluoro, and trifluoromethyl, unless stated otherwise. A67. In embodiment A67, the compound of any one of embodiments Al to A39b, or a pharmaceutically acceptable salt thereof, is wherein the Degron is an E3 ubiquitin ligase ligand of formula (ii):

(ii).

A68. In embodiment A68, the compound of any one of embodiments Al to A39b and A41 to A67, or a pharmaceutically acceptable salt thereof, is wherein Y^a is CH.

A69. In embodiment A69, the compound of any one of embodiments Al to A39b and A41 to A67, or a pharmaceutically acceptable salt thereof, is wherein Y^a is N.

A70. In embodiment A70, the compound of any one of embodiments Al to A39b and A41 to A69, or a pharmaceutically acceptable salt thereof, is wherein Z^a is a bond, -NH-, -O-, or -NHC(O)-.

A71. In embodiment A71, the compound of any one of embodiments Al to A39b and A41 to A70, or a pharmaceutically acceptable salt thereof, is wherein Z^a is a bond, -NH-, or -NHC(O)-.

A72. In embodiment A72, the compound of any one of embodiments Al to A39b and A41 to A71, or a pharmaceutically acceptable salt thereof, is wherein Z^a is a bond.

A73. In embodiment A73, the compound of any one of embodiments Al to A39b and A41 to A71, or a pharmaceutically acceptable salt thereof, is wherein Z^a is -NH-, or -NHC(O)-.

A74. In embodiment A74, the compound of any one of embodiments Al to A39b, A41 to A71, and A73, or a pharmaceutically acceptable salt thereof, is wherein Z^a is -NH-.

A74a. In embodiment A74a, the compound of any one of embodiments Al to A39b, A41 to A71, and A73, or a pharmaceutically acceptable salt thereof, is wherein Z^a is -NHC(O)-.

A75. In embodiment A75, the compound of any one of embodiments Al to A39b and A41 to A74a, or a pharmaceutically acceptable salt thereof, is wherein ring B is phenylene substituted with R^ee and R^ff.

A76. In embodiment A76, the compound of any one of embodiments Al to A39b, and A41 to A74a, or a pharmaceutically acceptable salt thereof, is wherein ring B is cyclylaminylene substituted with R^ee and R^ff.

A77. In embodiment A77, the compound of any one of embodiments Al to A39b and A41 to A74a, or a pharmaceutically acceptable salt thereof, is wherein ring B is a 5- or 6-membered monocyclic heteroarylene or a 9- or 10-membered fused bicyclic heteroarylene, wherein each heteroarylene ring contains one to three nitrogen ring atoms and each ring is substituted with R^ee and R^ff.

A78. In embodiment A78, the compound of any one of embodiments Al to A39b, A41 to A74a, and A77, or a pharmaceutically acceptable salt thereof, is wherein ring B is 5- or 6-membered monocyclic heteroarylene containing one or two nitrogen ring atoms substituted with R^ee and R^ff.

A79. In embodiment A79, the compound of any one of embodiments Al to A39b, A41 to A74a, and A77, or a pharmaceutically acceptable salt thereof, is wherein ring B is a 9- or 10-membered fused bicyclic heteroarylene containing one to three nitrogen ring atoms (and not containing any additional heteroatoms) and substituted with R^ee and R^ff.

A80. In embodiment A80, the compound of any one of embodiments Al to A39b, A41 to A74a, A77, and A79, or a pharmaceutically acceptable salt thereof, is wherein ring B is a 9- or 10-membered fused bicyclic heteroarylene containing one or two nitrogen ring atoms and substituted with R^ee and R^ff.

A81. In embodiment A81, the compound of any one of embodiments Al to A39b and A41 to A80, or a pharmaceutically acceptable salt thereof, is wherein the E3 ubiquitin ligase ligand of formula (ii) is: where ring B is as defined therein.

A82-1. In embodiment A82-1, the compound of any one of embodiments Al to A39b and A41 to A81, or a pharmaceutically acceptable salt thereof, is wherein the E3 ubiquitin ligase ligand of formula (ii) is:

where is cyclylaminylene. For the sake of clarity, it is to be understood that R^ee and/or R^ff are/is hydrogen when they are/is not drawn out in a structure.

A82. In embodiment A82, the compound of any one of embodiments Al to A39b and A41 to A82-1, or a pharmaceutically acceptable salt thereof, is wherein the E3 ubiquitin ligase ligand of formula (ii) is: where is cyclylaminylene and R is hydrogen when not drawn out in the above structures. A82A. In embodiment A82A, the compound of any one of embodiments Al to A39b and

A41 to A68, A70 to A72, A77, and A79 to A82, or a pharmaceutically acceptable salt thereof, is wherein the E3 ubiquitin ligase ligand of formula

A83. In embodiment A83, the compound of any one of embodiments Al to A39b and

A41 to A82, or a pharmaceutically acceptable salt thereof, is wherein the E3 ubiquitin ligase ligand of formula (ii) is:

unless otherwise stated.

A83A. In embodiment A83A, the compound of any one of embodiments Al to A39b and A41 to A67, A69 to A72, A77, A79 to A82, and A83, or a pharmaceutically acceptable salt thereof, is wherein the E3 ubiquitin ligase ligand of formula A84. In embodiment A84, the compound of any one of embodiments Al to A39b and

A41 to A83 A, or a pharmaceutically acceptable salt thereof, is wherein each R^ee and R^ff are independently selected from hydrogen, alkyl, alkoxy, halo, cyano, haloalkyl, and haloalkoxy unless stated otherwise.

A85. In embodiment A85, the compound of any one of embodiments Al to A39b and A41 to A83A, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are independently selected from hydrogen, alkyl, cycloalkyl, alkoxy, halo, haloalkyl, and cyano unless stated otherwise.

A86. In embodiment A86, the compound of any one of embodiments Al to A39b and A41 to A85, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, methoxy, ethoxy, fluoro, chloro, trifluoromethyl, 2,2,2-trifluoroethyl, difluoromethyl, difluoromethoxy, trifluoromethoxy, and cyano unless stated otherwise.

A87. In embodiment A87, the compound of any one of embodiments Al to A39b and A41 to A86, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are independently selected from hydrogen, methyl, ethyl, and isopropyl unless stated otherwise.

A88. In embodiment A88, the compound of any one of embodiments Al to A39b and A41 to A86, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are independently selected from hydrogen and methoxy unless stated otherwise.

A89. In embodiment A89, the compound of any one of embodiments Al to A39b and A41 to A86, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are independently selected from hydrogen, methyl, ethyl, isopropyl, chloro, and fluoro unless stated otherwise.

A90. In embodiment A90, the compound of any one of embodiments Al to A39b and A41 to A86, or a pharmaceutically acceptable salt thereof, is wherein one of R^ee and R^ff is hydrogen or fluoro and the other of R^ee and R^ff is selected from hydrogen, trifluoromethyl, 2,2,2-trifluoroethyl, and difluoromethyl unless stated otherwise.

A91. In embodiment A91, the compound of any one of embodiments Al to A39b and A41 to A86, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are independently selected from hydrogen, difluoromethoxy, and trifluoromethoxy unless stated otherwise.

A92. In embodiment A92, the compound of any one of embodiments Al to A39b and A41 to A86, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are independently selected from hydrogen, chloro, fluoro, and trifluoromethyl unless stated otherwise.

A93. In embodiment A93, the compound of any one of embodiments Al to A39b and A41 to A92, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are hydrogen.

A94. In embodiment A94, the compound of any one of embodiments Al to A39b and A41 to A86, A89 and A92, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are chloro unless stated otherwise. A95. In embodiment A95, the compound of any one of embodiments Al to A39b and A41 to A86, A89, and A92, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are fluoro unless stated otherwise.

A96. In embodiment A96, the compound of any one of embodiments Al to A39b and A41 to A86 and A90, or a pharmaceutically acceptable salt thereof, is wherein R^ee and R^ff are independently trifluoromethyl or 2,2,2-trifluoroethyl unless stated otherwise.

A97. In embodiment A97, the compound of any one of embodiments Al to A96, or a pharmaceutically acceptable salt thereof, is wherein Z is phenylene, monocyclic heteroarylene, bridged heterocyclylene, heterocyclylene, or unsaturated heterocyclylene, where each ring is substituted with R^d and R^e as defined therein.

A98. In embodiment A98, the compound of any one of embodiments Al to A96, or a pharmaceutically acceptable salt thereof, is wherein Z is cycloalkylene selected from cyclopropylene, cyclobutylene, cyclopentylene, and cyclohexylene and where each ring is substituted as defined therein.

A99. In embodiment A99, the compound of any one of embodiments Al to A96 and A98, or a pharmaceutically acceptable salt thereof, is wherein the cycloalkylene of Z is independently selected from 1,3 -cyclopentylene, 1,3 -cyclohexylene, and 1,4-cyclohexylene.

Al 00. In embodiment Al 00, the compound of any one of embodiments Al to A97, or a pharmaceutically acceptable salt thereof, is wherein Z is phenylene or monocyclic heteroarylene (such as imidazoldiyl, pyridindiyl, or pyrimidindiyl) and where each ring is substituted with R^d and R^e as defined therein.

A101. In embodiment A101, the compound of any one of embodiments Al to A97, and Al 00, or a pharmaceutically acceptable salt thereof, is wherein Z is monocyclic heteroarylene selected from imidazol-2,5-diyl, pyridin-2,4-diyl, pyridin-2,6-diyl, and pyri din-3, 5 -diyl.

Al 02. In embodiment Al 02, the compound of any one of embodiments Al to A97 and A100, or a pharmaceutically acceptable salt thereof, is wherein Z is 1,3-phenylene or 1,4-phenylene.

A103. In embodiment A103, the compound of any one of embodiments Al to A97, or a pharmaceutically acceptable salt thereof, is wherein Z is heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene (unless stated otherwise), where each ring is substituted with R^d and R^e as defined therein.

Al 04. In embodiment Al 04, the compound of any one of embodiments Al to A97, and A103, or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene, bridged heterocyclylene, and spiro heterocyclylene of Z are selected from:

wherein each ring is substituted with R^d and R^e independently selected from hydrogen, deuterium, alkyl, and halo.

A105. In embodiment A105, the compound of any one of embodiments Al to A97, A103, and Al 04, or a pharmaceutically acceptable salt thereof, is wherein the heterocyclylene, bridged heterocyclylene, and spiro heterocyclylene of Z are independently selected from: respectively.

Al 06. In embodiment Al 06, the compound of any one of embodiments Al to A97 and A103 to A105, or a pharmaceutically acceptable salt thereof, is wherein Z is heterocyclylene or bridged heterocyclylene selected from:

Al 07. In embodiment Al 07, the compound of any one of embodiments Al to A97 and

Al 03 to Al 06, or a pharmaceutically acceptable salt thereof, is wherein Z is

A108. In embodiment A108, the compound of any one of embodiments Al to A96, or a pharmaceutically acceptable salt thereof, is wherein Z is -O-, -NH-, or -NCH3-.

Al 09. In embodiment Al 09, the compound of any one of embodiments Al to Al 08, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkenylene substituted with R^f where R^f is hydrogen.

A110. In embodiment Al 10, the compound of any one of embodiments Al to A108, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkenylene substituted with R^f where R^f is fluoro or cyano.

Al l i. In embodiment Al l i, the compound of any one of embodiments Al to Al 08, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^g, R^h, and R¹ are hydrogen.

Al 12. In embodiment Al 12, the compound of any one of embodiments Al to A108, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^g, R^h, and R¹ are hydrogen or halo, provided at least one of R^g, R^h, and R¹ is halo.

Al 13. In embodiment Al 13, the compound of embodiment Al 12, or a pharmaceutically acceptable salt thereof, is wherein the halo of the at least one of R^g, R^h, and R¹ is fluoro.

Al 14. In embodiment Al 14, the compound of any one of embodiments Al to A108, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^h is other than hydrogen and R¹ is hydrogen or when R^h and R¹ are attached to the same carbon atom or to adjacent carbon atoms of the linear portion of the C3 to Ce alkylene, R^h and R¹ together with the carbon atom(s) to which they are attached can form cycloalkylene or heterocyclylene where the cycloalkylene and heterocyclylene formed by R^h and R¹ are substituted with R⁹ and R¹⁰.

Al 15. In embodiment Al 15, the compound of embodiment Al 14, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^h is other than hydrogen and R¹ is hydrogen.

Al 16. In embodiment Al 16, the compound of any one of embodiments Al to Al 15, or a pharmaceutically acceptable salt thereof, is wherein the C3 to Ce alkenylene and C3 to Ce alkylene of alk are linear alkenylene and alkylene, respectively, and substituted as defined therein.

Al 17. In embodiment Al 17, the compound of any one of embodiments Al to Al 16, or a pharmaceutically acceptable salt thereof, is wherein the linear C3 to Ce alkenylene of alk is -CH=C(R^f)CH2- and the linear alkylene of C3 to Ce alkylene of alk is -CH2CH(R^h)CH2-, -CH2CH₂CH(R^h)-, -CH₂C(R^g)(R^h)CH2-, or -CH₂CH₂C(R^g)(R^h)- where R^g and R^h are as defined therein and R¹ is hydrogen.

Al 18. In embodiment Al 18, the compound of any one of embodiments Al to A108 and Al 12 to Al 17, or a pharmaceutically acceptable salt thereof, is wherein the linear C3 to Ce alkylene of alk is -CH2CH(R^h)CH2- where R^h is as defined therein and R^g and R¹ are hydrogen.

Al 19. In embodiment Al 19, the compound of any one of embodiments Al to Al 08 and Al 14 to Al 18, or a pharmaceutically acceptable salt thereof, is wherein R^g of linear C3 to Ce alkylene of alk is, unless stated otherwise, hydrogen, deuterium, or halo and R^h of linear C3 to Ce alkylene of alk is, unless stated otherwise, halo, haloalkoxy, cycloalkyl, cycloalkyloxy, alkoxy, hydroxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, cyano, cyanoalkyloxy, phenyl, heteroaryl, heterocyclyl, or bridged heterocyclyl, where each ring is substituted as defined therein and R¹ is as defined therein.

A120. In embodiment A120, the compound of any one of embodiments Al to A108 and Al 14 to Al 19, or a pharmaceutically acceptable salt thereof, is wherein R^g of linear C3 to Ce alkylene of alk is hydrogen and R^h of linear C3 to Ce alkylene of alk is halo, haloalkoxy, cycloalkyl, cycloalkyloxy, alkoxy, hydroxy, dialkylaminocarbonyl, alkylcarbonylamino, cyano, phenyl, heteroaryl, heterocyclyl, or bridged heterocyclyl, where each ring is substituted as defined therein, and R¹ is as defined therein.

A121. In embodiment A121, the compound of any one of embodiments Al to A108 and Al 14 to A120, or a pharmaceutically acceptable salt thereof, is wherein R^g of linear C3 to Ce alkylene of alk is hydrogen and R^h of linear C3 to Ce alkylene of alk is halo, haloalkoxy, alkoxy, hydroxy, dialkylaminocarbonyl, cyano, heterocyclyl, or heteroaryl, where each ring is substituted as defined therein and R¹ is as defined therein.

A122. In embodiment A122, the compound of any one of embodiments Al to A108 and Al 14 to A121, or a pharmaceutically acceptable salt thereof, is wherein the heteroaryl, heterocyclyl, and bridged heterocyclyl (unless stated otherwise), when present, of R^h of linear C3 to Ce alkylene of alk are five or six membered rings and each ring is substituted as defined therein.

A123. In embodiment A123, the compound of any one of embodiments Al to A108 and Al 14 to A122, or a pharmaceutically acceptable salt thereof, is wherein R^g of linear C3 to Ce alkylene of alk is hydrogen, deuterium, or fluoro unless stated otherwise, R^h of linear C3 to Ce alkylene of alk is fluoro, cyclopropyl, cyclobutyl, cyclopropyloxy, cyclobutyloxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxy, cyano, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, methylcarbonylamino, ethylcarbonylamino, phenyl, pyrazolyl, furanyl, thiazolyl, pyridinyl, pyrrolidinyl, 2-oxopyrrolidinyl, piperidinyl, piperazinyl, or tetrahydrofuranyl, where each ring of R^h is substituted with R⁷ and R⁸ independently selected from hydrogen, deuterium, methyl, methoxy, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoroethyl, hydroxy, amino, methylamino, dimethylamino and cyano, unless stated otherwise, and R¹ is as defined therein.

A124. In embodiment A124, the compound of any one of embodiments Al to A108 and Al 14 to A123, or a pharmaceutically acceptable salt thereof, is wherein R^g of linear C3 to Ce alkylene of alk is hydrogen, deuterium, or fluoro, unless stated otherwise, R^h of linear C3 to Ce alkylene of alk is fluoro, cyclopropyl, cyclopropyloxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxy, cyano, methylaminocarbonyl, dimethylaminocarbonyl, methylcarbonylamino, phenyl, pyrazol-l-yl, pyrrazol-4-yl, pyridin-4-yl, pyrrolidin-l-yl, 2-oxopyrrolidin-l-yl, where each ring of R^h is substituted with R⁷ and R⁸ independently selected from hydrogen, deuterium, methyl, or fluoro unless stated otherwise, and R¹ is as defined therein.

A125. In embodiment A125, the compound of any one of embodiments Al to Al 15, or a pharmaceutically acceptable salt thereof, is wherein the C3 to Ce alkenylene and C3 to Ce alkylene of alk are branched C4 to Ce alkenylene and C4 to Ce alkylene, respectively, substituted as defined therein.

A126. In embodiment A126, the compound of any one of embodiments Al to A108, Al l i to Al 15, and A125, or a pharmaceutically acceptable salt thereof, is wherein the C3 to Ce alkylene of alk is branched C4 to Ce alkylene substituted as defined therein. A127. In embodiment A127, the compound of any one of embodiments Al to Al 15, A125, and A126, or a pharmaceutically acceptable salt thereof, is wherein the branched C4 to Ce alkenylene of alk is -CH₂CH₂C(CH₃)=C(R^f)-, -CH₂C(CH₃)=C(R^f)-, or -CH₂C(=CH₂)CH₂- and the branched C4 to Ce alkylene of alk is -C(CH3)(R^h)CH₂CH₂-, -CH(CH₃)CH₂CH₂-, -C(CH₂CH₃)(R^h)-CH₂CH₂-, -CH₂C(CH₃)(R^h)CH₂-, -CH₂C(C₂H₅)(R^h)CH₂-, -CH₂CH(CH₂R^h)CH₂-, -CH₂CH(CH₂CH₂R^h)CH₂-, -CH₂C(CH₃)(CH₂R^h)CH₂-, -CH₂C(C₂H₅)(CH₂R^h)CH₂-, -CH₂C(CH₃)(CH₂CH₂R^h)CH₂-, -CH₂CH(CH₃)CH(CH₂R^h)-, -CH₂CH₂C(CH₃)(CH₂R^h)-, -CH₂CH(CH₃)C(R^g)(R^h)-, -CH₂CH(C₂H₅)C(R^g)(R^h)-. -CH₂CH(C(R^g)(R^h)(Rⁱ))CH(CH₃)-, -CH₂C(CH₃)(C(R^g)(R^h)(Rⁱ))CH(CH₃)-, -CH₂CH(C(R^g)(R^h)(Rⁱ))CH₂-, -CH₂CH₂CH(C(R^g)(R^h)(Rⁱ))-, -CH₂CH₂CH(C(R^g)(R^h)(Rⁱ))CH₂-, or -CH₂CH₂CH₂CH(C(R^g)(R^h)(R‘))- where R^g, R^h, and R¹ are as defined therein. (For the sake of clarity, each of R^g, R^h, and/or R¹ is hydrogen if it is not specifically recited in any of the above groups).

A128. In embodiment A128, the compound of any one of embodiments Al to Al 15 and A125 to A127, or a pharmaceutically acceptable salt thereof, is wherein the branched C4 to Ce alkenylene of alk is -CH₂C(CH3)=C(R^f)- or -CH₂C(=CH₂)CH₂- and the branched C4 to Ce alkylene of alk is -C(CH₃)(R^h)CH₂CH₂-, -CH₂C(CH₃)(R^h)CH₂-, -CH₂CH(CH₂R^h)CH₂-, -CH₂CH(CH₂CH₂R^h)CH₂-, -CH₂CH(C(R^g)(R^h)(Rⁱ))CH₂-, -CH₂CH₂CH(C(R^g)(R^h)(Rⁱ))CH₂-, or -CH₂CH₂CH₂CH(C(R^g)(R^h)(R‘))- where R^g, R^h, and R¹ are as defined therein.

A129. In embodiment A129, the compound of any one of embodiments Al to A108, Al l i to Al 15, and A125 to A128, or a pharmaceutically acceptable salt thereof, is wherein the R^g and R¹ of branched C4 to Ce alkylene of alk are independently hydrogen or halo (unless stated otherwise) and R^h of branched C4 to Ce alkylene of alk is hydrogen, halo, haloalkoxy, cycloalkyl, cycloalkyloxy, alkoxy, hydroxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, cyano, cyanoalkyloxy, phenyl, heteroaryl, heterocyclyl, heterocyclyloxy, heterocyclylcarbonyl, or bridged heterocyclyl (unless stated otherwise) and each ring of R^h is substituted as defined therein.

A130. In embodiment A130, the compound of any one of embodiments Al to A108, Al l i to Al 15, and A125 to A129, or a pharmaceutically acceptable salt thereof, is wherein the R^g and R¹ of branched C4 to Ce alkylene of alk are hydrogen or fluoro (unless stated otherwise) and R^h of branched C4 to Ce alkylene of alk is hydrogen, halo, cycloalkyl, cycloalkyloxy, alkoxy, hydroxy, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, cyano, phenyl, heteroaryl, heterocyclyl, heterocyclyloxy, heterocyclylcarbonyl, or bridged heterocyclyl (unless stated otherwise) and each ring of R^h is substituted as defined therein.

A131. In embodiment A131, the compound of any one of embodiments Al to Al 08, Al l i to Al 15, and A125 to A130, or a pharmaceutically acceptable salt thereof, is wherein R^g and R¹ of branched C4 to Ce alkylene of alk are hydrogen or fluoro (unless stated otherwise) and R^h of branched C4 to Ce alkylene of alk is (unless stated otherwise) hydrogen, halo, alkoxy, hydroxy, dialkylaminocarbonyl, cyano, or heteroaryl substituted as defined therein.

Al 32. In embodiment Al 32, the compound of any one of embodiments Al to Al 08, Al l i to Al 15, and A125 to A131, or a pharmaceutically acceptable salt thereof, is wherein alk is branched C4 to Ce alkylene substituted as defined therein and the heteroaryl, heterocyclyl, by itself or as part of heterocyclyloxy or heterocyclylcarbonyl, and bridged heterocyclyl of branched C4 to Ce alkylene of alk, when present, are five or six membered rings and each ring of R^h is substituted as defined therein.

A133. In embodiment A133, the compound of any one of embodiments Al to A108, Al l i to Al 15, and A125 to A132, or a pharmaceutically acceptable salt thereof, is wherein the R^g of branched C4 to Ce alkylene of alk is hydrogen, deuterium, or fluoro (unless stated otherwise), R¹ of branched C4 to Ce alkylene of alk is hydrogen or fluoro (unless stated otherwise), and R^h of branched C4 to Ce alkylene of alk, when present and unless stated otherwise, is hydrogen, deuterium, fluoro, cyclopropyl, cyclobutyl, cyclopropyloxy, cyclobutyloxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxy, cyano, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, methylcarbonylamino, ethylcarbonylamino, phenyl, pyrazolyl, thiazolyl, furanyl, pyridinyl, pyrrolidinyl, 2-oxopyrrolidinyl, piperidinyl, piperazinyl, or tetrahydrofuranyl, where each ring of R^h is substituted with R⁷ and R⁸ independently selected from hydrogen, deuterium, methyl, methoxy, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethyl, hydroxy, amino, methylamino, dimethylamino and cyano, unless stated otherwise.

Al 34. In embodiment Al 34, the compound of any one of embodiments Al to Al 08, Al l i to Al 15, and A125 to 133, or a pharmaceutically acceptable salt thereof, is wherein R^g and R¹ of branched C4 to Ce alkylene of alk, unless stated otherwise, are hydrogen or fluoro and R^h of branched C4 to Ce alkylene of alk, unless stated otherwise, is hydrogen, fluoro, hydroxy, methoxy, cyano, pyrazolyl- 1-yl, or methylaminocarbonyl.

A135. In embodiment Al 35, the compound of any one of embodiments Al to Al 08 and Al 14, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^h and R¹ are attached to the same carbon atom or to adjacent carbon atoms of the linear portion of the C3 to Ce alkylene and R^h and R¹ together with the carbon atom(s) to which they are attached can form cycloalkylene or heterocyclylene where the cycloalkylene and heterocyclylene formed by R^h and R¹ are substituted with R⁹ and R¹⁰.

A136. In embodiment A136, the compound of any one of embodiments Al to A108, Al 14, and A135, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^h and R¹ are attached to the same carbon atom of the linear portion of C3 to Ce alkylene and together with the carbon atom to which they are attached can form cycloalkylene substituted with R⁹ and R¹⁰.

A137. In embodiment A137, the compound of any one of embodiments Al to A108, Al 14, and A135, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^h and R¹ are attached to the same carbon atom of the linear portion of the C3 to Ce alkylene and together with the carbon atom to which they are attached can form heterocyclylene substituted with R⁹ and R¹⁰.

A138. In embodiment A138, the compound of any one of embodiments Al to A108, Al 14 and A135, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^h and R¹ are attached to adjacent carbon atoms of the linear portion of the C3 to Ce alkylene and together with the carbon atoms to which they are attached can form cycloalkylene substituted with R⁹ and R¹⁰.

A139. In embodiment A139, the compound of any one of embodiments Al to A108, Al 14, and A135, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^h and R¹ are attached to adjacent same carbon atoms of the linear portion of the C3 to Ce alkylene and together with the carbon atoms to which they are attached can form heterocyclylene substituted with R⁹ and R¹⁰. In an embodiment of A139, R^h and R¹ are attached to adjacent same carbon atoms of the linear portion of the C3 to Ce alkylene and together with the carbon atoms to which they are attached form heterocyclylene substituted with R⁹ and R¹⁰.

A140. In embodiment A140, the compound of any one of embodiments Al to A108, Al 14, and A135 to A137, or a pharmaceutically acceptable salt thereof, is wherein R^h and R¹ are attached to the same carbon atom of the linear portion C3 to Ce alkylene and together with the carbon atom to which they are attached can form cycloalkylene of formula: or heterocyclylene of formula: where each ring is substituted with R⁹ and R¹⁰, in one embodiment R⁹ is hydrogen, halo, methyl or ethyl and R¹⁰ is hydrogen. In an embodiment of A140, R^h and R¹ form cycloalkylene or heterocycloalkylene as provided above.

A141. In embodiment A141, the compound of any one of embodiments Al to A108, Al 14, A135, A138, and A139, or a pharmaceutically acceptable salt thereof, is wherein R^h and R¹ are attached to adjacent carbon atoms of the linear portion of the C3 to Ce alkylene and together with the carbon atoms to which they are attached can form cycloalkylene of formula: or heterocyclylene of formula: where each ring is substituted with R⁹ and R¹⁰, (in one subembodiment R⁹ is hydrogen, halo, methyl or ethyl and R¹⁰ is hydrogen).

A142. In embodiment A142, the compound of any one of embodiments Al to A108, or a pharmaceutically acceptable salt thereof, is wherein the alk is C3 to Ce heteroalkylene substituted with R^g, R^h, and R¹.

A143. In embodiment A143, the compound of any one of embodiments Al to A108 and A142, or a pharmaceutically acceptable salt thereof, is wherein the alk is C3 to Ce heteroalkylene substituted with R^g, R^h, and R¹ where R^g, R^h, and R¹ are hydrogen.

A144. In embodiment A144, the compound of any one of embodiments Al to A108 and A142, or a pharmaceutically acceptable salt thereof, is wherein the alk is C3 to Ce heteroalkylene substituted with R^g, R^h, and R¹ where R^g, R^h, and R¹ are hydrogen or halo, provided at least one of R^g, R^h, and R¹ is halo.

A145. In embodiment A145, the compound of any one of embodiments Al to A108 and A142, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce heteroalkylene substituted with R^g, R^h, and R¹ where R^h is other than hydrogen and R¹ is hydrogen, or when R^h and R¹ are attached to the same carbon atom or to adjacent carbon atoms of the linear portion of the C3 to Ce heteroalkylene, R^h and R¹ together with the carbon atom to which they are attached can form cycloalkylene or heterocyclylene where the cycloalkylene and heterocyclylene are substituted with R⁹ and R¹⁰. In an embodiment of A145, R^h and R¹ together with the carbon atom to which they are attached form cycloalkylene or heterocyclylene where the cycloalkylene and heterocyclylene are substituted with R⁹ and R¹⁰.

A146. In embodiment A146, the compound of any one of embodiments Al to A108, A142, and A145, or a pharmaceutically acceptable salt thereof, is wherein R^h and R¹ are attached to the same carbon atom of the linear portion of the C3 to Ce heteroalkylene and together with the carbon atom to which they are attached can form cycloalkylene of formula: or heterocyclylene of formula: where each ring is substituted with R⁹ and R¹⁰, preferably R⁹ is hydrogen, halo, methyl or ethyl and R¹⁰ is hydrogen. In an embodiment of A146, R^h and R¹ form cycloalkylene or heterocycloalkylene as provided above.

A147. In embodiment A147, the compound of any one of embodiments Al to A108, A142, and A145, or a pharmaceutically acceptable salt thereof, is wherein R^h and R¹ are attached to adjacent carbon atoms of the linear portion of the C3 to Ce heteroalkylene and together with the carbon atoms to which they are attached can form cycloalkylene of formula: or heterocyclylene of formula: where each ring is substituted with R¹¹ and R¹², preferably R¹¹ is hydrogen, halo, methyl or ethyl and R¹² is hydrogen. In an embodiment of A147, R^h and R¹ form cycloalkylene or heterocycloalkylene as provided above. A148. In embodiment A148, the compound of any one of embodiments Al to A108, and A145, or a pharmaceutically acceptable salt thereof, is wherein alk is C3 to Ce heteroalkylene substituted with R^g, R^h, and R¹ where R^h is other than hydrogen and R¹ is hydrogen unless otherwise stated.

A149. In embodiment A149, the compound of any one of embodiments Al to A108 and A142 to A148, or a pharmaceutically acceptable salt thereof, is wherein the C3 to Ce heteroalkylene of alk is linear C3 to Ce heteroalkylene substituted with R^g, R^h, and R¹.

Al 50. In embodiment Al 50, the compound of any one of embodiments Al to Al 08 and A142 to A149, or a pharmaceutically acceptable salt thereof, is wherein the linear heteroalkylene of alk is -CH2CH₂X^aCH2-, -CH2X^aCH₂CH2-, -CH₂CH₂CH₂X^a-, -X^aCH2CH₂CH2-, -X^aCH₂CH2-, -CH2X^aCH2-, or -CH2CH2X^a-, where R^g, R^h, and R¹ are hydrogen and X^a is -NR^q-, -O-, or -CO-.

A151. In embodiment Al 51, the compound of any one of embodiments Al to Al 08 and A142 to Al 50, or a pharmaceutically acceptable salt thereof, is wherein R^q is hydrogen, methyl, ethyl, methylcarbonyl, or methyl sulfonyl.

Al 52. In embodiment Al 52, the compound of any one of embodiments Al to Al 08 and A142, A143, and A149 to A151, or a pharmaceutically acceptable salt thereof, is wherein the linear C3 to Ce heteroalkylene of alk is -CH₂CH₂CH₂X^a- or -CJbCJbX³ where R^g, R^h, and R¹ are hydrogen.

A153. In embodiment A153, the compound of any one of embodiments Al to A108 and A142, A145, A148, A149, and A151, or a pharmaceutically acceptable salt thereof, is wherein R^g of linear C3 to Ce heteroalkylene of alk is hydrogen or halo (unless stated otherwise) and R^h of linear heteroalkylene of alk is (unless stated otherwise) hydrogen, halo, haloalkoxy, cycloalkyl, cycloalkyloxy, alkoxy, hydroxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, cyano, cyanoalkyloxy, phenyl, heteroaryl, heterocyclyl, or bridged heterocyclyl, where each ring is substituted as defined therein, and R¹ is hydrogen.

Al 54. In embodiment Al 54, the compound of any one of embodiments Al to Al 08 and A142, A145, A148, A149, A151, and A153, or a pharmaceutically acceptable salt thereof, is wherein R^g of linear C3 to Ce heteroalkylene of alk is hydrogen or fluoro (unless stated otherwise) and R^h of linear heteroalkylene of alk (unless stated otherwise) is hydrogen, halo, haloalkoxy, alkoxy, hydroxy, dialkylaminocarbonyl, cyano, or heteroaryl substituted as defined therein.

A155. In embodiment A155, the compound of any one of embodiments Al to A108 and A142, A145, A148, A149, A151, A153, and A154, or a pharmaceutically acceptable salt thereof, is wherein the heteroaryl, heterocyclyl, and bridged heterocyclyl of R^h of linear C3 to Ce heteroalkylene of alk, when present, are five or six membered ring and each ring is substituted as defined therein.

Al 56. In embodiment Al 56, the compound of any one of embodiments Al to Al 08 and A142, A145, A148, A149, A151, and A153 to A155, or a pharmaceutically acceptable salt thereof, is wherein R^g of linear heteroalkylene of alk, unless stated otherwise, is hydrogen, deuterium, or fluoro, and R^h of linear heteroalkylene of alk, unless stated otherwise, is hydrogen, deuterium, fluoro, cyclopropyl, cyclobutyl, cyclopropyloxy, cyclobutyloxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxy, cyano, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, methylcarbonylamino, ethylcarbonylamino, phenyl, pyrazolyl, thiazolyl, furanyl, pyridinyl, pyrrolidinyl, 2-oxopyrrolidinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, where each ring is substituted with R⁷ and R⁸ independently selected from hydrogen, deuterium, methyl, methoxy, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethyl, hydroxy, amino, methylamino, dimethylamino, and cyano.

Al 57. In embodiment Al 57, the compound of any one of embodiments Al to Al 08 and A142, A145, A148, A149, A151, and A153 to A156, or a pharmaceutically acceptable salt thereof, is wherein R^g of linear C3 to Ce heteroalkylene of alk is hydrogen and R^h of linear C3 to Ce heteroalkylene of alk, unless stated otherwise, is fluoro, cyclopropyl, cyclopropyloxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxy, cyano, methylaminocarbonyl, dimethylaminocarbonyl, methylcarbonylamino, phenyl, pyrazol-l-yl, pyrrazol-4-yl, pyridin-4-yl, pyrrolidin-l-yl, 2-oxopyrrolidin-l-yl, where each ring is substituted with R⁷ and R⁸ independently selected from hydrogen, deuterium, methyl, or fluoro.

A158. In embodiment A158, the compound of any one of embodiments Al to A108 and A142 to Al 57, or a pharmaceutically acceptable salt thereof, is wherein X^a is -NR^q- where R^q is hydrogen or methyl.

Al 59. In embodiment Al 59, the compound of any one of embodiments Al to 108 and A142 to A148, or a pharmaceutically acceptable salt thereof, is wherein the C3 to Ce heteroalkylene of alk is branched C4 to Ce heteroalkylene.

Al 60. In embodiment Al 60, the compound of any one of embodiments Al to Al 08 and A142 to A148, and Al 50 to Al 59, or a pharmaceutically acceptable salt thereof, is wherein the branched C3 to Ce heteroalkylene of alk is -CH2X^aCH(CH3)CH2-, -X^aCH(CH3)CH2CH2-, -CH(CH3)CH₂X^a-, -X^aCH(CH₃)CH₂-, -X^aCH(CH₂R^h)CH2-, -X^aCH(CH2CH₂R^h)CH2-, -X^aC(CH₃)(CH₃)CH2-, -CH(CH2R^h)CH₂X^a-, -CH(CH2CH2R^h)CH₂X^a-, -C(CH₃)(CH₃)CH2X^a-, -CH2CH(CH₂R^h)X^a-, -CH2CH(CH2CH₂R^h)X^a-, -CH2C(CH₃)(CH₃)X^a-, -CH₂NR^qCOCH(CH₃)CH2-, or -NR^qCOCH(CH₃)CH₂- where X^a is -NR^q-, -O-, or -CO-. (For sake of clarity, each of R^g, R^h, and R¹ is hydrogen if it is not specifically recited in any of the above groups).

A161. In embodiment A161, the compound of any one of embodiments Al to Al 08, A142 to A145, A148, Al 59, and A160, or a pharmaceutically acceptable salt thereof, is wherein the branched C4 to Ce heteroalkylene of alk is -X^aCH(CH2CH2R^h)CH2-, or -X^aCH(CH2R^h)CH2. (For sake of clarity, each of R^g and R¹ is hydrogen).

Al 62. In embodiment Al 62, the compound of any one of embodiments Al to Al 08, A142 to A145, A148, and A159 to A161, or a pharmaceutically acceptable salt thereof, is wherein the R^g and R¹ of branched C4 to Ce heteroalkylene of alk are hydrogen or halo (unless stated otherwise) and R^h of branched C4 to Ce heteroalkylene of alk is (unless stated otherwise) hydrogen, halo, haloalkoxy, cycloalkyl, cycloalkyloxy, alkoxy, hydroxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, cyano, cyanoalkyloxy, phenyl, heteroaryl, heterocyclyl, heterocyclyloxy, heterocyclylcarbonyl, or bridged heterocyclyl substituted as defined therein.

A163. In embodiment A163, the compound of any one of embodiments Al to A108, A142 to A145, A148, and A159 to A162,or a pharmaceutically acceptable salt thereof, is wherein the R^g and R¹ of branched C4 to Ce heteroalkylene of alk are hydrogen or fluoro (unless stated otherwise) and R^h (unless stated otherwise) is hydrogen, halo, cycloalkyl, cycloalkyloxy, alkoxy, hydroxy, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, cyano, phenyl, heteroaryl, heterocyclyl, heterocyclyloxy, heterocyclylcarbonyl, or bridged heterocyclyl, substituted as defined therein.

Al 64. In embodiment Al 64, the compound of any one of embodiments Al to Al 08, A142 to A145, A148, and A159 to A163, or a pharmaceutically acceptable salt thereof, is wherein R^g and R¹ are hydrogen and R^h is (unless stated otherwise) hydrogen, heteroaryl, alkylaminocarbonyl, or cyano.

Al 65. In embodiment Al 65, the compound of any one of embodiments Al to Al 08, A142 to A145, A148, and A159 to A164, or a pharmaceutically acceptable salt thereof, is wherein the heteroaryl, heterocyclyl of branched C4 to Ce heteroalkylene of alk, by itself or as part of heterocyclyloxy or heterocyclylcarbonyl, and bridged heterocyclyl, when present, are five or six membered ring and each ring is substituted as defined therein.

Al 66. In embodiment Al 66, the compound of any one of embodiments Al to Al 08, A142 to A145, A148, and A159 to A165, or a pharmaceutically acceptable salt thereof, is wherein R^h of branched C4 to Ce heteroalkylene of alk, unless stated otherwise, is hydrogen, deuterium, fluoro, cyclopropyl, cyclobutyl, cyclopropyloxy, cyclobutyloxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxy, cyano, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, diethylaminocarbonyl, methylcarbonylamino, ethylcarbonylamino, phenyl, pyrazolyl, thiazolyl, furanyl, pyrrolidinyl, pyridinyl, piperidinyl, piperazinyl, or tetrahydrofuranyl, where each ring is substituted with R⁷ and R⁸ independently selected from hydrogen, deuterium, methyl, methoxy, fluoro, difluoromethyl, trifluoromethyl, difluoromethoxy, trifluoromethyl, hydroxy, amino, methylamino, dimethylamino and cyano.

A167. In embodiment A167, the compound of any one of embodiments A108, A142 to A148, and A159 to A166, or a pharmaceutically acceptable salt thereof, is wherein X^a is -NR^q- where R^q is hydrogen or methyl. A168. In embodiment A168, the compound of any one of embodiments A108, A142 to

A148, and A159 to A166, or a pharmaceutically acceptable salt thereof, is wherein X^a is -O-.

Al 69. In embodiment Al 69, the compound of any one of embodiments Al to Al 68, or a pharmaceutically acceptable salt thereof, is wherein alk is:

Al 70. In embodiment Al 70, the compound of any one of embodiments Al to Al 69, or a pharmaceutically acceptable salt thereof, is wherein alk is:

A171. In embodiment A171, the compound of any one of embodiments Al to A108, or a pharmaceutically acceptable salt thereof, is wherein alk is alkynylene substituted with R¹ and R^k independently selected from hydrogen, halo, haloalkyl, alkoxy, hydroxy, and cyano. A172. In embodiment A172, the compound of any one of embodiments Al to A108 and

A171, or a pharmaceutically acceptable salt thereof, is wherein alk is alkynylene substituted with R> and R^k where R¹ is hydrogen and R^k is selected from hydrogen, fluoro, difluoromethyl, trifluoromethyl, hydroxy, methoxy, and cyano. A173. In embodiment A173, the compound of any one of embodiments Al to A108, or a pharmaceutically acceptable salt thereof, is wherein alk is alkynylene substituted with R> and R^k which are attached to the same carbon atom of the alkynylene and are combined with the carbon to which they are attached to form cycloalkylene or heterocyclylene wherein the cycloalkylene and heterocyclylene are substituted with R¹¹ and R¹² independently selected from hydrogen, alkyl, and halo.

A174. In embodiment A174, the compound of any one of embodiments Al to A108 and

A171 to A173, or a pharmaceutically acceptable salt thereof, is wherein the alkynylene of alk is:

A175. In embodiment A175, the compound of any one of embodiments Al to A43, A45, A46, A48 to A56, A58 to A72, A75, A77 to A82, A83 to A93, and A96 to A174, or a pharmaceutically acceptable salt thereof, is wherein Degron is the E3 ubiquitin ligase ligand selected from:

where R^ee is hydrogen, methyl, ethyl, cyclopropyl, or 2,2,2-trifluoroethyl and R^ff is hydrogen, methyl, cyclopropyl, fluoro, cyano, methoxy, difluoromethoxy, trifluoromethoxy, or trifluoromethyl unless stated otherwise.

A176. In embodiment A176, the compound of any one of embodiments Al to A43, A45, A46, A48 to A56, A58 to A72, A75, A77 to A82, A83 to A93, and A96 to A175, or a pharmaceutically acceptable salt thereof, is wherein Degron is the E3 ubiquitin ligase ligand selected from: where R^ee is hydrogen, methyl, ethyl, cyclopropyl, or 2,2,2-trifluoroethyl and R^ff is hydrogen, methyl, cyclopropyl, fluoro, cyano, methoxy, difluoromethoxy, trifluoromethoxy, or trifluoromethyl unless stated otherwise.

A177. In embodiment A177, the compound of any one of embodiments Al to A43, A45, A46, A48 to A56, A58 to A67 to A72, A77, A79 to A82, A83 to A87, A89, and A97 to A176, or a pharmaceutically acceptable salt thereof, is wherein Degron is the E3 ligase ligand selected from: unless stated otherwise.

A178. In embodiment A178, the compound of any one of embodiments Al to A39b, A67, A69 to A72, A77, A79 to A82, A83 to A87, A89 to A93, and A97 to A176, or a pharmaceutically acceptable salt thereof, is wherein Degron is the E3 ubiquitin ligase ligand i (i.e. R^ff is hydrogen) where each R^ee is hydrogen, methyl, ethyl, cyclopropyl, or 2,2,2-trifluoroethyl, preferably methyl.

A179. In embodiment A179, the compound of any one of embodiments Al to A39b, A41 to A68, A70 to A72, A77, and A79 to A82A, A84 to A93, and A96 to A174, or a pharmaceutically acceptable salt thereof, is wherein Degron is the E3 ubiquitin ligase ligand is hydrogen, methyl, ethyl, cyclopropyl, or 2,2,2-trifluoroethyl and R^ff is hydrogen, methyl, cyclopropyl, fluoro, cyano, methoxy, difluoromethoxy, trifluoromethoxy, or trifluoromethyl. A180. In embodiment A180, the compound of embodiment A179, or a pharmaceutically acceptable salt thereof, is wherein Degron is the E3 ubiquitin ligase ligand is Regardless of whether the phrase “unless stated otherwise” is used in the above embodiments, when an embodiment refers to more than one preceding embodiment of varying scopes, only those groups that fall within the scope of group(s) recited in a preceding embodiment s) should be selected from the embodiment referring thereto. For example, of the groups recited in embodiment A6, while all the recited groups in A6 should be selected for embodiment Al, only fluoro, chloro, and bromo should be selected for embodiment A2 as scope of A2 is limited to halo; and only difluoromethyl, trifluoromethyl, difluoroethyl, and trifluoroethyl should be selected for embodiment A4 as scope of A4 is limited to haloalkyl.

Representative compounds of first aspect and Formula (I) are shown in Compound Table 1 below:

Table 1

Contemplated compounds are disclosed in Table 2 below:

Table 2

General Synthetic Scheme

Compounds Formula (I) (and any embodiment thereof disclosed herein including specific compounds) can be made by the methods depicted in the reaction schemes shown below.

The starting materials and reagents used in preparing these compounds are either available from commercial suppliers such as Aldrich Chemical Co., (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser’s Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd’s Chemistry of Carbon Compounds, Volumes 1-5 and Suppiementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March’s Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition) and Larock’s Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some methods by which the compounds Formula (I) (and any embodiment thereof disclosed herein including specific compounds) can be synthesized, and various modifications to these schemes can be made and will be suggested to one skilled in the art reading this disclosure. The starting materials and the intermediates, and the final products of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.

Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a temperature range from about -78 °C to about 150 °C, such as from about 0 °C to about 125 °C and further such as at about room (or ambient) temperature, e.g., about 20 °C.

Compounds of Formula (I), where Degron is an E3 ligase ligand of formula (i) and (ii) and Hy, R¹, R², R^2a, alk, and Z are as defined in the Summary or an embodiment thereof hereinabove, can be prepared as described in Scheme 1. Scheme 1

Treatment of a pyrimidine of formula 1-2 where A¹ is a halogen such as chlorine or bromine and R¹, R², and R^2a are as defined in the Summary, with an amine of formula 1-1 where Degron, Hy, alk, and Z are as defined in the Summary or an embodiment thereof hereinabove, under suitable conditions such as acidic, basic, or transition metal catalyzed reaction conditions well known in the art, provides a compound of Formula (I).

Alternatively, a compound of Formula (I) such as where R^2a is hydrogen, Hy is 1,4-piperidindiyl, Degron is a group of formula (i), alk is as defined in the Summary and Z is heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene containing at least one nitrogen ring atom, can be synthesized as illustrated and described in Scheme 2.

Scheme 2

Treatment of a pyrimidine of formula 2-1 where A¹ is a halogen such as chlorine or bromine and R¹ and R² are defined in the Summary or an embodiment thereof hereinabove, with a piperidine amine of formula 2-2 under conditions well known in the art, such as in the presence of DIPEA in tert-butanol at elevated temperature, provides a compound of formula 2-3. An amine compound of formula 2-4, prepared by removal of the Boc protecting group of 2-3 in the presence of an acid, such as TFA, is converted to a sulfonamide compound of formula 2-6 by treating it with a sulfonyl halide of formula 2-5 where A² is halogen such as chlorine and LG is a suitable leaving group such as halo or methylsulfonyl and alk is as defined in the Summary or an embodiment thereof hereinabove. Treatment of a compound of formula 2-6 with an amine compound of formula 2-7 where is heterocyclyl, bridged heterocyclyl or spiro heterocyclyl containing at least one nitrogen atom and ring A is defined as in the Summary or an embodiment thereof hereinabove, under basic conditions such as in the presence of DIPEA, provides a compound of Formula (I).

Compounds of formula 2-1, 2-5, and 2-7 are either commercially available or they can be prepared by methods known in the art.

Alternatively, a compound of Formula (I) such as where R^2a is hydrogen, Degron is a group of formula (i) and alk is attached to Degron of formula (i) via heterocyclylene such as 4-piperidin-l-yl, can be synthesized as illustrated and described in Scheme 3.

Scheme 3

Cross coupling of a compound of formula 3-1, where A¹ is a halogen and ring A as defined in the Summary or an embodiment thereof hereinabove, with a tetrahydropiperidinyl of formula 3-2 where M is a metal, such as boronic ester or zinc, provides a compound of formula 3-3. The reaction typically proceeds in the presence of a palladium catalyst; for example, when M is a boronic ester, a Suzuki reaction is conducted in the presence of Pd(dppf)C12 and Na2COs, in 1,4-di oxane and water.

Reduction of the double bond in compound 3-3 under conditions well known in the art, such as in the presence of a palladium catalyst and under hydrogen atmosphere, provides compound of formula 3-4. Removal of the Boc protection group of 3-4 under acidic conditions provides an amine compound of formula 3-5. Reaction of 3-5 with an aldehyde of formula 3-6 where Hy is as defined in the Summary or an embodiment thereof hereinabove and -CHO-(alk¹)n- 1 is a precursor to alk as defined in the Summary or an embodiment thereof hereinabove, under reductive amination conditions well known in the art such as in the presence of a reducing agent, such as NaBH(OAc)s, in a suitable solvent, such as DCM, provides compound of formula 3-7 where Hy is as defined in the Summary or an embodiment thereof hereinabove and -CH2-(alk¹)n-l is alk as defined in the Summary or an embodiment thereof.

Removal of the Boc protecting group in compound 3-7 using an acid like TFA provides an amine compound of formula 3-8. Treatment of compound 3-8 with a compound of formula 2-1 under suitable conditions such as acidic, basic or transition metal catalyzed reaction conditions well known in the art, provides a compound of Formula (I).

Utility

The compound of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) could cause degradation of CDK2 and/or CDK4 proteins and hence are useful in the treatment of diseases mediated by CDK2 and/or CDK4.

Increasing evidence suggests that overactivated CDK2 and/or CDK4 leads to abnormal cell cycle regulation and proliferation in cancer cells. While CDK2/4 mutations are rarely found, the kinase activity of CDK4/Cyclin D, CDK2/Cyclin E or CDK2/Cyclin A complexes is elevated via several mechanisms in human cancers. Aberrations of CDK4/cyclin D regulation have been identified in many human cancers. For example, amplification or overexpression of cyclin DI has been found in many cancers, including breast invasive ductal carcinoma, invasive breast carcinoma, bladder urothelial carcinoma, breast invasive lobular carcinoma, and lung adenocarcinoma. Translocation of cyclin DI Amplification of CDK4 is common in liposarcoma. CDK4 amplification has also been observed at lower frequency in other solid tumors and hematologic malignancies. Loss of the CDK4 inhibitor pl6 (CDKN2A) is also a common event in many cancers, including glioblastoma multiforme, head and neck squamous cell carcinoma, pancreatic adenocarcinoma, esophageal adenocarcinoma, mesothelioma, lung squamous cell carcinoma, bladder urothelial carcinoma, skin cutaneous melanoma, diffuse large B-cell lymphoma, cholangiocarcinoma, lung adenocarcinoma, and stomach adenocarcinoma.

Cyclin E has been found to be frequently amplified in cancers, for example, in uterine cancer, ovarian cancer, stomach cancer, and breast cancer. In some cancer types, loss-of-function mutations in FBXW7 or overexpression of USP28, which control the turnover of cyclin E, leads to cyclin E overexpression and CDK2 activation. Alternatively, certain cancer cells express a hyperactive, truncated form of cyclin E or cyclin A. In addition, cyclin A amplification and overexpression have also been reported in various cancers such as hepatocellular carcinomas, colorectal and breast cancers. In some tumors, catalytic activity of CDK2 is increased following loss of the expression or alteration of the location of the endogenous CDK2 inhibitor p27 or p21, or overexpression of SKP2, a negative regulator of p27. In addition, CDC25A and CDC25B, protein phosphatases responsible for the dephosphorylations that activate the CDK2, are overexpressed in various tumors. These various mechanisms of CDK2 activation have been validated using cancer cells or mouse cancer models. Furthermore, CDK2/cyclin E phosphorylates oncogenic Myc to oppose ras-induced senescence, highlighting the importance of CDK2 in myc/ras-induced tumorigenesis. Inactivation of CDK2 has been shown to be synthetically lethal to myc over-expressing cancer cells. In aneuploid cancer cells, for example KRAS-mutant lung cancer, CDK2 inhibition resulted in anaphase catastrophe and apoptosis. Moreover, inhibiting CDK2 effectively induced granulocytic differentiation in AML cell lines and arrested tumor growth in AML mice models.

CDK2 activation as a result of cyclin E amplification or overexpression has also been identified as a key primary or acquired resistance pathway to HR+ or HER2+ breast cancers treated by CDK4/6 inhibitors or trastuzumab. Accordingly, compounds of Formula (I) can be used in combination with CDK4/6 inhibitors or anti-HER2 therapies for the treatment of cancers that become refractory to CDK4/6 inhibitors or anti-HER2 therapies.

Therefore, a compound of this disclosure may be useful for treating tumors characterized by 1) overexpression of CDK2 and/or CDK4; 2) amplification /overexpression of cyclin D, cyclin E or cyclin A; 3) hyperphosphorylation of CDK2 (Thrl60) or CDK4 (Thrl72); 4) loss-of-function of mutation in FBXW7, depletion of AMBRA1, overexpression of USP28, or amplification/overexpression of CDC25A or/and CDC25B; 5) expression of truncated cyclin E or cyclin A, 6) dysregulation of pl 6, p21 or p27, or overexpression of SKP2;and 7) hyperactive MYC/RAS; 8) Aneuploid cancers, and 9) CDK4 and/or CDK6 inhibitor refractory cancers.

In some embodiments, the cancer is ovarian cancer (e.g. serous, clear cell, endometrioid, and mucinous ovarian carcinomas), uterine cancer (e.g. endometrial cancer and uterine sarcoma), stomach cancer (i.e. gastric cancer), lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, parvicellular and non-parvicellular carcinoma, bronchial carcinoma, bronchial adenoma, pleuropulmonary blastoma), renal cancer (e.g. clear cell renal cell carcinomas, papillary renal cell carcinomas, and chromophobe renal cell carcinomas), brain cancer (including astrocytoma, meningioma and glioblastoma), neuroblastoma, paraganglioma, pheochromocytoma, pancreatic neuroendocrine tumors, somatostatinomas, hemangioblastomas, gastrointestinal stromal tumors, pituitary tumors, leiomyomas, leiomyosarcomas, polycythaemia, retinal cancers, hereditary leiomyomatosis, renal cell cancer, astrocytoma, skin cancer (e.g. melanoma, squamous cell carcinoma, Kaposi sarcoma, Merkel cell skin cancer), bladder cancer (including bladder urothelial carcinoma), cervical cancer, colorectal cancer (e.g., cancer of the small intestine, colon cancer, rectal cancer, cancer of the anus), head and neck cancer (e.g., cancers of the larynx, hypopharynx, nasopharynx, oropharynx, lips, tongue and mouth), liver cancer (e.g., hepatocellular carcinoma and cholangiocellular carcinoma), prostate cancer, testicular cancer, gall bladder cancer, pancreatic cancer (e.g. exocrine pancreatic carcinoma and neuroendocrine pancreatic cancer), thyroid cancer, and parathyroid cancer, fallopian tube cancer, peritoneal cancer, vaginal cancer, biliary tract cancer, esophageal cancer (e.g. esophageal squamous cell carcinoma and esophageal adenocarcinoma), sarcoma (e.g. liposarcoma and osteosarcoma), bone cancer, chondrosarcoma, leukemia (including acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, and chronic lymphocytic leukemia), lymphoma (e.g. non-Hodgkin lymphoma NHL including mantel cell lymphoma, MCL and Hodgkin lymphoma) and multiple myeloma.

In other embodiments, the cancer is breast cancer, including, e.g., ER-positive/HR-positive breast cancer, HER2-negative breast cancer; ER-positive/HR-positive breast cancer, HER2- positive breast cancer; ER-negative/HR-negative, HER2-positive breast cancer, triple negative breast cancer (TNBC); or inflammatory breast cancer. In some embodiments, the breast cancer is endocrine resistant breast cancer, anti-HER2 therapy (e.g. trastuzumab) resistant breast cancer, or breast cancer demonstrating primary or acquired resistance to CDK4/CDK6 inhibition. In some embodiments, the breast cancer is advanced or metastatic breast cancer. In some embodiments of each of the foregoing, the breast cancer is characterized by amplification or overexpression of CCNE1 and/or CCNE2.

Besides cancer, compounds of Formula (I) as described in the Summary as described in the first aspect (or any of the embodiments thereof herein above) are useful in treating autoimmune diseases autoimmune diseases e.g., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), primary Sjogren’s syndrome (pSS), multiple sclerosis (MS), Crohn’s disease (CD), gout, uveitis, pemphigus vulgaris, and sepsis, and can also be used as a promising preventive treatment for noise-, cisplatin-, or antibiotic-induced or age-related hearing loss.

Testing

CDK2/4 potency and CDK2/4 degradation activities of the compounds of the present disclosure can be tested using the in vitro assays described in Biological Examples below. Pharmaceutical Compositions

In general, the compounds Formula (I) (unless stated otherwise, reference to compound/compounds of Formula (I) herein includes any embodiments thereof described herein or a pharmaceutically acceptable salt thereof) will be administered in a therapeutically effective amount by any of the accepted modes of administration for agents that serve similar utilities. Therapeutically effective amounts of compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may range from about 0.01 to about 500 mg per kg patient body weight per day, which can be administered in single or multiple doses. A suitable dosage level may be from about 0.1 to about 250 mg/kg per day; about 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to about 250 mg/kg per day, about 0.05 to about 100 mg/kg per day, or about 0.1 to about 50 mg/kg per day. Within this range the dosage can be about 0.05 to about 0.5, about 0.5 to about 5 or about 5 to about 50 mg/kg per day. For oral administration, the compositions can be provided in the form of tablets containing about 1.0 to about 1000 milligrams of the active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900, and 1000 milligrams of the active ingredient. The actual amount of the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds), i.e., the active ingredient, will depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the patient, the potency of the compound being utilized, the route and form of administration, and other factors.

In general, compounds Formula (I) (and any embodiment thereof disclosed herein including specific compounds) will be administered as pharmaceutical compositions by any one of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous) administration. The preferred manner of administration is oral using a convenient daily dosage regimen, which can be adjusted according to the degree of affliction. Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixirs, aerosols, or any other appropriate compositions.

The choice of formulation depends on various factors such as the mode of drug administration (e.g., for oral administration, formulations in the form of tablets, pills or capsules, including enteric coated or delayed release tablets, pills or capsules are preferred) and the bioavailability of the drug substance.

The compositions are comprised of in general, a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are generally non-toxic, aid administration, and do not adversely affect the therapeutic benefit of the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds). Such excipient may be any solid, liquid, semi-solid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.

Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liquid and semisolid excipients may be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose, and glycols.

The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi -dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. In addition to the formulations described previously, the compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may also be formulated as a depot preparation. Such long -acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.

The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.

Certain compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may be administered topically, that is by non-systemic administration. This includes the application of a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.

For administration by inhalation, compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator. Other suitable pharmaceutical excipients and their formulations are described in Remington’s Pharmaceutical Sciences, edited by E. W. Martin (Mack Publishing Company, 20th ed., 2000).

The level of the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt. %) basis, from about 0.01-99.99 wt. % of a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. For example, the compound is present at a level of about 1-80 wt. %.

Combinations and Combination Therapies

The compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) may be used in combination with one or more other drugs in the treatment of diseases or conditions for which compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) or the other drugs may have utility. Such other drug(s) may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds). When a compound of Formula (I)(or any embodiment thereof disclosed herein including specific compounds) is used contemporaneously with one or more other drugs, a pharmaceutical composition in unit dosage form containing such other drugs and the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) is preferred. However, the combination therapy may also include therapies in which the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present disclosure also include those that contain one or more other drugs, in addition to a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds).

The above combinations include combinations of a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) not only with one other drug, but also with two or more other active drugs. Likewise, a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) may be used in combination with other drugs that are used in the prevention, treatment, control, amelioration, or reduction of risk of the diseases or conditions for which a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) is useful. Such other drugs may be administered, by a route and in an amount commonly used therefore, contemporaneously or sequentially with a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds). When a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) can be used. Accordingly, the pharmaceutical compositions of the present disclosure also include those that also contain one or more other active ingredients, in addition to a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds). The weight ratio of the compound of this disclosure to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.

Where the subject in need is suffering from or at risk of suffering from cancer, the subject can be treated with a compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) in any combination with one or more other anti -cancer agents including but not limited to: MAP kinase pathway (RAS/RAF/MEK/ERK) inhibitors including but not limited to: Vemurafanib (PLX4032), Dabrafenib, Encorafenib (LGX818), TQ-B3233, XL-518 (CAS No. 1029872-29-4, available from ACC Corp); trametinib, selumetinib (AZD6244), TQ-B3234, PD184352, PD325901, TAK-733, pimasertinib, binimetinib, refametinib, cobimetinib (GDC-0973), AZD8330, BVD-523, LTT462, Ulixertinib, AMG510, ARS853, and any RAS inhibitors disclosed in patents WO2016049565, WO2016164675, WO2016168540, WO2017015562, WO2017058728, WO2017058768, WO2017058792, W02017058805,W02017058807, W02017058902, WO2017058915, W02017070256, WO20 17087528, WO2017100546, WO2017172979, W02017201161, WO2018064510, W02018068017, WO2018119183;

CSF1R inhibitors (PLX3397, LY3022855, etc.) and CSF1R antibodies (IMC-054, RG7155) TGF beta receptor kinase inhibitor such as LY2157299;

BTK inhibitor such as ibrutinib; BCR-ABL inhibitors: Imatinib (Gleevec®); Inilotinib hydrochloride; Nilotinib (Tasigna®); Dasatinib (BMS-345825); Bosutinib (SKI-606); Ponatinib (AP24534); Bafetinib (INNO406); Danusertib (PHA-739358), AT9283 (CAS 1133385-83-7); Saracatinib (AZD0530); and N-[2-[(lS,4R)-6-[[4-cyclobutylarmno)-5-(trifluoromethyl)-2- pyrimidinyl]amino]-l, 2,3,4-tetrahydronaphthalen-l,4-imin-9-yl]-2-oxoethyl]-acetamide (PF-03814735, CAS 942487-16-3);

ALK inhibitors: PF-2341066 (XALKOPJ ®; crizotinib); 5-chloro-N4-(2- (isopropyl- sulfonyl)phenyl)-N2-(2-methoxy-4-(4-(4-methylpiper azin-l-yl)piperi din-1- yl)phenyl)pyrimidine- 2,4-diamine; GSK1838705 A; CH5424802; Ceritinib (ZYKADIA); TQ-B3139, TQ-B3101 PI3K inhibitors: 4-[2-(lH-indazol-4-yl)-6-[[4-(methylsulfonyl)piperazin-l- yl]methyl]thieno[3,2-d]- pyrimidin-4-yl]morholine (also known as GDC 0941 and described in PCT Publication Nos. WO 09/036082 and WO 09/055730), 2-methyl-2-[4-[3-methyl-2-oxo-8- (quinolin-3-yl)-2,3-dihydro- imidazo[4,5-c]quinolin-l-yl]phenyl]propionitrile (also known as BEZ 235 or NVP-BEZ 235, and described in PCT Publication No. WO 06/122806);

Vascular Endothelial Growth Factor (VEGF) receptor inhibitors: Bevacizumab (sold under the trademark Avastin® by Genentech/Roche), axitinib, (N-methyl-2-[[3-[(E)-2-pyridin-2- ylethenyl]-lH-indazol-6-yl]sulfanyl]benzamide, also known as AG013736, and described in PCT Publication No. WO 01/002369), Brivanib Alaninate ((S)-((R)-l-(4-(4-fluoro-2-methyl-lH-indol- 5-yloxy)-5-methylpyrrolo[2,l-f][l,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, also known as BMS-582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-lH-indol-6-yl)-2-[(4- pyridinyl- methyl)amino]-3-pyridinecarboxamide, and described in PCT Publication No. WO 02/066470), pasireotide (also known as SOM230, and described in PCT Publication No. WO 02/010192), sorafenib (sold under the tradename Nexavar®); AL-2846 MET inhibitor such as foretinib, carbozantinib, or crizotinib;

FLT3 inhibitors - sunitinib malate (sold under the tradename Sutent® by Pfizer); PKC412 (midostaurin); tanutinib, sorafenib, lestaurtinib, KW-2449, quizartinib (AC220) and crenolanib;

Epidermal growth factor receptor (EGFR) inhibitors: Gefitnib (sold under the tradename Iressa®), N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3"S")-tetrahydro-3-furanyl]oxy]-6- quinazolinyl]-4(dimethylamino)-2-butenamide, sold under the tradename Tovok® by Boehringer Ingelheim), cetuximab (sold under the tradename Erbitux® by Bristol-Myers Squibb), panitumumab (sold under the tradename Vectibix® by Amgen);

HER2 receptor inhibitors: Trastuzumab (sold under the trademark Herceptin® by Genentech/Roche), neratinib (also known as HKI-272, (2E)-N-[4-[[3-chloro-4-[(pyridin-2- yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide, and described PCT Publication No. WO 05/028443), lapatinib or lapatinib ditosylate (sold under the trademark Tykerb® by GlaxoSmithKline); Trastuzumab emtansine (in the United States, ado- trastuzumab emtansine, trade name Kadcyla) - an antibody-drug conjugate consisting of the monoclonal antibody trastuzumab (Herceptin) linked to the cytotoxic agent mertansine (DM1); Trastuzumab deruxtecan (trade name Enhertu);

HER dimerization inhibitors: Pertuzumab (sold under the trademark Omnitarg®, by Genentech);

CD20 antibodies: Rituximab (sold under the trademarks Riuxan® and Mab Thera® by Genentech/Roche), tositumomab (sold under the trademarks Bexxar® by GlaxoSmithKline), ofatumumab (sold under the trademark Arzerra® by GlaxoSmithKline);

Tyrosine kinase inhibitors: Erlotinib hydrochloride (sold under the trademark Tarceva® by Genentech/Roche), Linifanib (N-[4-(3-amino-lH-indazol-4-yl)phenyl]-N'-(2-fluoro-5- methylphenyl)urea, also known as ABT 869, available from Genentech), sunitinib malate (sold under the tradename Sutent® by Pfizer), bosutinib (4-[(2,4-dichloro-5-methoxyphenyl)amino]-6- methoxy-7-[3-(4-methylpiperazin-l-yl)propoxy]quinoline-3-carbonitrile, also known as SKI-606, and described in US Patent No. 6,780,996), dasatinib (sold under the tradename Sprycel® by Bristol-Myers Squibb), armala (also known as pazopanib, sold under the tradename Votrient® by GlaxoSmithKline), imatinib and imatinib mesylate (sold under the tradenames Gilvec® and Gleevec® by Novartis);

DNA Synthesis inhibitors: Capecitabine (sold under the trademark Xeloda® by Roche), gemcitabine hydrochloride (sold under the trademark Gemzar® by Eli Lilly and Company), nelarabine ((2R3S,4R,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, sold under the tradenames Arranon® and Atriance® by GlaxoSmithKline);

Antineoplastic agents: oxaliplatin (sold under the tradename Eloxatin® ay Sanofi -Aventis and described in US Patent No. 4,169,846);

Human Granulocyte colony-stimulating factor (G-CSF) modulators: Filgrastim (sold under the tradename Neupogen® by Amgen); Immunomodulators: Afutuzumab (available from Roche®), pegfilgrastim (sold under the tradename Neulasta® by Amgen), lenalidomide (also known as CC-5013, sold under the tradename Revlimid®), thalidomide (sold under the tradename Thalomid®);

CD40 inhibitors: Dacetuzumab (also known as SGN-40 or huS2C6, available from Seattle Genetics, Inc); Pro-apoptotic receptor agonists (PARAs): Dulanermin (also known as AMG-951, available from Amgen/Genentech);

Hedgehog antagonists: 2-chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)- benzamide (also known as GDC-0449, and described in PCT Publication No. WO 06/028958);

Phospholipase A2 inhibitors: Anagrelide (sold under the tradename Agrylin®);

BCL-2 inhibitors: 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohexen-l-yl]methyl]-l- piperazinyl]-N-[[4-[[(lR)-3-(4-morpholinyl)-l-[(phenylthio)m ethyl]propyl]amino]-3- [(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide (also known as ABT-263 and described in PCT Publication No. WO 09/155386);

MC1-1 inhibitors: MIK665, S64315, AMG 397, and AZD5991;

Aromatase inhibitors: Exemestane (sold under the trademark Aromasin® by Pfizer), letrozole (sold under the tradename Femara® by Novartis), anastrozole (sold under the tradename Arimidex®);

Topoisomerase I inhibitors: Irinotecan (sold under the trademark Camptosar® by Pfizer), topotecan hydrochloride (sold under the tradename Hycamtin® by GlaxoSmithKline);

Topoisomerase II inhibitors: etoposide (also known as VP-16 and Etoposide phosphate, sold under the tradenames Toposar®, VePesid® and Etopophos®), teniposide (also known as VM-26, sold under the tradename Vumon®); mTOR inhibitors: Temsirolimus (sold under the tradename Torisel® by Pfizer), ridaforolimus (formally known as deferolimus, (lR,2R,4S)-4-[(2R)-2[(lR,9S,12S,15R,16E, 18R,19R,21R, 23S,24E,26E,28Z,30S,32S,35R)-l,18-dihydroxy-19,30- dimethoxy-15, 17, 21, 23, 29, 35-hexamethyl-2,3, 10, 14,20-pentaoxo-l 1, 36-dioxa-4- azatri cyclo[30.3.1.0 4 ' 9] hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate, also known as AP23573 and MK8669, and described in PCT Publication No. WO 03/064383), everolimus (sold under the tradename Afinitor® by Novartis);

Proteasome inhibitor such as carfilzomib, MLN9708, delanzomib, or bortezomib;

BET inhibitors such as INCB054329, OTX015, and CPI-0610;

LSD1 inhibitors such as GSK2979552, and INCB059872;

KAT6 inhibitors such as PF-07248144;

HIF-2a inhibitors such as PT2977, PT2385, imdatifan, and casdatifan; Osteoclastic bone resorption inhibitors: l-Hydroxy-2-imidazol-l-yl-phosphonoethyl) phosphonic acid monohydrate (sold under the tradename Zometa® by Novartis); CD33 Antibody Drug Conjugates: Gemtuzumab ozogamicin (sold under the tradename Mylotarg® by Pfizer/Wyeth);

CD22 Antibody Drug Conjugates: Inotuzumab ozogamicin (also referred to as CMC-544 and WAY-207294, available from Hangzhou Sage Chemical Co., Ltd.);

CD20 Antibody Drug Conjugates: Ibritumomab tiuxetan (sold under the tradename Zevalin®);

Somatostain analogs: octreotide (also known as octreotide acetate, sold under the tradenames Sandostatin® and Sandostatin LAR®);

Synthetic Interleukin- 11 (IL-11): oprelvekin (sold under the tradename Neumega® by Pfizer/Wyeth);

Synthetic erythropoietin: Darbepoetin alfa (sold under the tradename Aranesp® by Amgen);

Receptor Activator for Nuclear Factor K B (RANK) inhibitors: Denosumab (sold under the tradename Prolia® by Amgen);

Thrombopoietin mimetic peptibodies: Romiplostim (sold under the tradename Nplate® by Amgen);

Cell growth stimulators: Palifermin (sold under the tradename Kepivance® by Amgen);

Anti-Insulin-like Growth Factor-1 receptor (IGF-1R) antibodies: Figitumumab (also known as CP-751,871, available from ACC Corp), robatumumab (CAS No. 934235-44-6);

Anti-CSl antibodies: Elotuzumab (HuLuc63, CAS No. 915296-00-3);

CD52 antibodies: Alemtuzumab (sold under the tradename Campath®);

Histone deacetylase inhibitors (HDI): Voninostat (sold under the tradename Zolinza® by Merck);

Alkylating agents: Temozolomide (sold under the tradenames Temodar® and Temodal® by Schering-Plough/Merck), dactinomycin (also known as actinomycin-D and sold under the tradename Cosmegen®), melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, sold under the tradename Alkeran®), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename Hexal en®), carmustine (sold under the tradename BiCNU®), bendamustine (sold under the tradename Treanda®), busulfan (sold under the tradenames Busulfex® and Myleran®), carboplatin (sold under the tradename Paraplatin®), lomustine (also known as CCNU, sold under the tradename CeeNU®), cisplatin (also known as CDDP, sold under the tradenames Platinol® and Platinol®-AQ), chlorambucil (sold under the tradename Leukeran®), cyclophosphamide (sold under the tradenames Cytoxan® and Neosar®), dacarbazine (also known as DTIC, DIC and imidazole carboxamide, sold under the tradename DTIC-Dome®), altretamine (also known as hexamethylmelamine (HMM) sold under the tradename Hexalen®), ifosfamide (sold under the tradename Ifex®), procarbazine (sold under the tradename Matulane®), mechlorethamine (also known as nitrogen mustard, mustine and mechloroethamine hydrochloride, sold under the tradename Mustargen®), streptozocin (sold under the tradename Zanosar®), thiotepa (also known as thiophosphoamide, TESPA and TSP A, sold under the tradename Thioplex®; Biologic response modifiers: bacillus calmette-guerin (sold under the tradenames theraCys® and TICE® BCG), denileukin diftitox (sold under the tradename Ontak®);

Anti-tumor antibiotics: doxorubicin (sold under the tradenames Adriamycin® and Rubex®), bleomycin (sold under the tradename lenoxane®), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, sold under the tradename Cerubidine®), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DaunoXome®), mitoxantrone (also known as DHAD, sold under the tradename Novantrone®), epirubicin (sold under the tradename Ellence™), idarubicin (sold under the tradenames Idamycin®, Idamycin PFS®), mitomycin C (sold under the tradename Mutamycin®);

Anti -microtubule agents: Estramustine (sold under the tradename Emcyl®);

Cathepsin K inhibitors: Odanacatib (also known as MK-0822, N-(l-cyanocyclopropyl)-4- fluoro-N-2-{(lS)-2,2,2-trifluoro-l-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide, available from Lanzhou Chon Chemicals, ACC Corp., and ChemieTek, and described in PCT Publication no. WO 03/075836); Epothilone B analogs: Ixabepilone (sold under the tradename Lxempra® by Bristol-Myers Squibb);

Heat Shock Protein (HSP) inhibitors: Tanespimycin (17-allylamino-17- demethoxy- geldanamycin, also known as KOS-953 and 17-AAG, available from SIGMA, and described in US Patent No. 4,261,989), NVP-HSP990, AUY922, AT13387, STA-9090, Debio 0932, KW-2478, XL888, CNF2024, TAS-116

TpoR agonists: Eltrombopag (sold under the tradenames Promacta® and Revolade® by GlaxoSmithKline);

Anti-mitotic agents: Docetaxel (sold under the tradename Taxotere® by Sanofi -Aventis); Adrenal steroid inhibitors: aminoglutethimide (sold under the tradename Cytadren®);

Anti-androgens: Nilutamide (sold under the tradenames Nilandron® and Anandron®), bicalutamide (sold under tradename Casodex®), flutamide (sold under the tradename Fulexin™);

Androgens: Fluoxymesterone (sold under the tradename Halotestin®); CDK (CDK1, CDK2, CDK3, CDK5, CDK7, CDK8, CDK9, CDK11/12, or CDK16) inhibitors including but not limited to Alvocidib (pan-CDK inhibitor, also known as flovopirdol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-l-methyl-4-piperidinyl]-4- chromenone, and described in US Patent No. 5,621,002);

CDK4/6 inhibitors palbociclib, ribociclib, abemaciclib, and Trilaciclib; CDK9 inhibitors AZD 4573, P276-00, AT7519M, TP-1287; CDK2/4/6 inhibitor such as PF-06873600;

SHP-2 inhibitor such as TNO155;

MDM2/MDMX, MDM2/p53 and/or MDMX/p53 modulators;

Gonadotropin-releasing hormone (GnRH) receptor agonists: Leuprolide or leuprolide acetate (sold under the tradenames Viadure® by Bayer AG, Eligard® by Sanofi -Aventis and Lupron® by Abbott Lab);

Taxane anti -neoplastic agents: Cabazitaxel (l-hydroxy-7, 10 -dimethoxy-9-oxo-5,20- epoxytax-1 l-ene-2a,4,13a-triyl-4-acetate-2-benzoate-13-[(2R,3S)-3-{ [(tert- butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate), larotaxel ((2a,3^,4a,5p,7a,10p,13a)- 4, 10-bis(acetyloxy)-13-({(2R,3 S)-3-[(tert-butoxy carbonyl) amino] -2-hydroxy-3- phenylpropanoyl}oxy)-l-hydroxy-9-oxo-5,20-epoxy-7, 19-cyclotax-l l-en-2-yl benzoate);

5HTla receptor agonists: Xaliproden (also known as SR57746, l-[2-(2-naphthyl)ethyl]-4- [3-(trifluoromethyl)phenyl]-l,2,3,6-tetrahydropyridine, and described in US Patent No. 5,266,573); HPC vaccines: Cervarix® sold by GlaxoSmithKline, Gardasil® sold by Merck; Iron Chelating agents: Deferasinox (sold under the tradename Exjade® by Novartis);

Anti-metabolites: Claribine (2-chlorodeoxyadenosine, sold under the tradename leustatin®), 5 -fluorouracil (sold under the tradename Adrucil®), 6-thioguanine (sold under the tradename Purinethol®), pemetrexed (sold under the tradename Alimta®), cytarabine (also known as arabinosylcytosine (Ara-C), sold under the tradename Cytosar-U®), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DepoCyt™), decitabine (sold under the tradename Dacogen®), hydroxyurea (sold under the tradenames Hydrea®, Droxia™ and Mylocel™), fludarabine (sold under the tradename Fludara®), floxuridine (sold under the tradename FUDR®), cladribine (also known as 2-chlorodeoxyadenosine (2-CdA) sold under the tradename Leustatin™), methotrexate (also known as amethopterin, methotrexate sodium (MTX), sold under the tradenames Rheumatrex® and Trexall™), pentostatin (sold under the tradename Nipent®);

Bisphosphonates: Pamidronate (sold under the tradename Aredia®), zoledronic acid (sold under the tradename Zometa®); Demethylating agents: 5-azacitidine (sold under the tradename Vidaza®), decitabine (sold under the tradename Dacogen®); Plant Alkaloids: Paclitaxel protein-bound (sold under the tradename Abraxane®), vinblastine (also known as vinblastine sulfate, vincaleukoblastine and VLB, sold under the tradenames Alkaban-AQ® and Velban®), vincristine (also known as vincristine sulfate, LCR, and VCR, sold under the tradenames Oncovin® and Vincasar Pfs®), vinorelbine (sold under the tradename Navelbine®), paclitaxel (sold under the tradenames Taxol and Onxal™);

Retinoids: Ali tretinoin (sold under the tradename Panretin®), tretinoin (all -trans retinoic acid, also known as ATRA, sold under the tradename Vesanoid®), Isotretinoin (13-cis-retinoic acid, sold under the tradenames Accutane®, Amnesteem®, Claravis®, Clarus®, Decutan®, Isotane®, Izotech®, Oratane®, Isotret®, and Sotret®), bexarotene (sold under the tradename Targretin®);

Glucocorticosteroids: Hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate, and sold under the tradenames Ala-Cort®, Hydrocortisone Phosphate, Solu-Cortef®, Hydrocort Acetate® and Lanacort®), dexamethazone ((8S,9R,10S,l lS,13S,14S,16R,17R)-9-fhroro-l l,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16- trimethyl-6,7,8,9,10,1 l,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one), prednisolone (sold under the tradenames Delta-Cortel®, Orapred®, Pediapred® and Prelone®), prednisone (sold under the tradenames Deltasone®, Liquid Red®, Meticorten® and Orasone®), methylprednisolone (also known as 6-Methylprednisolone, Methylprednisolone Acetate, Methylprednisolone Sodium Succinate, sold under the tradenames Duralone®, Medralone®, Medrol®, M-Prednisol® and Solu-Medrol®);

Cytokines: interleukin-2 (also known as aldesleukin and IL-2, sold under the tradename Proleukin®), interleukin- 11 (also known as oprevelkin, sold under the tradename Neumega®), alpha interferon alfa (also known as IFN-alpha, sold under the tradenames Intron® A, and Roferon-A®); Estrogen receptor downregulators: Fulvestrant (sold under the tradename Faslodex®); and elacestrant and ARV-471 (vepdegestrant);

Anti-estrogens: tamoxifen (sold under the tradename Novaldex®); Toremifene (sold under the tradename Fareston®);

Selective estrogen receptor modulators (SERMs): Raloxifene (sold under the tradename Evista®);

Estrogen receptor PROTACs: Vepdegestrant (ARV-471);

Leutinizing hormone releasing hormone (LHRH) agonists: Goserelin (sold under the tradename Zoladex®); Progesterones: megestrol (also known as megestrol acetate, sold under the tradename Megace®); Miscellaneous cytotoxic agents: Arsenic trioxide (sold under the tradename Trisenox®), asparaginase (also known as L-asparaginase, Erwinia L-asparaginase, sold under the tradenames Elspar® and Kidrolase®);

One or more immune checkpoint inhibitors CD27, CD28, CD40, CD 122, CD96, CD73, CD39, CD47, 0X40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM kinase, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, A2BR, HIF-2a, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, 0X40, GITR, CD137 and STING. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from B7-H3, B7-H4, BTLA, CTLA-4, IDO, TDO, Arginase, KIR, LAG3, PD-1, TIM3, CD96, TIGIT and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD 160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, or pembrolizumab or PDR001. In some embodiments, the anti-PDl antibody is pembrolizumab.

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-Ll monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).

In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti -CTLA-4 antibody is ipilimumab or tremelimumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti- LAG3 antibody is BMS-986016 or LAG525. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or, MK-4166, INCAGN01876 or MK-1248. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of 0X40, e.g., an anti-OX40 antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562 or, INCAGNO 1949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600 or LAG525. In some embodiments, the OX40L fusion protein is MED 16383

Compounds of Formula (I) (and any embodiment thereof disclosed herein including specific compounds) can also be used to increase or enhance an immune response, including increasing the immune response to an antigen; to improve immunization, including increasing vaccine efficacy; and to increase inflammation. In some embodiments, the compounds of the invention can be used to enhance the immune response to vaccines including, but not limited, Listeria vaccines, oncolytic viral vaccines, and cancer vaccines such as GV AX® (granulocytemacrophage colony-stimulating factor (GM-CF) gene-transfected tumor cell vaccine). Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses. Other immune-modulatory agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4; Sting agonists and Toll receptor agonists.

Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer. Compounds of this application may be effective in combination with CAR (Chimeric antigen receptor) T cell treatment as a booster for T cell activation.

A compound of Formula (I) (or any embodiment thereof disclosed herein including specific compounds) can also be used in combination with the following adjunct therapies: antinausea drugs: NK-1 receptor antagonists: Casopitant (sold under the tradenames Rezonic® and Zunrisa® by GlaxoSmithKline); and

Cytoprotective agents: Amifostine (sold under the tradename Ethyol®), leucovorin (also known as calcium leucovorin, citrovorum factor and folinic acid).

Examples

The following preparations of Intermediates (References) and compounds of Formula (I) (Examples) are given to enable those skilled in the art to more clearly understand and to practice the present disclosure. They should not be considered as limiting the scope of the disclosure, but merely as being illustrative and representative thereof.

Reference 1

Synthesis of 3-(5-(azetidin-3-yl)-l-oxoisoindolin-2-yl)piperidine-2, 6-dione 2,2,2-trifluoroacetate Step 1 : ( l-(tert-Butoxycarbonyl)azeti din-3 -yl)zinc(II) iodide

To a mixture of Zn dust (300 mg, 4.59 mmol, 1.30 eq.) in DMA (3.0 mL) was added 1,2-dibromoethene (66 mg, 0.35 mmol, 0.10 eq.) and the mixture was stirred at 65 °C under N2 for 30 min. The mixture was allowed to cool to rt and TMSC1 (38 mg, 0.35 mmol, 0.10 eq.) was added. After stirring the mixture for 30 min, a solution of tert-butyl 3 -iodoazetidine- 1 -carboxylate (1.00 g, 3.53 mmol, 1.00 eq.) in DMA (1.0 mL) was added dropwise. The mixture was stirred at 65 °C under N2 for 2 h, and then cooled to rt. The solution was used in next step without further purification.

Step 2: tert-Butyl 3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)azetidine-l-carboxylate

A solution of (l-(tert-butoxycarbonyl)azetidin-3-yl)zinc(II) iodide (600 mg, 1.72 mmol, 3.00 eq.) in DMA was slowly added to a mixture of 3-(5-bromo-l-oxoisoindolin-2-yl)piperidine- 2, 6-dione (185 mg, 0.57 mmol, 1.00 eq.), Cui (12 mg, 0.06 mmol, 0.10 eq.), Pd(dppf)C12 (44 mg, 0.06 mmol, 0.10 eq.) in DMA (2.0 mL). The mixture was stirred at 90 °C under N2 overnight. The mixture was concentrated and purified by column chromatography on silica gel (EtOAc) to give the title compound as a brown solid.

Step 3: 3-(5-(Azetidin-3-yl)-l-oxoisoindolin-2-yl)piperidine-2, 6-dione 2,2,2-trifluoroacetate

To a solution of tert-butyl 3-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)azetidine-l- carboxylate (44 mg, 0.11 mmol, 1.00 eq.) in DCM (1.0 mL) was added TFA (0.2 mL) dropwise and the solution was stirred for 3 h. The resulting mixture was concentrated to give the title product as a brown oil. Reference 2

Synthesis of 3-(4-(azetidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l- yl)piperidine-2, 6-dione 2,2,2-trifluoroacetate

Step 1: tert-Butyl 3-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]- imidazol-4-yl)azetidine- 1 -carboxylate

A solution of (l-(tert-butoxycarbonyl)azetidin-3-yl)zinc (II) iodide (600 mg, 1.72 mmol,

3.00 eq.) in DMA was slowly added to a mixture of 3-(4-bromo-3-methyl-2-oxo-2,3-dihydro-lH- benzo[d]imidazol-l-yl)piperidine-2, 6-dione (193 mg, 0.57 mmol, 1.00 eq.) in DMA (2.0 mL) Cui (12 mg, 0.06 mmol, 0.10 eq.) and Pd(dppf)C12 (44 mg, 0.06 mmol, 0.10 eq.). The mixture was stirred at 90 °C under N2 overnight. The mixture was concentrated and purified by column chromatography on silica gel (EtOAc) to afford the title compound as a yellow solid.

Step 2: 3-(4-(Azetidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-

2,6-dione 2,2,2-trifluoroacetate

To a solution of tert-butyl 3-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH- benzo[d]imidazol-4-yl)azetidine-l -carboxylate (23 mg, 0.055 mmol, 1.00 eq.) in DCM (1.0 mL) was added TFA (0.2 mL) dropwise and the solution was stirred at rt for 3 h. The resulting mixture was concentrated to give the title compound as a brown oil.

Reference 3

Synthesis of 3-(l-Oxo-5-(piperazin-l-yl)isoindolin-2-yl)piperidine-2, 6-dione 2,2,2- trifluoroacetate Step 1 : tert-Butyl 4-(3-cyano-4-(methoxycarbonyl)phenyl)piperazine-l -carboxylate

To a stirred solution of methyl 2-cyano-4-fluorobenzoate (10.00 g, 55.80 mmol, 1.00 eq.) in DMSO (150.0 mL) was added tert-butyl piperazine- 1 -carboxylate (11.40 g, 61.38 mmol, 1.10 eq.) and DIEA (34.70 g, 268.96 mmol, 4.80 eq.), and the resulting mixture was stirred at 110 °C for 12 h. The mixture was diluted with water and extracted with EtOAc, and the combined organic layers was washed with brine, dried over Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluting with PE/EtOAc (3 : 1) to give the title compound as yellow solid.

Step 2: tert-Butyl 4-(3-formyl-4-(m ethoxy carbonyl)phenyl)piperazine-l -carboxylate

A mixture of tert-butyl 4-(3-cyano-4-(methoxycarbonyl)phenyl)piperazine-l -carboxylate (8.00 g, 23.20 mmol, 1.00 eq.), NaJEPCh.JhO (5.20 g, 48.70 mmol, 2.10 eq.) and Raney-Ni (5.10 g) in pyridine:H2O:AcOH=2:l : l (80.0 mL) was stirred at 70 °C for 12 h. The mixture was adjusted pH=7~8 with aq.NaHCCh, and the mixture was filtered, and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4. After filtration, the filtrate was concentrated and the residue was purified by silica gel column chromatography eluting with PE/EtOAc (3 : 1) to give the title compound as yellow solid.

Step 3: tert-Butyl 4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazine-l-carboxylate

A mixture of 3 -aminopiperidine-2, 6-dione hydrochloride (2.60 g, 15.50 mmol, 1.20 eq.) DIEA (4.03 g, 31.22 mmol, 2.42 eq.), AcOH (10.63 g, 188.76 mmol, 13.78 eq.) and tert-butyl 4-(3-formyl-4-(methoxycarbonyl)phenyl)piperazine-l -carboxylate (4.50 g, 12.90 mmol, 1.00 eq.) in DCM (50.0 mL) was stirred at 35 °C for 4 h. Then NaBH(OAc)3 (8.20 g, 38.70 mmol, 3.00 eq.) was added the above mixture, and the mixture was stirred at 40 °C for 12 h. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4. After filtration, the filtrate was concentrated, and the residue was purified by silica gel column chromatography eluting with PE/EtOAc (1 :2) to give the title compound as white solid. Step 4: 3-(l-Oxo-5-(piperazin-l-yl)isoindolin-2-yl)piperidine-2, 6-dione 2,2,2-trifluoroacetate

To a solution of tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazine- 1-carboxylate (72 mg, 0.17 mmol, 1.00 eq.) in DCM (4.0 mL) was added TFA (1.0 mL). The resulting mixture was stirred at rt for 2 h and then concentrated to give the title compound as yellow oil.

The following Reference compounds were synthesized by proceeding analogously as described in Reference 3.

Reference 5

Synthesis of l-(l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione 2, 2, 2-2, 2, 2-tri fluoroacetate

Step 1 : 6-Bromo-l-methyl-lH-indazol-3-amine

To a stirred solution of 4-bromo-2-fluorobenzonitrile (10 g, 0.05 mol, 1.00 eq.) in EtOH (50.0 mL) was added methylhydrazine (57 g, 0.50 mol, 10.00 eq.) and the mixture was stirred at 100°C 30 h in sealed tube. Then the mixture was concentrated, and diluted with water. The mixture was filtered to give the title compound as pale yellow solid. Step 2: Methyl 3-((6-bromo-l-methyl-lH-indazol-3-yl)amino)propanoate

Methyl acrylate (209.00 g, 2.43 mol, 10.00 eq.) was added to a solution of 6-bromo-l- methyl-lH-indazol-3-amine (55.00 g, 0.24 mol, 1.00 eq.), DBU (55.00 g, 0.36 mol, 1.50 eq.), lactic acid (33.00 g, 0.36 mol, 1.50 eq.) at 0 °C, and the mixture was stirred at 90 °C 20 h under N2. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (EtOAc:PE = 0 to 100%) to give the title compound as yellow solid. Step 3: Methyl 3-(l-(6-bromo-l-methyl-lH-indazol-3-yl)ureido)propanoate

NaOCN (26.00 g, 0.32 mol, 2.00 eq.) was added to a solution of methyl 3-((6-bromo-l- methyl-lH-indazol-3-yl)amino)propanoate (50.00 g, 0.16 mol, 1.00 eq.) in AcOH (500.0 mL), and the mixture was stirred at 80 °C 20 h under N2. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over ISfeSC After filtration, the filtrate was concentrated to give the title compound as yellow solid.

Step 4: l-(6-Bromo-l -methyl- lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-di one

To a solution of methyl 3-(l-(6-bromo-l-methyl-lH-indazol-3-yl)ureido)propanoate (56.00 g, 0.16 mol, 1.00 eq.) in MeCN (500.0 mL) was added Triton-B (7.90 g, 0.05 mol, 0.30 eq.) and stirred at rt for 20 h under N2. The mixture was concentrated, then diluted with water. The mixture was filtered and solid was washed with water, air dried to give the title compound as pale yellow solid.

- I l l - Step 5: tert-Butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-5,6- dihydropyridine- 1 (2H)-carboxylate

To a mixture of l-(6-bromo-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)- dione (1.10 g, 3.41 mmol, 1.00 eq.) in l,4-dioxane/H2O (10 mL/1 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-l(2H)-carboxylate (1.60 g, 5.11 mmol, 1.50 eq.), K3PO4 (2.20 g, 10.22 mmol, 3.00 eq.) and X-Phos-Pd G3 (289 mg, 0.34 mmol, 0.10 eq. ), and the mixture was stirred at 60 °C under N2 for 3 h. The mixture was diluted with DCM, and the organic layer was washed with brine, dried over Na2SO4. After filtration, the filtrate was concentrated, and the residue was purified by column chromatography on silica gel (DCM:MeOH = 20 : 1) to give the title compound as yellow solid.

Step 6: tert-Butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6- yl)piperidine- 1 -carboxylate

A mixture of tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH- indazol-6-yl)-5,6-dihydropyridine-l(2H)-carboxylate (300 mg, 0.71 mmol, 1.00 eq.), Pd/C (150 mg, 50% wt) and Pd(OH)2 (150 mg, 50% wt) in THF (20.0 mL) was stirred under H2 at 50 °C and 50 psi overnight. The mixture was filtered and the filtrate was concentrated and purified by column chromatography on silica gel (PE:EtOAc = 1 : 1) to give the title compound as yellow solid. Step 7: l-(l-Methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione 2, 2, 2-2, 2, 2-tri fluoroacetate

A mixture of tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH- indazol-6-yl)piperi dine- 1 -carboxylate (100 mg, 0.25 mmol, 1.00 eq.) in TFA/DCM (0.5 mL/2.0 mL) was stirred at rt for 2 h. The mixture was concentrated to give the title compound as brown oil.

The following Reference compounds were synthesized by proceeding analogously as described in Reference 5.

Reference 8

Synthesis of 3-((4-(Piperidin-4-yl)phenyl)amino)piperidine-2, 6-dione 2,2,2-trifluoroacetate Step 1 : tert-Butyl 4-(4-nitrophenyl)-5,6-dihydropyridine-l(2H)-carboxylate

A mixture of l-bromo-4-nitrobenzene (1.0 g, 4.95 mmol, 1.00 eq), tert-butyl 4-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-l(2H)-carboxylate (2.30 g, 7.43 mmol, 1.50 eq.), K2CO3 (1.37 g, 9.90 mmol, 2.00 eq.), and Pd(dppf)C12 (724 mg, 0.99 mmol, 0.20 eq) in dioxane/EEO (15 mL, 5/1 ) was stirred at 100 °C for 4 h. The mixture was filtered and extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated. The residue was purified by silica flash column PEZEtOAc (10: 1) to give the title compound as yellow solid.

Step 2: tert-Butyl 4-(4-aminophenyl)piperidine-l -carboxylate

A mixture of tert-butyl 4-(4-nitrophenyl)-5,6-dihydropyridine-l(2H)-carboxylate (1.20 g, 3.95 mmol, 1.00 eq.), Pd/C (360 mg, 10% w/w) in MeOH/THF (30 mL, 1 : 1) was stirred at 45 °C under EE overnight. The mixture was filtered, and the filtrate was concentrated. The residue was purified by silica flash column PEZEtOAc (3 : 1) to give the title compound as yellow solid. Step 3: tert-Butyl 4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidine-l-carboxylate

A mixture of tert-butyl 4-(4-aminophenyl)piperidine-l -carboxylate (332 mg, 1.20 mmol, 1.00 eq.), 3 -brom opiperidine-2, 6-dione (242 mg, 1.26 mmol, 1.05 eq.) and NaHCCh (302 mg, 3.60 mmol, 3.00 eq.) in DMF (4.0 mL) was stirred at 70 °C overnight. The mixture was diluted with water and extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4, filtered, and then concentrated. The residue was purified by silica flash column PE/EtOAc (1 : 1) to give the title compound as yellow solid.

Step 4: 3 -((4-(Piperidin-4-yl)phenyl)amino)piperidine-2, 6-dione 2,2,2-trifluoroacetate

TFA (0.5 mL) was added to a mixture of tert-butyl 4-(4-((2, 6-dioxopiperi din-3 - yl)amino)phenyl)piperidine-l -carboxylate (100 mg, 0.26 mmol, 1.00 eq.) in DCM (2.0 mL) and the mixture was stirred at rt for 2 h. The mixture was concentrated to give the title compound as a yellow solid. Reference 9

Synthesis of 3-(4-(piperazin-l-yl)phenyl)piperidine-2, 6-dione 2,2,2-trifluoroacetate

Step 1 : 2,6-Bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine

A mixture of 2,6-bis(benzyloxy)-3-bromopyridine (19.00 g, 0.05 mol, 1.00 eq.),

4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (19.60 g, 0.08 mol, 1.50 eq.), KO Ac (10.00 g, 0.10 mol, 2.00 eq.), and Pd(dppf)C12 (3.7 g, 5.00 mmol, 0.10 eq.) in 1,4-dioxane (200.0 mL) was stirred at 100 °C for 25 h under N2. The mixture was diluted with water and extracted with EtOAc, and the combined organic layer was washed with brine, dried over Na2SO4. After filtration, the filtrate was concentrated and the residue was purified by silica gel column chromatography eluting with EtOAc:PE= 0 to 100% to give the title compound as yellow solid. Step 4: 2,6-Bis(benzyloxy)-3-(4-bromophenyl)pyridine

A mixture of 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (4.42 g, 10.60 mmol, 1.20 eq.), l-bromo-4-iodobenzene (2.50 g, 8.83 mol, 1.00 eq.), K3PO4 (5.63 g, 26.50 mmol, 3.00 eq.), and Pd(PPhs)4 (510 mg, 0.44 mmol, 0.05 eq.) in l,4-dioxane/H2O=10: l (40.0 mL) was stirred at 100 °C for 16 h under N2. The mixture was diluted with water and extracted with EtOAc, and the combined organic layer was washed with brine, dried over Na2SO4. After filtration, the filtrate was concentrated and the residue was purified by silica gel column chromatography eluting with EtOAc:PE= 0 to 100% to give the title compound as yellow solid. Step 5: tert-Butyl 4-(4-(2,6-bis(benzyloxy)pyridin-3-yl)phenyl)piperazine-l-carboxylate

A mixture of 2,6-bis(benzyloxy)-3-(4-bromophenyl)pyridine (500 mg, 1.12 mmol, 1.00 eq.), tert-butyl piperazine- 1 -carboxylate (417 mg, 2.24 mmol, 2.00 eq.), CS2CO3 (730 mg, 2.24 mmol, 2.00 eq.), Pd2(dba)s (51 mg, 0.06 mmol, 0.05 eq.), and RuPhos (52 mg, 0.11 mmol, 0.10 eq.) in toluene (15.0 mL) was stirred at 110 °C for 20 h under N2. The mixture was diluted with water and extracted with EtOAc, and the combined organic layer was washed with brine, dried over Na2SO4. After filtration, the filtrate was concentrated and the residue was purified by silica gel column chromatography eluting with EtOAc:PE= 0 to 100% to give the title compound as yellow solid.

Step 6: tert-Butyl 4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazine-l -carboxylate

A mixture of tert-butyl 4-(4-(2,6-bis(benzyloxy)pyridin-3-yl)phenyl)piperazine-l- carboxylate (260 mg, 0.47 mmol, 1.00 eq.), 10% Pd/C (260 mg) in EtOAc (5.0 mL) and

1,4-dioxane (5.0 mL) was stirred at rt for 20 h under H2. The mixture was filtered and the filtrate was concentrated to give the title compound as yellow oil.

Step 7: 3-(4-(Piperazin-l-yl)phenyl)piperidine-2, 6-dione 2,2,2-trifluoroacetate

TFA (0.5 mL) was added to a stirred solution of tert-butyl 4-(4-(2, 6-dioxopiperi din-3 - yl)phenyl)piperazine-l -carboxylate (160 mg, 0.43 mmol, 1.00 eq.) in DCM (2.0 mL) and the mixture was stirred at rt for 2 h under N2. The mixture was concentrated to give the title compound as yellow oil. Reference 10

Synthesis of 2-chloro-5-(difluoromethyl)pyrimidine

To a solution of 2-chloropyrimidine-5-carbaldehyde (250 mg, 1.60 mmol, 1.00 eq.) in DCM (3.0 mL) was added DAST (45 mg, 31.93 mmol, 20.00 eq.) at 0 °C and the mixture was stirred at r.t overnight. The mixture was diluted with water and extracted DCM. The organic layer was washed with brine, dried over Na2SO4. After filtration, the filtrate was concentrated, and the residue was purified by flash chromatography (PE:EtOAc=10: 1) to give the title compound as a white solid.

The following Reference compound was prepared by proceeding analogously as described in Reference 10.

Reference 11

Synthesis of 2-chloro-5-(difluoromethoxy)pyrimidine

A mixture of 2-chloropyrimidin-5-ol (1.00 g, 7.69 mmol, 1.00 eq.), methyl 2-chloro-2,2- difluoroacetate (3.32 g, 23.08 mmol, 3.00 eq.) and CS2CO3 (3.01 g, 9.23 mmol, 1.20 eq.) in DMF (10.0 mL) was stirred at 100 °C under N2 lh. The mixture was poured into water, and the resulting mixture was extracted with DCM. The combined organic layers was dried over Na2SO4. After filtration, the filtrate was concentrated and the residue was purified by column chromatography on silica gel (PE : EtOAc =20: 1) give the title compound as yellow oil. Reference 12

Synthesis of l-(6-(pipendin-4-yl)-l-(2,2,2-tnfluoroethyl)-lH-mdazol-3-yl)dihydropyrimidme- 2,4(lH,3H)-dione 2,2,2-trifluoroacetate

Step 1 : 6-Bromo-l-(2,2,2-trifluoroethyl)-lH-indazol-3-amine

NaH (2.10 g, 52.83 mmol, 2.00 eq.) was added to a stirred solution of 6-bromo-lH- indazol-3 -amine (5.60 g, 26.42 mmol, 1.00 eq.) in DMF (20.0 mL) at 0 °C and the mixture was stirred at 0 °C for Ih. 2,2,2-Trifluoroethyl trifluoromethanesulfonate (6.7 g, 29.06 mmol, 1.10 eq.) was added and the mixture was stirred at rt for 3 h under N2. The mixture was poured into cold water and filtered. The solid was washed with water and dried to give the title compound as yellow solid.

Step 2: l-(6-(Piperidin-4-yl)-l-(2,2,2-trifluoroethyl)-lH-indazol-3-yl)dihydropyrimidine- 2,4(lH,3H)-dione 2,2,2-trifluoroacetate

The title compound was synthesized by proceeding analogously as described in Reference

5, Steps 2-7. Reference 13

Synthesis of 1 -(1 -methyl-6-(piperazin- 1 -yl)- lH-indazol-3 -yl)dihydropyrimidine-2,4( 1H,3H)- dione

Step 1 : Benzyl 4-(4-cyano-3-fluorophenyl)piperazine-l -carboxylate

A mixture of 2,4-difluorobenzonitrile (18.95 g, 136.20 mmol, 1.50 eq.), benzyl piperazine- 1-carboxylate (20 g, 90.80 mmol, 1.00 eq.) and potassium carbonate (25.10 g, 181.6 mmol, 2.00 eq.) in ACN (200.0 mL) was stirred at 80 °C under N2 for 16 h. The mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography eluting with PE/EtOAc (3 : 1) to give the title compound as white solid.

Step 2: Benzyl 4-(3-amino-lH-indazol-6-yl)piperazine-l-carboxylate

A mixture of benzyl 4-(4-cyano-3-fluorophenyl)piperazine-l -carboxylate (11.00 g, 32.40 mmol, 1.00 eq.) and ^JL/LEO (10.14g, 161.99 mmol, 5.00 eq) in BuOH (100.0 mL) was stirred at 100 °C under N2 for 16 h. The mixture was concentrated and purified by flash chromatography to give the title compound as yellow solid.

Step 3: Benzyl 4-(3-amino-l-methyl-lH-indazol-6-yl)piperazine-l-carboxylate

To a solution of benzyl 4-(3-amino-lH-indazol-6-yl)piperazine-l-carboxylate (4.00 g, 11.40 mmol, 1.00 eq.) in dry DMF (50.0 mL) at 0 °C was added NaH (0.91 g, 22.80 mmol, 2.00 eq.) under N2, and the mixture was stirred at rt for 30 min. The mixture was cooled to 0 °C, CH3I (1.78 g, 12.54 mmol, 1.10 eq.) in dry DMF (10.0 mL) was added dropwise, and the mixture was stirred for 3 h. The mixture was quenched with water, extracted with EtOAc. The combined organic layers were washed with brine, dried with Na2SO4. After filtration, the filtrate was concentrated and the residue was purified by silica gel column chromatography eluting with DCM/MeOH = (50: 1) to give the title compound as yellow solid.

Step 4: Benzyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)- piperazine- 1 -carboxylate

The title compound was synthesized by proceeding analogously as described in Reference 5, Steps 2-4.

Step 5: l-(l-Methyl-6-(piperazin-l-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione

A mixture of benzyl 4-[3-(2,4-dioxo-l,3-diazinan-l-yl)-l-methylindazol-6-yl]piperazine- 1-carboxylate (500 mg, 1.08 mmol, 1.00 eq.), 10% Pd/C (400 mg) and ammonium formate (682 mg, 10.81 mmol, 10.00 eq.) in MeOH (20.0 mL) was stirred at 60 °C under N2 for 16 h. The mixture was filtered and the filtrate was concentrated to give the title compound as white solid.

The following Reference compound was synthesized by proceeding analogously as described in Reference 13. Reference 15

Synthesis of l-(6-(3,3-difluoropiperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine- 2,4(lH,3H)-dione 2,2,2-trifluoroacetate

Step 1 : l-(l-Methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazol-3- yl)dihydropyrimidine-2,4(lH,3H)-dione

A mixture of l-(6-bromo-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione (626 mg, 2.00 mmol, 1.00 eq.), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (762 mg, 3.00 mmol, 1.50 eq.), KO Ac (589 mg, 6.00 mmol, 3.00 eq.) and Pd(dppf)C12 (146 mg, 0.20 mmol, 0.10 eq.) in 1,4-dioxane (10 mL) was stirred at 85 °C under N2 overnight. The mixture was filtered and the filtrated was concentrated. The residue was purified by column chromatography on silica gel (DCM:MeOH = 100 : 1) to give the title compound as a yellow solid.

Step 2: tert-Butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-3,3- difluoro-3,6-dihydropyridine-l(2H)-carboxylate

A mixture of l-(l-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-indazol-3- yl)dihydropyrimidine-2,4(lH,3H)-dione (800 mg, 2.00 mmol, 1.00 eq.), tert-butyl 3,3-difluoro-4- (((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-l(2H)-carboxylate (1.10 g, 3.00 mmol, 1.50 eq.), Na2CC>3 (636 mg, 6.00 mmol, 3.00 eq.), Pd(dppf)C12 (146 mg, 0.20 mmol, 0.1 eq.) and H2O (2.5 mL) in 1,4-dioxane (10.0 mL) was stirred at 55 °C under N2 overnight. The mixture was filtered and the filtrated was concentrated. The residue was purified by column chromatography on silica gel (DCM:MeOH = 120 : 1) to give the title compound as a yellow solid. Step 3: tert-Butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-3,3- difluoropiperidine-1 -carboxylate

A mixture of tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH- indazol-6-yl)-3,3-difluoro-3,6-dihydropyridine-l(2H)-carboxylate (940 mg, 2.00 mmol, 1.00 eq.), 10% Pd/C (900mg) and Pd(OH)2 (900mg) in MeOH (10.0 mL) was stirred at 50 °C under H2 (50 PSI) overnight. The mixture was filtered, and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (DCM:MeOH = 1 : 1) to give the title as yellow solid.

Step 4: l-(6-(3,3-Difluoropiperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine- 2,4(lH,3H)-dione 2,2,2-trifluoroacetate

A mixture of tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH- indazol-6-yl)-3,3-difluoropiperidine-l-carboxylate (102 mg, 0.22 mmol, 1.00 eq.) in TFA/DCM (0.5 mL/2.0 mL) was stirred at rt for 2h. The mixture was concentrated to give the title compound as brown oil.

Reference 16

Synthesis of tert-butyl 6-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)- 2,6-diazaspiro[3 ,3]heptane-2-carboxylate 2,2,2-trifluoroacetate

Step 1: tert-Butyl 6-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-2,6- di azaspiro [3.3 ]heptane-2 -carb oxy 1 ate A mixture of l-(6-bromo-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione (300 mg, 0.93 mmol, 1.00 eq.), tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate (570 mg, 2.32 mmol, 2.50 eq.), t-BuOK(627 mg, 5.6 mmol, 6.00 eq.), t-BuBrettphos Pd G3 (81mg, 0.093 mmol, 0.10 eq.) and t-BuXphos (76mg, 0.186 mmol, 0.20 eq.) in 1,4-dioxane (6 mL) was stirred at 100 °C under N2 for 3 h. The mixture was diluted with DCM and the organic layer was washed with water and brine, dried over ISfeSC After filtration, the filtrate was concentrated, and the residue was purified by column chromatography on silica gel (DCM:MeOH = 20 : 1) to give the title compound as yellow solid.

Step 2: l-(l-Methyl-6-(2,6-diazaspiro[3.3]heptan-2-yl)-lH-indazol-3-yl)dihydropyrimidine- 2,4(lH,3H)-dione 2,2,2-trifluoroacetate

A mixture of tert-butyl 6-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH- indazol-6-yl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (90 mg, 0.204 mmol, 1.00 eq.) in TFA/DCM (0.5 mL/2 mL) was stirred at rt for 2 h. The mixture was concentrated to give the title compound as brown oil.

Reference 17

Synthesis of 3-(6-(piperidin-4-yl)benzo[b]thiophen-3-yl)piperidine-2, 6-dione hydrochloride

To a stirred solution of 6-chloro-l -benzothiophene (500 mg, 2.97 mmol, 1.00 eq.) in CH3CN (3 mL) was added NBS (528 mg, 2.96 mmol, 1.00 eq.) in portions at 0 °C. The resulting mixture was stirred for 2 h at room temperature, then diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase chromatography to afford the title compound as an off- white solid.

Step 2: 2,6-Bis(benzyloxy)-3-(6-chlorobenzo[b]thiophen-3-yl)pyridine

To a stirred solution of 3-bromo-6-chloro-l-benzothiophene (370 mg, 1.49 mmol, 1.00 eq.) and 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (624 mg, 1.50 mmol, 1.00 eq.) in dioxane (4 mL) and water (1 mL) were added CS2CO3 (1.5 g, 4.60 mmol, 3.09 eq.) and Pd(dppf)C12 CH2CI2 (243.5 mg, 0.33 mmol, 0.22 eq.) at room temperature. The resulting mixture was stirred for 2 h at 75 °C under nitrogen atmosphere. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with EtOAc/PE (0-25%), to afford the title compound as a white solid.

Step 3: tert-Butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)benzo[b]thiophen-6-yl)-3,6-dihydro- py ri dine- 1 (2H)-carb oxy 1 ate

To a stirred solution of 2,6-bis(benzyloxy)-3-(6-chlorobenzo[b]thiophen-3-yl)pyridine (260 mg, 0.57 mmol, 1.00 eq.), K3PO4 (362 mg, 1.71 mmol, 3.00 eq.) and tert-butyl 4-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l-carboxylate (175 mg, 0.57 mmol, 1.00 eq.) in dioxane and H2O (2.6 mL, 10: 1) was added X-Phos Pd G3 (48 mg, 0.06 mmol, 0.10 eq.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 3 h at 60 °C under nitrogen atmosphere. The reaction mixture was diluted with EtOAc and the organic layer was washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with EtOAc/PE (0-50%), to afford the title compound as a light brown solid. Step 4: tert-Butyl 4-(3 -(2, 6-dioxopiperi din-3 -yl)benzo[b]thi ophen-6-yl)piperi dine- 1 -carboxylate

To a stirred solution of tert-butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)benzo[b]thiophen- 6-yl)-3,6-dihydropyridine-l(2H)-carboxylate (220 mg, 0.36 mmol, 1.00 eq.) in EtOH (3 mL) and AcOH (0.3 mL) was added 20 mg of 10% w/w Pd/C. The resulting mixture was stirred at room temperature for 3 h under hydrogen atmosphere using a hydrogen balloon. The reaction mixture was filtered through a Celite pad and the filtrate was concentrated under reduced pressure to afford the title compound as a white solid.

Step 5: 3 -(6-(Piperidin-4-yl)benzo[b]thi ophen-3 -yl)piperidine-2, 6-dione hydrochloride

To a stirred solution of tert-butyl 4-(3 -(2, 6-dioxopiperi din-3 -yl)benzo[b]thi ophen-6- yl)piperidine-l -carboxylate (130 mg, 0.30 mmol, 1.00 eq.) in DCM (2 mL) was added HC1 in 1,4- dioxane (4 M, 0.7 mL) dropwise at 0 °C. The resulting mixture was stirred for 1 h at room temperature. The reaction mixture was concentrated under reduced pressure to afford the title compound as a white solid.

Reference 18

Synthesis of tert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indol-6-yl)piperidine-l- Step 1 : tert-Butyl 4-(l-methyl-lH-indol-6-yl)-3,6-dihydropyridine-l(2H)-carboxylate

To a stirred solution of 6-bromo-l-methylindole (5.0 g, 23.8 mmol, 1.00 eq.) and tert-butyl 4-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l -carboxylate (7.51 g, 24.3 mmol, 1.02 eq.) in 1,4-dioxane (50 mL) and H2O (5 mL) was added XPhos Pd G3 (2.0 g, 2.4 mmol, 0.10 eq.) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 3 h at 60 °C under nitrogen atmosphere. The resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with EtOAc/PE (0-20%), to afford the title compound as an off-white solid.

Step 2: tert-Butyl 4-(l-methyl-lH-indol-6-yl)piperidine-l-carboxylate

To a stirred solution of tert-butyl 4-(l-methyl-lH-indol-6-yl)-3,6-dihydropyridine-l(2H)- carboxylate (4.0 g, 12.8 mmol, 1.00 eq.) in THF (40 mL) was added 400 mg of 10% w/w Pd/C at room temperature. The mixture was hydrogenated at 50 °C for 16 h under hydrogen atmosphere using a hydrogen balloon. The reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography, eluted with EtOAc/PE (0-20%), to afford the title compound as a yellow oil.

Step 3: tert-Butyl 4-(3-iodo-l-methyl-lH-indol-6-yl)piperidine-l-carboxylate

To a stirred solution of tert-butyl 4-(l-methylindol-6-yl)piperidine-l -carboxylate (2.3 g, 7.3 mmol, 1.00 eq.) in DMF (35 mL) was added NIS (1.64 g, 7.3 mmol, 1.00 eq.) in portions at 0- 5 °C, and the resulting mixture was stirred for 2 h at 0-5 °C. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with EtOAc/PE (0-30%), to afford the title compound as a yellow solid.

Step 4: tert-Butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH-indol-6-yl)piperidine-l- carboxylate

To a stirred mixture of tert-butyl 4-(3-iodo-l-methylindol-6-yl)piperidine-l-carboxylate (2.5 g, 5.7 mmol, 1.00 eq.) and 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridine (2.51 g, 6.0 mmol, 1.05 eq.) in l,4-dioxane/H2O (10: 1, 25 mL) were added K2CO3 (2.38 g, 17.2 mmol, 3.00 eq.) and Pd^ppfJCh CEECh (462 mg, 0.57 mmol, 0.10 eq.) at room temperature. The resulting mixture was stirred overnight at 80 °C under nitrogen atmosphere. The reaction mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EtOAc (0-40%), to afford the crude product. The crude product was purified by prep-HPLC to afford the title compound as a light yellow solid.

Step 5: tert-Butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indol-6-yl) piperidine-1- carboxylate

To a stirred solution of tert-butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH- indol-6-yl)piperidine-l -carboxylate (50 mg, 0.083 mmol, 1.00 eq.) in EtOH (1 mL) was added Pd/C (10% w/w, 50 mg) and 1 drop of AcOH at room temperature. The resulting mixture was stirred at room temperature for 3 h under hydrogen atmosphere using a hydrogen balloon. The reaction mixture was filtered and the filtrate was concentrated to afford the title compound. Step 6: 3-(l-Methyl-6-(piperidin-4-yl)-lH-indol-3-yl)piperidine-2, 6-dione hydrochloride

The title compound was synthesized by proceeding analogously as described in Reference

17, Step 5 with tert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indol-6-yl)piperidine-l- carboxylate.

The following Reference compound was synthesized by proceeding analogously as described in Reference 18.

Reference 20 Synthesis of 5-Chloro-N-(piperidin-4-yl)pyrimidin-2-amine hydrogen chloride

Step 1 : tert-Butyl 4-((5-chloropyrimidin-2-yl)amino)piperidine-l -carboxylate

Boc

A mixture of tert-butyl 4-aminopiperidine-l -carboxylate (3.50 g, 23.49 mmol, 1.00 eq.), 2,5-dichloropyrimidine (5.17 g, 25.84 mmol, 1.10 eq.) and DIEA (6.06 g, 46.98 mmol, 2.00 eq.) in DMSO (50.0 mL) was stirred at 90 °C under N2 for 3 h. The mixture was diluted with water and extracted with EA. The organic layer was washed with brine, dried over ISfeSCU, concentrated and the residue was purified by silica gel column chromatography eluting with PEZEtOAc (8: 1) to give the title compound as white solid. Step 2: 5-Chloro-N-(piperidin-4-yl)pyrimidin-2-amine hydrogen chloride

A mixture of tert-butyl 4-((5-chloropyrimidin-2-yl)amino)piperidine-l -carboxylate (500 mg, 1.60 mmol, 1.00 eq.) and 4 M hydrogen chloride in dioxane (5.0 mL) was stirred at r.t. for 2 h. The mixture was concentrated to give the title compound.

The following Reference compounds were synthesized by proceeding analogously as described in Reference 20.

Reference 23

Synthesis of 3-(2,6-difluoro-4-(piperidin-4-yl)phenyl)piperidine-2, 6-dione hydrochloride

Step 1 : tert-Butyl 4-(4-bromo-3,5-difluorophenyl)-3,6-dihydropyridine-l(2H)-carboxylate

To a stirred solution of 2-bromo-l,3-difluoro-5-iodobenzene (1.0 g, 3.14 mmol) in 1,4- dioxane/EEO (10.0 mL/2.0 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-3,6-dihydropyridine-l(2H)-carboxylate (1.16 g, 3.76 mmol), ISfeCCh (997 mg, 9.41 mmol) and Pd(dppf)C12 (229 mg, 0.31 mmol) at 60 °C and the mixture was stirred for 16 h. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE/ethyl acetate=3: 1, to afford the title compound as a white solid. Step 2: tert-butyl 4-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)-3,6-dihydropyridine-

1 (2H)-carboxylate

To a stirred solution of tert-butyl 4-(4-bromo-3,5-difluorophenyl)-3,6-dihydropyridine- l(2H)-carboxylate (500 mg, 1.34 mmol) in l,4-dioxane/H2O (8.0 mL/1.0 mL) was added 2,6- bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (616 mg, 1.47 mmol), K2CO3 (555 mg, 4.02 mmol) and Pd(dppf)C12 (98 mg, 0.13 mmol) and the mixture was stirred for 16 h at 100 °C. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE/ethyl acetate=2: 1, to afford the title compound as a white solid.

Step 3: tert-butyl 4-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)piperidine-l-carboxylate

To a stirred solution of tert-butyl 4-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluoro- phenyl)-3,6-dihydropyridine-l(2H)-carboxylate (300 mg, 0.51 mmol) in THF (5.0 mL) was added Pd/C (150 mg) and Pd(OH)2 (150 mg) at 50 °C and stirred for 16 h under 1 atm H2. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE: ethyl acetate=l : 1, to afford the title compound as a white solid. Step 4: 3-(2,6-Difluoro-4-(piperidin-4-yl)phenyl)piperidine-2, 6-dione hydrochloride

To a stirred solution of tert-butyl 4-(4-(2,6-dioxopiperidin-3-yl)-3,5-difluorophenyl)- piperidine-1 -carboxylate (192 mg, 0.47 mmol) in ethyl acetate (3.0 mL) was added HC1 solution in ethyl acetate (2.0 M, 3.0 mL) at r.t. and the mixture was stirred for 3 h. The mixture was concentrated to give the title compound as brown oil.

Reference 24

Synthesis of 3-(l-cyclopropyl-6-(piperidin-4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2- tri fluoroacetate

To a solution of tert-butyl 4-(lH-indazol-6-yl)piperidine-l-carboxylate (1.50 g, 5.0 mmol) in AcOH (20.0 mL) was added NIS (2.25 g, 10.0 mmol). The reaction mixture was stirred at 30 °C for 5 h. The mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and the organic layer was dried over anhydrous ISfeSC The residue was purified by column chromatography on silica gel (PE:ethyl acetate = 5:1) to give the title compound as yellow solid.

Step 2: tert-Butyl 4-(l-cyclopropyl-3-iodo-lH-indazol-6-yl)piperidine-l-carboxylate

To a solution of tert-butyl 4-(3-iodo-lH-indazol-6-yl)piperidine-l-carboxylate (270 mg, 0.63 mmol) in DCE (10.0 mL) was added cyclopropylboronic acid (108 mg, 1.26 mmol), CU(OAC)2 (114 mg, 0.63 mmol), 2,2-bipyridine (98 mg, 0.63 mmol) and ISfeCCL (134 mg, 1.26 mmol) at 70 °C under N2 for 3 h. The mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and the organic layer was dried over anhydrous Na2SO4. The residue was purified by column chromatography on silica gel (PE:ethyl acetate = 15:1) to give the title compound as white solid. Step 3: tert-Butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-cyclopropyl-lH-indazol-6-yl)- piperidine-1 -carboxylate

To a mixture of tert-butyl 4-(l-cyclopropyl-3-iodo-lH-indazol-6-yl)piperidine-l- carboxylate (200 mg, 0.43 mmol) in l,4-dioxane/H2O (10.0 mL/1.0 mL) was added 2,6- bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (535 mg, 1.30 mmol), X- Phos Pd G3 (36 mg, 0.04 mmol) and K3PO4 (272 mg, 1.30 mmol). The reaction mixture was stirred at 100°C under N2 for 6 h. The mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated and the residue was purified by column chromatography on silica gel (PE:ethyl acetate = 5: 1) to give the title compound as yellow oil.

Step 4: tert-Butyl 4-(l-cyclopropyl-3-(2,6-dioxopiperidin-3-yl)-lH-indazol-6-yl)piperidine-l- carboxylate

A mixture of tert-butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-cyclopropyl-lH-indazol-6- yl)piperidine-l -carboxylate (130 mg, 0.2 mmol), Pd/C (50 mg) and Pd(OH)2/C (50 mg) in EtOH (5.0 mL) was stirred at 50 °C under N2 for 16 h. The mixture was filtered and the filtration was concentrated to give the title compound as white solid.

Step 5: 3-(l-Cyclopropyl-6-(piperidin-4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2- tri fluoroacetate To a solution of tert-butyl 4-(l-cyclopropyl-3-(2,6-dioxopiperidin-3-yl)-lH-indazol-6- yl)piperidine-l -carboxylate (90 mg, 0.2 mmol) in DCM (2.0 mL) was added TFA (0.5 mL). The mixture was stirred at r.t for 3 h. Then the solution was concentration to give the title compound as yellow oil.

Reference 25

Synthesis of 3-[l-methyl-6-(2-propyl-4-piperidyl)indazol-3-yl]piperidine-2, 6-dione hydrochloride

Step 1 : tert-Butyl 4-hydroxy-2-propyl-piperidine-l -carboxylate

To a stirred solution of tert-butyl 4-oxo-2-propyl-piperidine-l -carboxylate (500 mg, 2.07 mmol) in methanol (5 mL) was added NaBFL (118.1 mg, 3.11 mmol) at 0 °C and stirred for 0.5 h under argon atmosphere. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure to afford the title compound as a white solid.

Step 2: tert-Butyl 4-iodo-2-propyl-piperidine-l -carboxylate

To a stirred solution of tert-butyl 4-hydroxy-2-propyl-piperidine-l -carboxylate (500 mg, 2.05 mmol), PPhs (807.48 mg, 3.08 mmol) and imidazole (279.76 mg, 4.11 mmol) in DCM (10 mL) was added iodine (808.31 mg, 3.18 mmol) at rt, and the mixture was stirred for 2 h. The reaction mixture was quenched with sat.aq sodium thiosulphate and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate/petroleum ester (0~5%) to afford the title compound as a colorless oil. Step 3: tert-Butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-2-propyl-piperidine-l- carboxylate

To a solution of 6-bromo-3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazole (241 mg, 0.48 mmol), tert-butyl 4-iodo-2-propyl-piperidine-l -carboxylate (340.25 mg, 0.96 mmol), Mn (52.92 mg, 0.96 mmol), Nal (18.05 mg, 0.12 mmol) and pyridine-2-carboximidamide (7.57 mg, 0.05 mmol) in DMA (4 mL) was added NiCLfDME) (10.58 mg, 0.05 mmol), then the reaction mixture was stirred at 45 °C for 17 h under argon atmosphere. The mixture was diluted with water and ethyl acetate, then filtered through celite. The filtrate was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography to afford the title compound.

Step 4: tert-Butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-2-propyl-piperidine-l- carboxylate

To a solution of tert-butyl 4-[3-(2,6-dibenzyloxy-3-pyridyl)-l-methyl-indazol-6-yl]-2- propyl-piperidine-1 -carboxylate (85 mg, 0.13 mmol) in acetic acid (1 mL) and ethanol (1 mL) was added Pd/C (43.19 mg), then the reaction mixture was stirred at 40 °C for 17 h under 1 atm hydrogen atmosphere. The mixture was filtered through celite, and the residue was purified by flash chromatography to afford the title compound. Step 5: 3-[l-Methyl-6-(2-propyl-4-piperidyl)indazol-3-yl]piperidine-2, 6-dione hydrochloride

To a solution of tert-butyl 4-[3-(2,6-dioxo-3-piperidyl)-l-methyl-indazol-6-yl]-2-propyl- piperidine-1 -carboxylate (48.35 mg, 0.1 mmol) in DCM (1 mL) was added HCl-dioxane solution (0.5 mL, 4.0 M), then the reaction mixture was stirred at r.t for 1 h. The solvent was removed under reduced pressure to afford the title compound.

Reference 26

Synthesis of 3-((3-(piperidin-4-yl)phenyl)amino)piperidine-2, 6-dione hydrochloride

Step 1 : tert-Butyl 4-(3-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidine-l-carboxylate

To a mixture of tert-butyl 4-(3-aminophenyl)piperidine-l -carboxylate (500 mg, 1.81 mmol) in DMF (10.0 mL) was added 3 -brom opiperidine-2, 6-dione (521 mg, 2.71 mmol) NaHCCh (456 mg, 5.43 mmol) and the mixture was stirred at 65 °C for 16 h under N2. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layer was washed with water, brine, dried over Na2SO4, concentrated. The residue was purified by flash column chromatography (ethyl acetate:PE=0~100%) to afford the title compound as a yellow solid. Step 2: 3-((3-(Piperidin-4-yl)phenyl)amino)piperidine-2,6-dione hydrochloride A mixture of tert-butyl 4-{3-[(2,6-dioxopiperidin-3-yl)amino]phenyl}piperidine-l- carboxylate (600 mg, 1.55 mmol) in HC1 ethyl acetate solution (2.0 M, 10.0 mL) was stirred at rt for 1 h. The mixture was concentrated to afford the title compound as a pale yellow solid.

Reference 27

Synthesis of 3-(l-methyl-6-(piperidin-4-yl)-lH-pyrazolo[4,3-c]pyridin-3-yl)piperidine-2, 6-dione hydrochloride

To a stirred solution of 6-bromo-lH-pyrazolo[4,3-c]pyridine (3.50 g, 17.67 mmol), KOH

(2.97 g, 53.01 mmol) in DMF (200.0 mL) was added I2 (8.97 g, 35.34 mmol), and the mixture was stirred at rt for 16 h. The mixture was diluted with water and filtered to afford the title compound as a brown solid.

Step 2: 6-Bromo-3-iodo-l-methyl-lH-pyrazolo[4,3-c]pyridine

To a stirred solution of 6-bromo-3-iodo-lH-pyrazolo[4,3-c]pyridine (3.00 g, 9.26 mmol) in DMF (100.0 mL) was added NaH (60%) (741 mg, 18.52 mmol) at 0 °C, and the mixture was stirred at 0 °C for 0.5 h. CH3I (2.63 g, 18.52 mmol, 2.00 eq.) was added to the mixture and stirred. After 2 h, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE:ethyl acetate = 3: 1 to afford the title compound as a pale yellow solid. Step 3: 3-(l-Methyl-6-(piperidin-4-yl)-lH-pyrazolo[4,3-c]pyridin-3-yl)piperidine-2, 6-dione hydrochloride

The title compound was synthesized by proceeding analogously as described in Reference 17, Steps 2-5 with 6-bromo-3-iodo-l-methyl-lH-pyrazolo[4,3-c]pyridine replacing 3-bromo-6- chl oro- 1 -b enzothi ophene .

Reference 28

Synthesis of 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-bromo-l,5-dimethyl-lH-indazole

Step 1 : 6-Bromo-3-iodo-5-methyl-lH-indazole

To a stirred solution of 6-bromo-5-methyl-lH-indazole (5.00 g, 23.70 mmol), KOH (3.98 g, 71.10 mmol) in DMF (200.0 mL) was added I2 (12.04 g, 47.40 mmol) and the resulting mixture was stirred at rt for 16 h. The mixture was diluted with water and the precipitate was collected by filtration to afford the title compound as a brown solid.

Step 2: 6-Bromo-3-iodo-l,5-dimethyl-lH-indazole

To a stirred solution of 6-bromo-3-iodo-5-methyl-lH-indazole (5.50 g, 16.32 mmol) in DMF (100.0 mL) was added NaH (60%) (1.30 g, 32.64 mmol) at 0 °C, and the resulting mixture reaction was stirred at 0 °C for 0.5 h. CH3I (4.63 g, 32.64 mmol) was then added to the above mixture, and the resulting mixture was stirred overnight. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous ISfeSCU and concentrated. The residue was purified by silica gel column chromatography, eluting with PE/ethyl acetate = 3/ 1 to afford the title compound as a yellow solid.

Step 3: 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-bromo-l,5-dimethyl-lH-indazole

To a mixture of 6-bromo-3-iodo-l,5-dimethyl-lH-indazole (2.60 g, 7.40 mmol) in dioxane/EEO (10: 1) (50.0 mL) was added CS2CO3 (7.23 g, 22.20 mmol), 2,6-bis(benzyloxy)-3- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (3.08 g, 7.40 mmol), Pd(dppf)C12 (541 mg, 0.74 mmol) and the resulting mixture was stirred at 70 °C for 16 h. After cooling to rt, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE: ethyl acetate = 8: 1 to afford the title compound as a yellow solid.

Reference 29

Synthesis of 3-(l,5-dimethyl-6-(piperazin-l-yl)-lH-indazol-3-yl)piperidine-2, 6-dione

Step 1 : tert-Butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l,5-dimethyl-lH-indazol-6-yl) piperazine- 1 -carboxylate

A mixture of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-bromo-l,5-dimethyl-lH-indazole (900 mg, 1.75 mmol), tert-butyl piperazine- 1 -carboxylate (651 mg, 3.50 mmol), CS2CO3 (1711 mg, 5.25 mmol), Pd2(dba)3 (160 mg, 0.175 mmol), X-Phos (166 mg, 0.35 mmol) in DMF (20.0 mL) was stirred at 80 °C for 16 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE:ethyl acetate = 5: 1 to give the title compound as a yellow solid.

Step 2: tert-Butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl) piperazine-1-

To a stirred solution of tert-butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l,5-dimethyl-lH- indazol-6-yl) piperazine- 1 -carboxylate (800 mg, 1.29 mmol) in EtOH (10.0 mL) was added Pd/C (5%) (100 mg) at rt. The mixture was stirred for 2 h under 1 atm EE. The mixture was diluted with DCM and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluting with PE:ethyl acetate = 1 : 1 to give the title compound as a yellow solid.

Step 3: 3-(l,5-Dimethyl-6-(piperazin-l-yl)-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride

A mixture of tert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6- yl)piperazine-l -carboxylate (150 mg, 0.34 mmol) in 4 M HCl/ethyl acetate solution (5.0 mL) was stirred at 0 °C for 2 h. The mixture was concentrated under reduced pressure to afford the title compound as white solid.

The following compounds were synthesized by proceeding analogously as described in

Reference 29.

Reference 30

Synthesis of l-[l,5-dimethyl-6-(4-piperidyl)indazol-3-yl]hexahydropyrimidine-2, 4-dione hydrochloride

Step 1 : l-(6-Bromo-l,5-dimethyl-indazol-3-yl)hexahydropyrimidine-2, 4-dione

To a stirred solution of 6-bromo-3-iodo-l,5-dimethyl-indazole (730 mg, 2.08 mmol), 5,6- dihydrouracil (711.93 mg, 6.24 mmol) and K3PO4 (1324.56 mg, 6.24 mmol) in DMSO (7.5 mL) was added Cui (198.07 mg, 1.04 mmol), followed by 1,10-phenanthroline (234.27 mg, 1.3 mmol). The resulting mixture was stirred at 100 °C under argon atmosphere for 18 h. After cooling to rt, the mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue was purified by flash chromatography, eluted with methanol/dichloromethane (0-15%) to afford the title compound as a yellow solid. Step 2: l-[l,5-Dimethyl-6-(4-piperidyl)indazol-3-yl]hexahydropyrimidine-2, 4-dione hydrochloride The title compound was synthesized by proceeding analogously as described in Reference

17, Steps 3-5.

Reference 31

Synthesis of 3-((2 -methoxy -4-(piperidin-4-yl)phenyl)amino)piperidine-2, 6-dione hydrochloride

Step 1 : tert-Butyl 4-(3-methoxy-4-nitrophenyl)-3,6-dihydropyridine-l(2H)-carboxylate

To a stirred solution of 4-chl oro-2-m ethoxy- 1 -nitrobenzene (500 mg, 2.67 mmol) in dioxane/FLO (10.0 mL/5.0 mL) was added tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-3,6-dihydropyridine-l(2H)-carboxylate (992 mg, 3.21 mmol), ISfeCCh (850 mg, 8.02 mmol) and Pd(PPh3)C12 (113 mg, 0.16 mmol). The resulting mixture was stirred at 120 °C for 30 min. The resulting mixture was diluted with water and extracted with ethyl acetate and the combined organic layers were washed with brine, dried over anhydrous ISfeSCU, and concentrated. The residue was purified by silica gel column chromatography (DCM:MeOH=15: 1) to give the title compound as a yellow oil.

Step 2: tert-Butyl 4-(4-amino-3-methoxyphenyl)piperidine-l -carboxylate

To a stirred solution of tert-butyl 4-(3-methoxy-4-nitrophenyl)-3,6-dihydropyridine-l(2H)- carboxylate (850 mg, 2.54 mmol) in MeOH (8.0 mL) was added Pd/C (430 mg) and the mixture was stirred for 16 h under 1 atm H2. The resulting mixture was filtered, and the filtrate was concentrated to afford the title compound as a yellow solid. Step 3: tert-Butyl 4-(4-((2,6-dioxopiperidin-3-yl)amino)-3-methoxyphenyl)piperidine-l- carboxylate

To a stirred solution of tert-butyl 4-(4-amino-3-methoxyphenyl)piperidine-l-carboxylate (300 mg, 0.98 mmol) in DMF (5.0 mL) was added 3-bromopiperidine-2, 6-dione (281 mg, 1.47 mmol), NaHCCh (247 mg, 2.94 mmol) and the mixture was stirred at 65 °C for 16 h. The resulting mixture was diluted with water and extracted with EtOAc. The combined organic layer was washed with brine, dried over anhydrous Na2SO4, concentrated under vacuum to afford the title compound as a yellow oil.

Step 4: 3-((2 -Methoxy -4-(piperidin-4-yl)phenyl)amino)piperidine-2, 6-dione hydrochloride

A mixture of tert-butyl 4-(4-((2,6-dioxopiperidin-3-yl)amino)-3-methoxyphenyl)- piperidine-1 -carboxylate (384 mg, 0.92 mmol) in HC1 EtOAc solution (2 M, 2.0 ml) was stirred for 16 h. The reaction mixture was then concentrated under reduced pressure to afford the compound as a white solid.

The following Reference compounds were synthesized by proceeding analogously as described in Reference 31.

Reference 32

Synthesis of 3-[[3-methoxy-5-(4-piperidyl)-2-pyridyl]amino]piperidine-2, 6-dione hydrochloride Step 1: 2,6-Dibenzyloxy-N-(5-bromo-3-methoxy-2-pyridyl)pyridin-3-amine To a solution of 5 -bromo-3 -methoxy -pyridin-2-amine (200 mg, 1.0 mmol), 2,6-dibenzyl- oxy-3 -iodo-pyridine (493.2 mg, 1.2 mmol) and sodium tert-butoxide (189.1 mg, 2.0 mmol) in 1,4- dioxane (4 mL) was added RuPhos (92 mg, 0.2 mmol) and Pd2(dba)s (90.2 mg, 0.1 mmol), then the reaction mixture was stirred at 90 °C for 12 h under argon atmosphere. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford the title compound. Step 2: 3-[[3-methoxy-5-(4-piperidyl)-2-pyridyl]amino]piperidine-2, 6-dione hydrochloride

The title compound was synthesized by proceeding analogously as described in Reference 17, Steps 3-5, using 2,6-dibenzyloxy-N-(5-bromo-3-methoxy-2-pyridyl)pyridin-3-amine instead of 2,6-bis(benzyloxy)-3-(6-chlorobenzo[b]thiophen-3-yl)pyridine in step 3.

The following Reference compounds were synthesized by proceeding analogously as described in Reference 32.

Reference 33

Synthesis of 3-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-methoxy-5-methyl-anilino]piperidine-2,6- dione hydrochloride Step 1 : tert-Butyl 3-[4-[(2,6-dioxo-3-piperidyl)amino]-5-methoxy-2-methyl-phenyl]-3,8-diaza- bicyclo[3.2.1]octane-8-carboxylate

A mixture of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (584 mg, 2.75 mmol), 3-(4-bromo-2-methoxy-5-methyl-anilino)piperidine-2, 6-dione (300 mg, 0.92 mmol), CS2CO3 (597.8 mg, 1.83 mmol) and Pd-PEPP SI-IP entC (78.9 mg, 0.09 mmol) in 1,4-dioxane (3 mL) was stirred at 100 °C for 2 h under argon atmosphere. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with DCM/MeOH (0~5%) to afford the title compound.

Step 2: 3-[4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-2-methoxy-5-methyl-anilino] piperidine-2,6- dione hydrochloride

To a stirred solution of tert-butyl 3-[4-[(2,6-dioxo-3-piperidyl)amino]-5-methoxy-2- methyl-phenyl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (200 mg, 0.44 mmol) in DCM (2.0 mL) was added HC1 in dioxane (2.0 mL, 4.0 M) at rt and the mixture was stirred for 1 h. The solvent was removed under reduced pressure to afford the title compound.

The following Reference compound was synthesized by proceeding analogously as described in Reference 33. Reference 34

Synthesis of 3-[(5-methyl-6-piperazin-l-yl-pyridazin-3-yl)amino]piperidine-2, 6-dione hydrochloride

Step 1 : 6-Chloro-N-(2,6-dibenzyloxy-3-pyridyl)-5-methyl-pyridazin-3-amine

To a stirred solution of 6-chloro-5-methyl-pyridazin-3-amine (500 mg, 3.48 mmol) and 2,6-dibenzyloxy-3-bromopyridine (1547.3 mg, 4.18 mmol) in toluene (10 mL) was added CS2CO3 (3398 mg, 10.44 mmol), Brettphos (373.87 mg, 0.696 mmol) and Pd2(dba)3 (318.91 mg, 0.348 mmol), and the resulting mixture was stirred at 100 °C for 16 h under argon atmosphere. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate/petroleum ester (0-30%) to afford the title compound as a white solid.

Step 2: tert-Butyl 4-[6-[(2,6-dibenzyloxy-3-pyridyl)amino]-4-methyl-pyridazin-3-yl]piperazine-l- carboxylate

To a stirred solution of 6-chloro-N-(2,6-dibenzyloxy-3-pyridyl)-5-methyl-pyridazin-3- amine (250 mg, 0.577 mmol) and 1-boc-piperazine (322.6 mg, 1.73 mmol) in 1,4-dioxane (5 mL) was added CS2CO3 (166.5 mg, 1.73 mmol), and Pd-PEPP SI-IP ent catalyst (49.6 mg, 0.057 mmol), and the resulting mixture was stirred at 100 °C for 3 h under argon atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate/petr oleum ester (0-40%) to afford the title compound as a white solid. Step 3: 3-[(5-Methyl-6-piperazin-l-yl-pyridazin-3-yl)amino]piperidine-2, 6-dione hydrochloride

The title compound was synthesized by proceeding analogously as described in Reference 17, Steps 4-5.

Reference 35

Synthesis of 3-[(2-methoxy-5-methyl-6-piperazin-l-yl-3-pyridyl)amino]piperidine-2, 6-dione hydrochloride

Step 1 : 2-Chloro-6-methoxy-3-methyl-5-nitro-pyridine

Sodium methoxide (287.05 mg, 5.31 mmol) was added to the solution of 2,6-dichloro-3- methyl-5-nitro-pyridine (1000 mg, 4.83 mmol) in toluene (10 mL) at 0 °C under Ar, and the mixture was stirred at rt for 16 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over ISfeSCU and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate/petroleum ester (0-20%) to afford the title compound as colorless oil.

Step 2: tert-Butyl 4-(6-methoxy-3-methyl-5-nitro-2-pyridyl)piperazine-l -carboxylate

A mixture of 1-Boc-piperazine (275.8 mg, 1.48 mmol), 2-chl oro-6-m ethoxy-3 -methyl-5- nitro-pyridine (200 mg, 0.99 mmol) and K2CO3 (409.33 mg, 2.96 mmol) in DMF (2 mL) was stirred at 50 °C for 16 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate/petroleum ester (0-30%) to afford the title compound as colorless oil. Step 3: tert-Butyl 4-(5-amino-6-methoxy-3-methyl-2-pyridyl)piperazine-l -carboxylate

A mixture of tert-butyl 4-(6-methoxy-3-methyl-5-nitro-2-pyridyl)piperazine-l-carboxylate (150 mg, 0.43 mmol) and Pd/C (50 mg) in methanol (5 mL) was stirred for 16 h under 1 atm H2. The mixture was filtered, and the filtrate was concentrated to give the title compound. Step 4: tert-Butyl 4-[5-[(2,6-dibenzyloxy-3-pyridyl)amino]-6-methoxy-3-methyl-2-pyridyl]- piperazine- 1 -carboxylate

A mixture of tert-butyl 4-(5-amino-6-methoxy-3-methyl-2-pyridyl)piperazine-l- carboxylate (140 mg, 0.43 mmol), RuPhos (40.53 mg, 0.09 mmol), Pd2(dba)s (39.76 mg, 0.04 mmol), CS2CO3 (423.7 mg, 1.3 mmol) and 2, 6-dibenzyloxy-3 -iodo-pyridine (217.42 mg, 0.52 mmol) in tert-butanol (1.5 mL) was stirred at 100 °C for 16 h under Ar. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate/petroleum ester (0-15%) to afford the title compound as a yellow solid.

Step 5: 3-[(2-Methoxy-5-methyl-6-piperazin-l-yl-3-pyridyl)amino]piperidine-2, 6-dione hydrochloride

The title compound was synthesized by proceeding analogously as described in Reference 17, Steps 4-5. Reference 36

Synthesis of l-(l-methyl-6-(2-azaspiro[3.3]heptan-6-yl)-lH-indazol-3-yl)dihydropyrimidine- 2,4(lH,3H)-dione hydrochloride

Step 1 : tert-Butyl 6-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)-2- azaspiro[3.3]heptane-2-carboxylate

A mixture of l-(6-bromo-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione (300 mg, 0.93 mmol), tert-butyl 6-iodo-2-azaspiro[3.3]heptane-2-carboxylate (602 mg, 1.86 mmol), Mn (102 mg, 1.86 mmol), 2H-pyrrole-2-carboximidamide hydrochloride (29 mg, 0.19 mmol), Nal (35 mg, 0.23 mmol) and NiC12(ClMe2) (41 mg, 0.19 mmol) in DMA (5.0 mL) was stirred at 50 °C for 16 h. The resulting mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, DCM:MeOH=20: l to give the title compound as a white solid.

Step 2: l-(l-Methyl-6-(2-azaspiro[3.3]heptan-6-yl)-lH-indazol-3-yl)dihydropyrimidine- 2,4(lH,3H)-dione hydrochloride

To a stirred solution of tert-butyl 6-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl- lH-indazol-6-yl)-2-azaspiro[3.3]heptane-2-carboxylate (347 mg, 0.79 mmol) in ethyl acetate (2.5 mL) was added 2 M HC1 in ethyl acetate (2.5 mL) at rt and stirred for 2 h. The resulting mixture was concentrated under reduced pressure to afford the title compound as a white solid. Reference 37

Synthesis of 3-(6-(piperidin-4-yl)pyrazolo[l,5-a]pyridin-3-yl)piperidine-2, 6-dione hydrochloride

Step 1 : 6-Bromo-3-iodopyrazolo[l,5-a]pyridine

To a stirred solution of 6-bromopyrazolo[l,5-a]pyridine (3.0 g, 15.23 mmol) in DMF (30.0 mL) was added I2 (5.80 g, 22.85 mmol) and KOH (2.56 g, 45.69 mmol) at r.t., and the mixture was stirred for 16 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE/ethyl acetate=4: l, to afford the title compound as a white solid.

Step 2: 3-(6-(Piperidin-4-yl)pyrazolo[l,5-a]pyridin-3-yl)piperidine-2, 6-dione hydrochloride

The title compound was synthesized by proceeding analogously as described in Reference 17 Steps 2-5 using 6-bromo-3-iodopyrazolo[l,5-a]pyridine instead of 3-bromo-6-chloro-l- benzothiophene.

Reference 38

Synthesis of 3-(l,7-dimethyl-6-(piperazin-l-yl)-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride Step 1 : 6-Bromo-3-iodo-7-methyl-lH-indazole

To a stirred solution of 6-bromo-7-methyl-lH-indazole (5.00 g, 23.70 mmol), KOH (3.98 g, 71.10 mmol) in DMF (200 mL) was added I2 (12.04 g, 47.40 mmol) and the mixture was stirred at rt for 16 h. The mixture was diluted with water and filtered to afford the title compound as a brown solid.

Step 2: 6-Bromo-3-iodo-l,5-dimethyl-lH-indazole

To a stirred solution of 6-bromo-3-iodo-7-methyl-lH-indazole (5.50 g, 16.32 mmol) in DMF (100.0 mL) was added NaH (60%) (1.30 g, 32.64 mmol) at 0 °C, and the mixture was stirred at 0 °C for 0.5 h. Then CH3I (4.63 g, 32.64 mmol) was added. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE: ethyl acetate = 3 : 1 to afford the title compound as a yellow solid.

Step 3: 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-bromo-l,7-dimethyl-lH-indazole

A mixture of 6-bromo-3-iodo-l,5-dimethyl-lH-indazole (2.60 g, 7.40 mmol), CS2CO3 (7.23 g, 22.2 mmol), 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (3.08 g, 7.40mmol) , Pd(dppf)C12 (0.541 g, 0.74 mmol) in dioxane/TEO (10: 1) (50.0 mL) was stirred at 70 °C for 16 h under argon. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE:ethyl acetate = 8:1 to afford the title compound as a yellow solid. Step 4: tert-Butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l,7-dimethyl-lH-indazol-6-yl)piperazine- 1 -carboxylate

A mixture of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-bromo-l,7-dimethyl-lH-indazole (900 mg, 1.75 mmol), tert-butyl piperazine- 1 -carboxylate (651 mg, 3.50 mmol), CS2CO3 (1711 mg, 5.25 mmol), Pd2(dba)s (160 mg, 0.175 mmol), X-Phos (166 mg, 0.35 mmol) in DMF (20 mL) was stirred at 80 °C for 16 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous ISfeSCU and concentrated. The residue was purified by silica gel column chromatography, eluted with PE: ethyl acetate = 5:1 to afford the title compound as a yellow solid.

Step 5: tert-Butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l,7-dimethyl-lH-indazol-6-yl)piperazine-l-

To a stirred solution of tert-butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l,7-dimethyl-lH- indazol-6-yl)piperazine-l -carboxylate (800 mg, 1.29 mmol) in EtOH (10 mL) was added Pd/C (5%) (100 mg), and the mixture was stirred under 1 atm H2 for 2 h. The mixture was diluted with DCM and filtered. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE:ethyl acetate = 1 : 1 to afford the title compound as a yellow solid.

Step 6: 3-(l,7-Dimethyl-6-(piperazin-l-yl)-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride

A solution of HC1 in ethyl acetate (4.0 M, 5.0 mL) was added to tert-butyl 4-(3-(2,6- dioxopiperidin-3-yl)-l,7-dimethyl-lH-indazol-6-yl)piperazine-l-carboxylate (150 mg, 0.34 mmol) at 0 °C, and the mixture was stirred for 2 h. The mixture was concentrated under reduced pressure to afford the title compound as white solid as a white solid. The following Reference compound was synthesized by proceeding analogously as described in Reference 38.

Reference 39

Synthesis of 3-(6-(8-azabicyclo[3.2. l]octan-3-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride

Step 1 : tert-Butyl 3-(((trifluoromethyl)sulfonyl)oxy)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate oc

To a solution of tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (500 mg, 2.22 mmol) in THF (6.0 mL) was added LDA (2 M in THF, 1.7 mL) at -78 °C, and the mixture was stirred for 30 min. Then l,l,l-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methane- sulfonamide was added (872 mg, 2.44 mmol) at -78 °C. The mixture was warmed to rt and stirred for 3 h and quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous ISfeSCU and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE:ethyl acetate =10: 1, to afford the title compound as a yellow oil.

Step 2: tert-Butyl 3-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH-indazol-6-yl)-8- azabicyclo[3.2.1 ]oct-2-ene-8-carboxylate To a solution of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-6-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-indazole (300 mg, 0.55 mmol) and tert-butyl 3-(((trifluoromethyl)- sulfonyl)oxy)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (314 mg, 0.88 mmol) in dioxane/EEO = 5/1 (10.0 mL) was added Pd(dppf)C12 (59 mg, 0.08 mmol) and K3PO4 (350 mg, 1.65 mmol). The mixture was stirred at 65 °C under nitrogen for 3 h. Then the mixture was filtrated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:ethyl acetate =3: 1) to afford the title compound as a yellow oil. Step 3: tert-Butyl 3-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-8- azabicyclo[3.2.1 ]octane-8-carboxylate

The title compound was synthesized by proceeding analogously as described in Reference 23, Step 3-4, using tert-butyl 3-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH-indazol-6-yl)-8- azabicyclo[3.2.1]oct-2-ene-8-carboxylate instead of tert-butyl 4-(4-(2,4-dioxotetrahydropyrimidin- 1 (2H)-yl)phenyl)piperidine- 1 -carboxylate. The following Reference compounds were synthesized by proceeding analogously as described in Reference 39. Reference 40

Synthesis of 3-(3-(Difluoromethyl)-5-(piperidin-4-yl)-lH-indazol-l-yl)piperidine-2, 6-dione

Step 1 : 5-Bromo-3-(difhioromethyl)-lH-indazole

To a stirred solution of 5-bromo-lH-indazole-3-carbaldehyde (3 g, 13.33 mmol) in DCM (30 mL) was added DAST (2.47 g, 66.66 mmol) dropwise at 0 °C under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 16 h under nitrogen atmosphere. The reaction mixture was quenched with water and extracted with DCM. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSCU and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-50%) to afford the title compound as a light yellow solid.

Step 2 : 3 -(5-Bromo-3 -(difluoromethyl)- IH-indazol- 1 -yl)piperidine-2, 6-dione

To a solution of 5 -bromo-3 -(difluoromethyl)- IH-indazole (1.6 g, 6.477 mmol) in DMF (16 mL) was added NaH (0.78 g, 19.431 mmol) at 0 °C and the resulting mixture was stirred for 30 min under nitrogen atmosphere. A solution of 3-bromopiperidine-2, 6-dione (1.87 g, 9.716 mmol, 1.5 equiv) in DMF (10 mL) was added dropwise at 0 °C and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was then quenched with sat. NH4CI aq. solution at 0 °C and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSCU and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-60%) to afford the title compound as a light yellow solid. Step 3 : tert-Butyl 4-(3-(difluoromethyl)-l-(2,6-dioxopiperidin-3-yl)-lH-indazol-5-yl)piperidine-l- carboxylate

To a stirred mixture of 3-(5-bromo-3-(difluoromethyl)-lH-indazol-l-yl)piperidine-2,6- dione (700 mg, 1.96 mmol), TBAI (725 mg, 1.96 mmol), pyridine-2-carboximidamide hydrochloride (62 mg, 0.39 mmol), NiCh(DME) (80 mg) and tert-butyl 4-iodopiperidine-l- carboxylate (1.82 g, 5.87 mmol) in DMAc (7 mL) was added zinc powder (260 mg, 3.98 mmol) and TFA (112 mg, 0.982 mmol) in DMAc (2 mL) under nitrogen atmosphere. The resulting mixture was stirred at rt for 5 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-80%) to afford the title compound as a light yellow solid.

Step 4: 3-(3-(Difluoromethyl)-5-(piperidin-4-yl)-lH-indazol-l-yl)piperidine-2, 6-dione hydrochloride

To a stirred solution of tert-butyl 4-(3-(difluoromethyl)-l-(2,6-dioxopiperidin-3-yl)-lH- indazol-5-yl)piperidine-l-carboxylate (120 mg, 0.156 mmol) in DCM (1 mL) were added 4 M HC1 in dioxane (1 mL) in portions at rt, and the resulting mixture was stirred at rt for 1 h. The reaction mixture was then concentrated under reduced pressure to afford the title compound as an off-white solid.

The following Reference compounds were synthesized by proceeding analogously as described in Reference 40.

Reference 41

Synthesis of 3-(6-(2,2-dimethylpiperazin-l-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride

Step 1 : 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-bromo-l-methyl-lH-indazole

To a solution of 6-bromo-3-iodo-l-methyl-lH-indazole (5.00 g, 14.84 mmol, 1.00 eq.) and 2,6- bis(benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (6.81 g, 16.32 mmol) in dioxane/water = 5/1 (70.0 mL) was added Pd(dppf)C12 (1.08g, 1.48 mmol) and CS2CO3 (12.09 g, 37.10 mmol). The mixture was stirred at 80 °C under nitrogen for 12 h. After cooling to rt, the mixture was filtrated and the filtrate was concentrated. The residue was purified by silica gel column chromatography (PE :ethyl acetate = 7 : 1) to give the title compound as a yellow solid.

Step 2: 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-6-iodo-l-methyl-lH-indazole

To a solution of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-bromo-l-methyl-lH-indazole (4.50 g, 8.99 mmol), KI (7.46 g, 44.95 mmol) and Cui (1.71 g, 8.99 mmol) in DMF (50.0 mL) was added N,N'-dimethylethylenediamine (1.58 g, 17.98 mmol) and the resulting mixture was stirred at 110 °C for 16 h. The mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (PE: ethyl acetate = 8 : 1) to give the title compound as a yellow solid.

Step 3: tert-Butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3- dimethylpiperazine-1 -carboxylate

To a solution of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-iodo-l-methyl-lH-indazole (800 mg, 1.46 mmol) and tert-butyl 3,3-dimethylpiperazine-l-carboxylate (782 mg, 3.65 mmol) in dioxane (10.0 mL) was added RuPhos Pd G4 (128 mg, 0.15 mmol) and t-BuONa (323 mg, 3.36 mmol). The mixture was stirred at 90 °C under microwave irradiation for 2.5 h. After cooling at rt, the reaction mixture was filtrated and the filtrate was concentrated. The residue was purified by silica gel column chromatography (DCM : MeOH = 30 : 1) to give the title compound as a brown solid.

Step 4: tert-Butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3- dimethylpiperazine-1 -carboxylate

To a solution of tert-butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH-indazol-6-yl)- 3,3-dimethylpiperazine-l-carboxylate (50 mg, 0.08 mmol) in EtOH (4.0 mL) was added Pd/C (25 mg) and Pd(OH)2 (25 mg) and the resulting mixture was stirred at 40 °C under EE for 16 h. The mixture was filtrated and the filtrate was concentrated. The residue was purified by prep TLC (DCM : MeOH = 30 : 1) to give the title compound as a brown solid.

Step 5 : 3 -(6-(2,2-Dimethylpiperazin- 1 -yl)- 1 -methyl- lH-indazol-3 -yl)piperidine-2, 6-dione hydrochloride

To a solution of tert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-3,3- dimethylpiperazine-1 -carboxylate (27 mg, 0.06 mmol) in ethyl acetate (1.0 mL) was added ethyl acetate/HCl (1.0 mL) and the resulting mixture was stirred at rt for 2 h. The mixture was concentrated to give the title compound as a white solid. The following Reference compounds were synthesized by proceeding analogously as described in Reference 41.

Reference 42 Synthesis of 3-(l-methyl-6-((2R)-2-methylpiperidin-4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione

2, 2, 2-tri fluoroacetate Step 1 : tert-Butyl (R)-6-methyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-l(2H)- carboxylate i Boc Boc

To a solution of tert-butyl (R)-2-methyl-4-oxopiperidine-l -carboxylate (426 mg, 2.0 mmol) in THF (10.0 mL) was added LDA (2.0 M in THF, 3.0 mL, 6.0 mmol) dropwise at -78 °C under N2 and the resulting mixture was stirred at -78 °C for 30 mins. 1,1,1-Trifluoro-N-phenyl-N- ((trifluoromethyl)sulfonyl)methanesulfonamide (1.1g, 3.0 mmol) was added to the above solution and the mixture was stirred at rt under N2 for 3 h. The reaction mixture was quenched with water and extracted with EtOAc and the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (PE:ethyl acetate = 30: 1) to give the title compound as a yellow oil.

Step 2: 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-l-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-lH-indazole

To a mixture of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-bromo-l-methyl-lH-indazole (1.00 g, 2.0 mmol) in 1,4-dioxane (10.0 mL) was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2- dioxaborolane) (762 mg, 3.0 mmol), Pd(dppf)C12 (146 mg, 0.20 mmol) and KO Ac (588 mg, 6.0 mmol), and the resulting mixture was stirred at 80 °C under N2 for 16 h. After cooling to rt, the reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (PE:ethyl acetate = 5: 1) to give the title compound as a yellow oil. Step 3: tert-Butyl (R)-4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH-indazol-6-yl)-6-methyl-

3 ,6-dihydropyridine- 1 (2H)-carboxylate

To a mixture of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-6-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-indazole (110 mg, 0.2 mmol) in l,4-dioxane/H2O (5.0 mL/0.5mL) was added tert-butyl (R)-6-methyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-l(2H)- carboxylate (104 mg, 0.3 mmol), Pd(dppf)C12 (14.6 mg, 0.02 mmol) and K2CO3 (83 mg, 0.6 mmol). The resulting mixture was stirred at 60 °C for 16 h and then quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography (PE:ethyl acetate = 7: 1) to give the title compound as a yellow oil. Step 4: tert-Butyl (2R)-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)-2-methyl- piperidine-1 -carboxylate

A mixture of tert-butyl (R)-4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH-indazol-6- yl)-6-methyl-3,6-dihydropyridine-l(2H)-carboxylate (100 mg, 0.16 mmol), Pd/C (50 mg) and Pd(OH)2/C (50 mg) in EtOH (5.0 mL) was stirred at 50 °C under 1 atom hydrogen for 16 h. The mixture was filtered and the filtration was concentration to give the title compound as a yellow solid.

Step 5: 3-(l-Methyl-6-((2R)-2-methylpiperidin-4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2- tri fluoroacetate To a solution of tert-butyl (2R)-4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)- 2-methylpiperidine-l -carboxylate (70 mg, 0.16 mmol) in DCM (2.0 mL) was added TFA (0.5 mL) and the resulting mixture was stirred at rt for 3 h. The solution was then concentrated to give the title compound as a yellow oil. The following Reference compounds were synthesized by proceeding analogously as described in Reference 42.

Reference 43

Synthesis of 3-(3-chloro-6-(difluoromethyl)-5-(piperazin-l-yl)-lH-indazol-l-yl)piperidine-2,6- dione hydrochloride

Step 1 : (5-Bromo-lH-indazol-6-yl)methanol

To a stirred mixture of methyl 5-bromo-lH-indazole-6-carboxylate (10 g, 39.2 mmol) and CaCh (10.9 g, 98 mmol) in THF (50 mL) and EtOH (50 mL) were added NaBH₄ (7.42 g, 196 mmol) in portions at 0 °C under nitrogen atmosphere, and the resulting mixture was stirred at rt for 4 h. The reaction mixture was quenched with sat. NH4CI aq. at 0°C and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-70%) to afford the title compound as a light yellow solid.

Step 2: 5-Bromo-lH-indazole-6-carbaldehyde

To a stirred mixture of (5-bromo-lH-indazol-6-yl)methanol (3.2 g, 14.09 mmol) in DCM (32 mL) were added MnCL (12.3 g, 140.9 mmol) in portions, and the resulting mixture was stirred at rt for 36 h. The reaction mixture was then diluted with DCM and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-40%) to afford the title compound as a light yellow solid.

Step 3: 5-Bromo-3-chloro-lH-indazole-6-carbaldehyde

To a stirred solution of 5-bromo-lH-indazole-6-carbaldehyde (1.5 g, 6.67 mmol) in DMF (15 mL) was added NCS (1.1 g, 8 mmol) at rt under nitrogen atmosphere, and the resulting mixture was stirred at room temperature for 6 h under nitrogen atmosphere. The reaction mixture was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSCU, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-30%) to afford the title compound as a light yellow solid.

Step 4: 5-Bromo-3-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-indazole-6-carbaldehyde

To a stirred mixture of 5-bromo-3-chloro-lH-indazole-6-carbaldehyde (1.2 g, 4.6 mmol) in THF (12 mL) were added NaH (740 mg, 18.5 mmol, 60% in mineral oil) in portions at 0 °C, and the resulting mixture was stirred at rt for 0.5 h. SEM-C1 (1.15 g, 6.9 mmol) was added to the above mixture dropwise at 0°C, and the resulting mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with sat. NELC1 aq. solution at 0 °C and then extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSCU and concentrated. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-20%) to afford the title compound as a light yellow oil.

Step 5: 5-Bromo-3-chloro-6-(difluoromethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-indazole

To a stirred solution of 5-bromo-3-chloro-l-((2-(trimethylsilyl)ethoxy)methyl)-lH- indazole-6-carbaldehyde (620 mg, 1.6 mmol) in DCM (6 mL) was added DAST (770 mg, 4.8 mmol) dropwise at -10 °C under nitrogen atmosphere, and the resulting mixture was stirred at rt overnight under nitrogen atmosphere. The reaction mixture was quenched with ice water and then extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSCU, and concentrated. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-25%) to afford the title compound as a light yellow oil.

Step 6: tert-Butyl 4-(3-chloro-6-(difluoromethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH- indazol-5-yl)piperazine-l -carboxylate

A mixture of 5-bromo-3-chloro-6-(difluoromethyl)-l-((2-(trimethylsilyl)ethoxy)methyl)- IH-indazole (400 mg, 0.97 mmol), tert-butyl piperazine- 1 -carboxylate (272 mg, 1.5 mmol), Pd2(dba)s (178 mg, 0.2 mmol), XantPhos (113 mg, 0.2 mmol) and CS2CO3 (950 mg, 2.9 mmol) in dioxane (4 mL) was stirred at 100 °C for 16 h under nitrogen atmosphere. After cooling to rt the reaction was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSCU and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-20%) to afford the title compound.

Step 7: tert-Butyl 4-(3-chloro-6-(difluoromethyl)-lH-indazol-5-yl)piperazine-l-carboxylate

A mixture of tert-butyl 4-(3-chloro-6-(difluoromethyl)-l-((2-(trimethylsilyl)ethoxy)- methyl)-lH-indazol-5-yl)piperazine-l-carboxylate (233 mg, 0.45 mmol) and 1.0 M TBAF in THF (5 mL, 5 mmol) in THF (4 mL) was stirred at 60 °C overnight under nitrogen atmosphere. After cooling at rt, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-70%) to afford the title compound as a yellow solid.

Step 8: tert-Butyl 4-(3-chloro-6-(difluoromethyl)-l-(2,6-dioxopiperidin-3-yl)-lH-indazol-5- yl)piperazine-l -carboxylate

To a solution of tert-butyl 4-(3-chloro-6-(difluoromethyl)-lH-indazol-5-yl)piperazine-l- carboxylate (120 mg, 0.31 mmol) in DMF (2 mL) was added NaH (50 mg, 1.25 mmol, 60%) at 0 °C under nitrogen atmosphere, and the reaction mixture was stirred for 30 min. A solution of 3- bromopiperidine-2, 6-dione (120 mg, 0.63 mmol) in DMF (2 mL) was added dropwise to the above mixture at 0°C, and the resulting mixture was stirred at room temperature for 2 h under nitrogen atmosphere. The reaction mixture was cooled in an ice water bath and quenched with sat. NH4CI aq. solution at 0 °C, then extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSCU and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-60%) to afford the title compound as a light yellow solid.

Step 9 : 3 -(3 -Chloro-6-(difluoromethyl)-5-(piperazin- 1 -yl)- IH-indazol- 1 -yl)piperidine-2, 6-dione hydrochloride

A mixture of tert-butyl 4-(3-chloro-6-(difluoromethyl)-l-(2,6-dioxopiperidin-3-yl)-lH- indazol-5-yl)piperazine-l -carboxylate (63 mg, 0.13 mmol) and 4 M HC1 in dioxane (1 mL) in DCM (1 mL) was stirred at room temperature for 1 h. The resulting mixture was concentrated under reduced pressure to afford the title compound as a light yellow solid.

The following Reference compound was synthesized by proceeding analogously as described in Reference 43.

Reference 44

Synthesis of 3-chloro-l-(2,6-dioxopiperidin-3-yl)-5-(piperazin-l-yl)-lH-indazole-6-carbonitrile

Step 1 : 5-Amino-2-bromo-4-methylbenzonitrile

To a stirred solution of 3-amino-4-methylbenzonitrile (5 g, 37.8 mmol) in DMF (50 mL) was added NBS (6.7g, 37.8 mmol) in portions at room temperature, and the resulting mixture was stirred at rt for 1 h under nitrogen atmosphere. Water was added to the reaction mixture and the precipitate was collected by filtration to give the title compound as a yellow solid.

Step 2: 5-Bromo-lH-indazole-6-carbonitrile

To a stirred solution of 5-amino-2-bromo-4-methylbenzonitrile (3.5 g, 17 mmol) in AcOH (90 mL) and H2O (3 mL) were added NaNCL (1.3 g, 18.2 mmol) in portions at room temperature, and the resulting mixture was stirred at room temperature for 16 h. The reaction mixture was basified to pH 8 with Na2COs aq solution, and then extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-100%) to afford the title compound as a yellow solid. Step 3: 3-Chloro-l-(2,6-dioxopiperidin-3-yl)-5-(piperazin-l-yl)-lH-indazole-6-carbonitrile hydrochloride

The title compound was synthesized by proceeding analogously as described in Reference 43, Steps 3-9.

Reference 45

Synthesis of 3-(6-methyl-5-(piperazin-l-yl)-lH-pyrazolo[3,4-b]pyridin-l-yl)piperidine-2, 6-dione hydrochloride

Step 1 : 3-(5-Bromo-6-methyl-lH-pyrazolo[3,4-b]pyridin-l-yl)piperidine-2, 6-dione

To a stirred solution of 5-bromo-6-methyl-lH-pyrazolo[3,4-b]pyridine (2 g, 9.4 mmol) in DMF (20 mL) was added NaH (1.13 g, 28.3 mmol, 60%) in portions at 0 °C, and the resulting mixture was stirred at 0 °C for 30 min. A solution of 3 -brom opiperidine-2, 6-dione (3.6 g, 18.9 mmol) in DMF (20 mL) was added to the above mixture dropwise at 0°C, and the resulting mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with sat. NH4CI aq. solution at 0°C and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous ISfeSCU, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-100%) to afford the title compound as a yellow solid. Step 2: tert-Butyl 4-(l-(2,6-dioxopiperidin-3-yl)-6-methyl-lH-pyrazolo[3,4-b]pyridin-5-yl)- piperazine- 1 -carboxylate

To a stirred solution of 3-(5-bromo-6-methyl-lH-pyrazolo[3,4-b]pyridin-l-yl)piperidine- 2, 6-dione (820 mg, 2.54 mmol) and tert-butyl piperazine- 1 -carboxylate (709 mg, 3.81 mmol) in dioxane (10 mL) were added Pd-PEEP SI-IP entCl (426 mg, 0.51 mmol) and CS2CO3 (2.5 g, 7.61 mmol), and the resulting mixture was stirred at 100 °C for 5 h under nitrogen atmosphere. After cooling at rt, the reaction mixture was diluted with water, and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-80%) to afford the title compound as a yellow oil.

Step 3: 3-(6-Methyl-5-(piperazin-l-yl)-lH-pyrazolo[3,4-b]pyridin-l-yl)piperidine-2, 6-dione hydrochloride

To a stirred solution of tert-butyl 4-(l-(2,6-dioxopiperidin-3-yl)-6-methyl-lH- pyrazolo[3,4-b]pyri din-5 -yl)piperazine-l -carboxylate (107 mg, 0.25 mmol) in DCM (1.5 mL) was added 4 M HC1 in dioxane (1 mL) at 0 °C. The resulting mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure to afford the title compound as a yellow solid.

Reference 46

Synthesis of 3-(5-methyl-2-oxo-6-(piperidin-4-yl)benzo[d]oxazol-3(2H)-yl)piperidine-2, 6-dione Step 1 : 3-(6-Bromo-5-methyl-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2, 6-dione

To a stirred solution of 6-bromo-5-methylbenzo[d]oxazol-2(3H)-one (2.93 g, 12.0 mmol) in DMF (50.0 mL) was added CS2CO3 (7.8 g, 24.0 mmol) and 3 -brom opiperidine-2, 6-dione (9.2 g, 48.0 mmol) at rt, and the resulting mixture was stirred at 70 °C for 16 h. After cooling at rt, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, and the organic layer was dried over anhydrous ISfeSCU and concentrated. The residue was purified by column chromatography (DCM: MeOH= 20: 1) to afford the title compound as a yellow solid.

Step 2: tert-Butyl 4-(3-(2,6-dioxopiperidin-3-yl)-5-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-6- yl)piperidine- 1 -carboxylate

To a stirred solution of 3-(6-bromo-5-methyl-2-oxobenzo[d]oxazol-3(2H)-yl)piperidine-2,6- dione (1.70 g, 5.03 mmol) in DMA (10.0 mL) was added tert-butyl 4-iodopiperidine-l- carboxylate (3.1 g, 10.06 mmol), NiCh (HO mg, 0.50 mmol), Mn (553 mg, 10.06 mmol), Nal (188 mg, 1.26 mmol) and picolinimidamide hydrochloride (78.8 mg, 0.15 mmol), and the mixture was stirred for 16 h at 45 °C under N2. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous ISfeSCU, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM:MeOH=20: l, to afford the title compound as white solid.

Step 3 : 3-(5-Methyl-2-oxo-6-(piperidin-4-yl)benzo[d]oxazol-3(2H)-yl)piperidine-2, 6-dione hydrochloride A mixture of tert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-5-methyl-2-oxo-2,3-dihydro- benzo[d]oxazol-6-yl)piperidine-l -carboxylate (100 mg, 0.23 mmol) in ethyl acetate/HCl (3.0 mL) was stirred at rt for 2 h. The mixture was concentrated to afford the title compound as an off-white solid.

The following Reference compound was synthesized by proceeding analogously as described in Reference 46.

Reference 47

Synthesis of l-[5-chloro-l-methyl-6-(4-piperidyl)indazol-3-yl]hexahydropyrimidine-2, 4-dione hydrochloride

To a solution of 6-bromo-5-chloro-lH-indazole (2.31 g, 10 mmol) in DMF (20 mL) at 0 °C was added KOH (2.24 g, 40 mmol), and the mixture was stirred at 0 °C for 10 min. L (5.08 g, 20 mmol) was added in portions, and the mixture was stirred at 0 °C for 30 min. The mixture was warmed to rt and stirred for 3 h. The reaction mixture was diluted with ice water, quenched with sat. sodium bisulfite aq. solution, extracted with ethyl acetate, washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a yellow solid.

Step 2: 6-Bromo-5-chloro-3-iodo-l-methyl-indazole To a mixture of 6-bromo-5-chl oro-3 -iodo- IH-indazole (3.2 g, 8.95 mmol) and CS2CO3 (5.83 g, 17.91 mmol) in MeCN (128 mL) at 0 °C was added Mel (1.11 mL, 17.91 mmol) dropwise. The mixture was warmed to rt and stirred for 4 h. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-5%) to afford the title compound as a yellow solid.

Step 3 : l-(6-Bromo-5-chloro-l-methyl-indazol-3-yl)hexahydropyrimidine-2, 4-dione

A mixture of 6-bromo-5 -chi oro-3 -iodo- 1-methyl-indazole (557 mg, 1.5 mmol), 5,6- dihydrouracil (514 mg, 4.5 mmol), Cui (142.84 mg, 0.75 mmol), K3PO4 (955 mg, 4.5 mmol), (R,R)-l,2-diaminocyclohexane (85.64 mg, 0.75 mmol), anhydrous DMSO (7.5 mL) was stirred at 100 °C under the argon atmosphere in a sealed tube for 10 h. After cooling to rt, the reaction mixture was filtered and the filtrate was purified by Cl 8 column chromatography, eluted with MeCN/water (0-25%, 0.05% FA) to afford the title compound as a yellow solid.

Step 4: l-[5-Chloro-l-methyl-6-(4-piperidyl)indazol-3-yl]hexahydropyrimidine-2, 4-dione hydrochloride

The title compound was synthesized by proceeding analogously as described in Reference 17, Steps 3-5.

The following Reference compound was synthesized by proceeding analogously as described in Reference 47.

Reference 48 Synthesis of 3-[6-fluoro-3-methyl-2-oxo-5-(4-piperidyl)benzimidazol-l-yl]piperidine-2, 6-dione

Step 1 : 5-Bromo-6-fluoro-3-methyl-lH-benzimidazol-2-one

To a stirred mixture of 4-bromo-5-fluoro-N2-methyl-benzene-l,2-diamine (2.3 g, 10.5 mmol) in acetonitrile (70 mL) was added CDI (2.55 g, 15.75 mmol) at rt under argon atmosphere, and the resulting mixture was stirred at 85 °C for 18 h. After cooling to rt, the reaction mixture was concentrated under reduced pressure. Water was added to the mixture and the resulting mixture was stirred for 1 h and then filtered. The collected solid was triturated with di chloromethane, filtered and dried to afford the title compound as a yellow solid.

Step 2: 3-(5-Bromo-6-fluoro-3-methyl-2-oxo-benzimidazol-l-yl)-l-[(4-methoxyphenyl)methyl]- piperidine-2, 6-dione

To a stirred mixture of 5-bromo-6-fluoro-3 -methyl- IH-benzimidazol -2-one (500 mg, 2.04 mmol) in THF (20 mL) was added 1.0 M potassium tert-butoxide solution in THF (3.06 mL, 3.06 mmol) at -10 °C and the mixture was stirred for 15 minutes under argon atmosphere. A solution of [l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl] trifluoromethanesulfonate (933.65 mg, 2.45 mmol) in THF (10 mL) was added dropwise, and the resulting mixture was stirred at -10 °C for 1 h. The mixture was quenched with sat. ammonium chloride aq. solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate/di chloromethane (0-10%) to afford the title compound as a yellow solid. Step 3: tert-Butyl 4-[6-fluoro-l-[l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3-piperidyl]-3-methyl- 2-oxo-benzimidazol-5-yl]piperidine-l -carboxylate

The title compound was synthesized by proceeding analogously as described in Reference 17, Steps 3-4.

Step 4: 3-[6-Fluoro-3-methyl-2-oxo-5-(4-piperidyl)benzimidazol-l-yl]piperidine-2, 6-dione

A solution of tert-butyl 4-[6-fluoro-l-[l-[(4-methoxyphenyl)methyl]-2,6-dioxo-3- piperidyl]-3-methyl-2-oxo-benzimidazol-5-yl]piperidine-l-carboxylate (400 mg, 0.69 mmol) in TFA (4 mL) and TfOH (0.4 mL) was stirred at 75 °C for 2 h under argon atmosphere. After cooling at rt, the mixture was concentrated under reduced pressure. The residue was purified by reverse phase silica gel column chromatography, eluted with (5% ~ 25% acetonitrile in water with 0.05% ammonium bicarbonate) to afford the title compound as a white solid.

The following Reference compounds were synthesized by proceeding analogously as described in Reference 48. Reference 49

Synthesis of 3-[[5-(4-piperidyl)-8-quinolyl]amino]piperidine-2, 6-dione hydrochloride

Step 1 : tert-Butyl 4-(8-nitro-5-quinolyl)-3,6-dihydro-2H-pyridine-l-carboxylate

A mixture of 5 -bromo-8 -nitro-quinoline (500 mg, 1.98 mmol), tert-butyl 4-(4, 4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-l-carboxylate (916.4 mg, 2.96 mmol), Na2CC>3 (417.1 mg, 3.95 mmol) and Pd(dppf)C12 (144.6 mg, 0.20 mmol) in 1,4-dioxane (5 mL) / water (1 mL) was stirred at 100 °C for 5 h under argon atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with PE/ethyl acetate (0-50%) to afford the title compound as a brown solid.

Step 2: tert-Butyl 4-(8-amino-5-quinolyl)piperidine-l -carboxylate

A mixture of crude tert-butyl 4-(8-nitro-5-quinolyl)-3,6-dihydro-2H-pyridine-l- carboxylate (700 mg, 2.00 mmol) and Pd/C (280 mg) in MeOH (7 mL) was stirred for 5 h under 1 atm hydrogen atmosphere. The reaction mixture was diluted with dichloromethane and filtered through Celite. The filtrate was concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with PE/ethyl acetate (0-50%) to afford the title compound as a brown solid. Step 3: tert-Butyl 4-[8-[(2,6-dioxo-3-piperidyl)amino]-5-quinolyl]piperidine-l-carboxylate

A mixture of NaHCCL (76.97 mg, 0.92 mmol), 3-bromopiperidine-2, 6-dione (87.96 mg, 0.46 mmol), tert-butyl 4-(8-amino-5-quinolyl)piperidine-l -carboxylate (100 mg, 0.31 mmol) in DMF (2 mL) was stirred at 75 °C for 15 h under argon atmosphere. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried over anhydrous sodium sulphate and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with PE/ethyl acetate (0-50%) to afford the title compound.

Step 4: 3-[[5-(4-Piperidyl)-8-quinolyl]amino]piperidine-2, 6-dione hydrochloride

To a stirred solution of tert-butyl 4-[8-[(2,6-dioxo-3-piperidyl)amino]-5- quinolyl]piperidine-l -carboxylate (57 mg, 0.13 mmol) in DCM (1.0 mL) was added HC1 in dioxane (1.0 mL, 4.0 M) and the mixture was stirred for 1 h. The solvent was removed under reduced pressure to afford the title compound.

Reference 50

Synthesis of l-[6-(4-piperidyl)pyrazolo[l,5-a]pyridin-3-yl]hexahydropyrimidine-2, 4-dione hydrochloride Step 1 : l-(6-Bromopyrazolo[l,5-a]pyridin-3-yl)-3-[(4-methoxyphenyl)methyl]hexahydro- pyrimidine-2, 4-dione

The mixture of (lR,2R)-(-)-l,2-diaminocyclohexane (35.36 mg, 0.31 mmol), 3-[(4- methoxyphenyl)methyl]hexahydropyrimidine-2, 4-dione (304.66 mg, 1.30 mmol), 6-bromo-3- iodo-pyrazolo[ 1,5 -a] pyridine (400 mg, 1.24 mmol), Cui (58.98 mg, 0.31 mmol) and K3PO4 (657.31 mg, 3.1 mmol) in DMF (2 mL) was stirred at 80 °C for 16 h under Ar. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, dried and concentrated under reduced pressure. The residue was purified with silica gel column chromatography, eluted with ethyl acetate/petroleum ester (0-30%) to afford the title compound as a white solid.

Step 2: l-(6-Bromopyrazolo[l,5-a]pyridin-3-yl)hexahydropyrimidine-2, 4-dione

Methanesulfonic acid (0.6 mL) was added to the solution of l-(6-bromopyrazolo[l,5- a]pyridin-3-yl)-3-[(4-methoxyphenyl)methyl]hexahydropyrimidine-2, 4-dione (260 mg, 0.61 mmol) in toluene (2.5 mL) and the the mixture was stirred at 110 °C for 3 h. The mixture was concentrated, and the residue was purified with silica gel column chromatography, eluted with ethyl acetate/petroleum ester (0-50%) to afford the title compound.

Step 3: l-[6-(4-Piperidyl)pyrazolo[l,5-a]pyridin-3-yl]hexahydropyrimidine-2, 4-dione

The title compound was synthesized by proceeding analogously as described in Reference 17, Steps 3-5. Reference 51

Synthesis of 3-(3,6-dimethyl-2-oxo-5-(piperazin-l-yl)-2,3-dihydro-lH-imidazo[4,5-b]pyridin-l- yl)piperidine-2,6-dione

Step 1 : 6-Chloro-N,5-dimethyl-3-nitropyridin-2-amine

Methylamine (30 % in MeOH, 660 mg, 6.38 mmol) was added to a mixture of 2,6- dichloro-3-methyl-5-nitropyridine (1.20 g, 5.80 mmol) in DCM (20.0 mL) and TEA (1.17 g, 11.60 mmol) at 0 °C, and the resulting mixture was stirred at rt under N2 for 5 h. The mixture was quenched by water and extracted with DCM. The combined organic layers were washed with brine, dried over ISfeSCU, and concentrated. The residue was purified by column chromatography on silica gel (PE:ethyl acetate=5: 1) to afford the title compound as a yellow solid.

Step 2: tert-Butyl 4-(3-methyl-6-(methylamino)-5-nitropyridin-2-yl)piperazine-l -carboxylate

A mixture of 6-chloro-N,5-dimethyl-3-nitropyridin-2-amine (550 mg, 2.73 mmol) and K2CO3 (755 mg, 5.46 mmol) in CH3CN (10.0 mL) was added tert-butyl piperazine- 1 -carboxylate (1.02 g, 5.46 mmol), and the resulting mixture was stirred at 50 °C under N2 for 4 h. The reaction mixture was quenched by water and extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel (PE:ethyl acetate=5: 1) to afford the title compound as a yellow solid. Step 3: tert-Butyl 4-(5-amino-3-methyl-6-(methylamino)pyridin-2-yl)piperazine-l-carboxylate To a mixture of tert-butyl 4-(3-methyl-6-(methylamino)-5-nitropyridin-2-yl)piperazine-l- carboxylate (400 mg, 1.14 mmol) in MeOH (10.0 mL) was added Raney -Ni (400 mg), and the resulting mixture was stirred at rt under 1 atm H2 for 2 h. The reaction mixture was filtered, and the organic layer was concentrated to afford the title compound as a pale yellow solid.

Step 4: tert-butyl 4-(l-(l-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)-3,6-dimethyl-2-oxo-2,3- dihydro-lH-imidazo[4,5-b]pyridin-5-yl)piperazine-l-carboxylate

The title compound was synthesized by proceeding analogously as described in Reference

48, Steps 1-2.

Step 5: 3-(3,6-Dimethyl-2-oxo-5-(piperazin-l-yl)-2,3-dihydro-lH-imidazo[4,5-b]pyridin-l- yl)piperidine-2, 6-dione

The title compound was synthesized by proceeding analogously as described in Reference 48, Steps 4.

Reference 52

Synthesis of l-(l-(piperidin-4-yl)-lH-indol-4-yl)dihydropyrimidine-2,4(lH,3H)-dione 2,2,2- tri fluoroacetate

Step 1 : tert-Butyl 4-(4-bromo-lH-indol-l-yl)piperidine-l-carboxylate To a stirred solution of 4-bromo-lH-indole (2.00 g, 10.28 mmol) in toluene (20.0 mL) was added tert-butyl 4-hydroxypiperidine-l -carboxylate (3.10 g, 15.42 mmol) and (cyanomethylene)- tributylphosphorane (3.72 g, 15.42 mmol). The resulting mixture was stirred at 100 °C for 16 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated and purified by silica gel column chromatography, eluted with PE:ethyl acetate=10:l to afford the title compound.

Step 2: tert-Butyl 4-(4-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-lH-indol-l-yl)piperidine-l- carboxylate

To a stirred solution of tert-butyl 4-(4-bromo-lH-indol-l-yl)piperidine-l -carboxylate (280 mg, 0.74 mmol) in 1,4-dioxane (4.0 mL) was added dihydropyrimidine-2,4(lH,3H)-dione (44 mg, 2.96 mmol), CS2CO3 (724 mg, 2.22 mmol), Ephos (59 mg, 0.11 mmol) and Ephos Pd G4 (102 mg, 0.11 mmol), and the resulting mixture was stirred at 100 °C for 16 h. After cooling to rt, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous ISfeSCL After filtration, the filtrate was concentrated, and the residue was purified by silica gel chromatography, eluting with PE:ethyl acetate=5:l to afford the title compound.

Step 3: l-(l-(Piperidin-4-yl)-lH-indol-4-yl)dihydropyrimidine-2,4(lH,3H)-dione 2,2,2- tri fluoroacetate

A mixture of tert-butyl 4-(4-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-lH-indol-l- yl)piperidine-l -carboxylate (38 mg, 0.09 mmol) in TFA/DCM (1.0 ml/5.0 ml) was stirred at 40 °C for 2 h. The mixture was concentrated under reduced pressure to afford the title compound. Reference 53

Synthesis of 3-(2-methyl-5-(pipendin-4-yl)-lH-benzo[d]imidazol-l-yl)pipendine-2,6-dione

Step 1 : 2,6-Bis(benzyloxy)-N-(4-bromo-2-nitrophenyl)pyridin-3-amine

To a solution of 2,6-bis(benzyloxy)pyridin-3-amine (10.49 g, 34.26 mmol) in THF (100.0 mL) was added NaH (60% in mineral oil, 600 mg, 34.26 mmol) at 0 °C, and the mixture was stirred for 0.5 h. 4-Bromo-l-fluoro-2 -nitrobenzene (5.00 g, 22.83 mmol) was added to the above mixture at 0 °C, and the resulting mixture was stirred at 40 °C for 16 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated, and the residue was purified by silica gel column chromatography (PE:ethyl acetate = 5: 1) to afford the title compound as a yellow solid.

Step 2: Nl-(2,6-bis(benzyloxy)pyridin-3-yl)-4-bromobenzene-l,2-diamine

To a mixture of 2,6-bis(benzyloxy)-N-(4-bromo-2-nitrophenyl)pyridin-3-amine (4 g, 7.92 mmol) and NH4CI (4.24 g, 79.2 mmol) in THF/H2O (30 mL) was added Zn (5.17 g, 79.2 mmol), and the mixture was stirred at 40 °C for 3 h. The reaction mixture was filtered, and filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM: ethyl acetate = 4: 1) to afford the title compound as a yellow solid. Step 3 : l-(2,6-Bis(benzyloxy)pyridin-3-yl)-5-bromo-2-methyl-lH-benzo[d]imidazole

To a solution of Nl-(2,6-bis(benzyloxy)pyridin-3-yl)-4-bromobenzene-l,2-diamine (1.5 g, 3.16 mmol) in 1,1,1 -trimethoxy ethane (20.0 mL) was added p-toluenesulfonic acid (54.4 mg, 0.316 mmol), and the mixture was stirred at 80 °C for 4 h under N2. After cooling to rt, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated, and the residue was purified by column chromatography (DCM: MeOH= 20: 1) to afford the title compound as a white solid. Step 4: 3-(2-Methyl-5-(piperidin-4-yl)-lH-benzo[d]imidazol-l-yl)piperidine-2, 6-dione hydrochloride

The title compound was synthesized by proceeding analogously as described in Reference 17, Steps 3-5. Reference 54

Synthesis of 3-(3-methyl-2-oxo-5-(2-oxopiperazin-l-yl)-2,3-dihydro-lH-benzo[d]imidazol-l-yl)- piperidine-2, 6-dione Step 1 : 5-Bromo-3-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H-benzo[d]- imidazol-2-one

To a solution of 6-bromo-l-methyl-l,3-dihydro-2H-benzo[d]imidazol-2-one (500 mg, 2.20 mmol) in DMF (7.0 mL) was added NaH (132 mg, 3.30 mmol) at 0 °C. After 30 min, SEM-C1 (403 mg, 2.42 mmol) was added to above mixture at 0 °C, and the resulting mixture was stirred at rt under N2 for 3 h. The reaction mixture was quenched with sat. NH4CI aq. solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE : ethyl acetate = 8 : 1) to give the title compound as a yellow solid. Step 2: tert-Butyl 4-(3-methyl-2-oxo-l-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydro-lH- benzo[d]imidazol-5-yl)-3-oxopiperazine-l-carboxylate

To a solution of 5-bromo-3-methyl-l-((2-(trimethylsilyl)ethoxy)methyl)-l,3-dihydro-2H- benzo[d]imidazol-2-one (450 mg, 1.26 mmol) and tert-butyl 3 -oxopiperazine- 1 -carboxylate (505 mg, 2.52 mmol) in 2-methyl-2-butanol (10.0 mL) was added tBuBrettPhos Pd G3 (111 mg, 0.13 mmol) and CS2CO3 (863 mg, 2.65 mmol). The mixture was stirred at 90 °C under nitrogen for 16 h. After cooling to rt, the reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM : MeOH = 30 : 1) to afford the title compound as a brown oil.

Step 3: tert-Butyl 4-(3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-5-yl)-3-oxopiperazine-l- carboxylate

To a solution of tert-butyl 4-(3-methyl-2-oxo-l-((2-(trimethylsilyl)ethoxy)methyl)-2,3- dihydro-lH-benzo[d]imidazol-5-yl)-3-oxopiperazine-l-carboxylate (350 mg, 0.73 mmol) in THF (8.0 mL) was added TBAF (2.2 mL, 2.20 mmol), and the resulting mixture was stirred at 80 °C under N2 for 16 h. After cooling to rt, the mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM : MeOH = 25 : 1) to afford the title compound as a brown solid.

Step 4: tert-Butyl 4-(l-(l-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3- dihydro-lH-benzo[d]imidazol-5-yl)-3-oxopiperazine-l-carboxylate

To a solution of tert-butyl 4-(3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-5-yl)-3- oxopiperazine-1 -carboxylate (100 mg, 0.29 mmol) in DMF (4.0 mL) was added t-BuOK (98 mg, 0.87 mmol). l-(4-Methoxybenzyl)-2,6-dioxopiperidin-3-yl trifluoromethanesulfonate (145 mg, 0.38 mmol) was added at 0 °C slowly and the resulting mixture was stirred at rt for 4 h under N2. The reaction mixture was quenched with sat. NH4CI aq. solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep TLC (DCM : MeOH = 25: 1) to afford the title compound.

Step 5: 3-(3-Methyl-2-oxo-5-(2-oxopiperazin-l-yl)-2,3-dihydro-lH-benzo[d]imidazol-l- yl)piperidine-2, 6-dione

A mixture of tert-butyl 4-(l-(l-(4-methoxybenzyl)-2,6-dioxopiperidin-3-yl)-3-methyl-2- oxo-2, 3-dihydro-lH-benzo[d]imidazol-5-yl)-3-oxopiperazine-l-carboxylate (60 mg, 0.10 mmol) in TFA (3.0 mL) and trifluoromethanesulfonic acid (1.0 mL) was stirred at 70 °C under nitrogen for 2 h. The mixture was concentrated and the residue was purified by prep-HPLC (ACN-H2O = 1 : 99 ~ 95 : 5) to afford the title compound as a brown solid. Reference 55

Synthesis of (l-(bromomethyl)cyclopropyl)methanesulfonyl chloride

Step 1 : S-(( 1 -(brom omethyl)cy cl opropyl)methyl) benzothioate

Benzothioic S-acid (0.36 g, 2.63 mmol) was added to a mixture of K2CO3 (0.18 g, 1.32 mmol) in MeOH (15.0 mL), and the resulting mixture was stirred under nitrogen for 1 h. The reaction mixture was then concentrated, and the residue was dissolved in DMF (4.0 mL). A solution of l,l-bis(bromomethyl)cyclopropane (1.00 g, 4.39 mmol) in DMF (8.0 mL) was then added to the above solution at - 40 °C slowly, and the resulting mixture was stirred at rt under nitrogen for 16 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous ISfeSCU, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE : ethyl acetate = 13 : 1) to afford the title compound. Step 2: (l-(Bromomethyl)cyclopropyl)methanesulfonyl chloride

To a solution of benzyltrimethylammonium chloride (400 mg, 0.80 mmol) in ACN (5.0 mL) was added trichloroisocyanuric acid (88 mg, 0.12 mmol), and the reaction mixture was stirred at rt under nitrogen for 0.5 h. A solution of S-((l-(bromomethyl)cyclopropyl)methyl) benzothioate (180 mg, 0.63 mmol) in ACN (5.0 mL) was added the above solution slowly at 0 °C, and the resulting mixture was stirred at 0 °C under nitrogen for 0.5 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a yellow oil. Reference 56

Synthesis of N-(l-((3-chloropropyl)sulfonyl)piperidin-4-yl)-5-(difluoromethoxy)pyrimidin-2- amine

To a solution of 5-(difluoromethoxy)-N-(piperidin-4-yl)pyrimidin-2-amine hydrochloride (1.00 g, 3.57 mmol) and TEA (1.08 g, 10.71 mmol) in DCM (20.0 mL) was added 3- chloropropane-1 -sulfonyl chloride (632.1 mg, 3.57 mmol) slowly at 0 °C and the resulting mixture was stirred at rt under nitrogen for 2 h. The mixture was then treated with water and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous ISfeSCU and concentrated. The residue was purified by silica gel column chromatography (PE:ethyl acetate = 3 : 1) to give the title compound as a white solid.

The following Reference compounds were synthesized by proceeding analogously as described in Reference 56.

Reference 57

Synthesis of 3-[[4-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]-l-piperidyl]sulfonyl]propanal

Step 1 : Methyl 3-[[4-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]-l-piperidyl]sulfonyl] propanoate To a solution of 5-(difluoromethoxy)-N-(4-piperidyl)pyrimidin-2-amine hydrochloride (5.61g, 20 mmol) and TEA (6.07 g, 60 mmol) in THF (200 mL) at 0 °C was added a solution of methyl 4-chlorosulfonylbutanoate (5.22 g, 26 mmol) in THF (40 mL) dropwise. The resulting mixture was stirred at 0 °C for 4 h and then at rt overnight. The reaction mixture was quenched with ice/water and extracted with ethyl acetate. The combined organic layers were washed with sat. NH4CI aq. solution and brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with MeOH/DCM (0-3%) to afford the title compound as a yellow solid.

Step 2: 3-[[4-[[5-(Difluoromethoxy)pyrimidin-2-yl]amino]-l-piperidyl]sulfonyl] propan-l-ol

To a solution of methyl 3-[[4-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]-l- piperidyl]sulfonyl]propanoate (2.3 g, 5.83 mmol) in THF (20 mL) was added DIBAL-H (11.67 mL, 11.66 mmol) at 5 °C, and the resulting mixture was stirred at rt for 4 hrs. The mixture was dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography column to afford the title compound as a yellow solid.

Step 3: 3-[[4-[[5-(Difluoromethoxy)pyrimidin-2-yl]amino]-l-piperidyl]sulfonyl] propanal

To a solution of 3-[[4-[[5-(difhioromethoxy)pyrimidin-2-yl]amino]-l-piperidyl] sulfonyl]propan-l-ol (1.6 g, 4.37 mmol) in DCM (20 mL) was added Dess-Martin periodinane (2.8 g, 6.55 mmol) at rt, and the resulting mixture was stirred at rt for 4 hrs. The reaction mixture was quenched with sat. Na2S20s aq. solution and sat. NaHCCh aq. solution. The mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The residue was purified by silica gel column chromatography column (DCM/MeOH=0-5%) to afford the title compound as a white solid. Example 1

Synthesis of l-(l-methyl-6-(l-(3-((4-((5-(trifluoromethyl)pyrimidin-2-yl)amino)piperidin-l- yl)sulfonyl)propyl)piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione

Step 1 : N-(l-((3-chloropropyl)sulfonyl)piperidin-4-yl)-5-(trifluoromethyl)pyrimidin-2-amine

To a stirred solution of N-(piperidin-4-yl)-5-(trifluoromethyl)pyrimidin-2-amine hydrogen chloride (400 mg, 1.62 mmol, 1.20 eq.) in DCM (5.0 mL) was added 3 -chloropropane- 1 -sulfonyl chloride (239 mg, 1.35 mmol, 1.00 eq.) and TEA (410 mg, 4.06 mmol, 3.00 eq.) at 0 °C, and the resulting mixture was stirred at r.t. for 2 h. The mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure, to afford the title compound as a yellow solid.

Step 2: l-(l-Methyl-6-(l-(3-((4-((5-(trifluoromethyl)pyrimidin-2-yl)amino)piperi din-1- yl)sulfonyl)propyl)piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione

To a stirred solution of N-(l-((3-chloropropyl)sulfonyl)piperidin-4-yl)-5-(trifluoromethyl)- pyrimidin-2-amine (220 mg, 0.57 mmol, 1.00 eq.) in MeCN (4.0 mL) was added 1-(1 -methyl -6- (piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione (186 mg, 0.57 mmol, 1.00 eq.), K2CO3 (237 mg, 1.71 mmol, 3.00 eq.) and KI (189 mg, 1.14 mmol, 2.00 eq.) and the resulting mixture was stirred at 80 °C for 16 h. The mixture was diluted with water and extracted with EtOAc. The combined organic layers was washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as off-white solid. MS (ES, m/z): [M+l]⁺ = 678.1.

The following compounds were synthesized by proceeding analogously as described in Example 1.

Example 5

Synthesis of 4-((5-(difhioromethoxy)pyrimidin-2-yl)amino)-N-(2-(4-(3-(2,4-dioxotetrahydro- pyrimidin- 1 (2H)-yl)- 1 -methyl- lH-indazol-6-yl)piperi din- 1 -yl)ethyl)piperidine- 1 -sulfonamide Step 1 : N-(2-chloroethyl)-4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidine-l -sulfonamide

To a stirred solution of 5-(difluoromethoxy)-N-(piperidin-4-yl)pyrimidin-2-amine hydrogen chloride (100 mg, 0.36 mmol, 1.00 eq.) in DCM (3.0 mL) was added (2- chloroethyl)sulfamoyl chloride (64 mg, 0.36 mmol, 1.00 eq.) and TEA (109 mg, 1.08 mmol, 3.00 eq.) at 0 °C and the resulting mixture was stirred for 2 h. The mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, to afford the title compound as a yellow oil.

Step 2: 4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)-N-(2-(4-(3-(2,4-dioxotetrahydropyrimidin- l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)ethyl)piperidine-l-sulfonamide

To a stirred mixture of N-(2-chloroethyl)-4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)- piperidine-l-sulfonamide (160 mg, 0.42 mmol, 1.00 eq.) in MeCN (5.0 mL) was added 1-(1- methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione (137 mg, 0.42 mmol, 1.00 eq.), K2CO3 (174 mg, 1.26 mmol, 3.00 eq.) and KI (139 mg, 0.84 mmol, 2.00 eq.) and the resulting mixture was stirred at 80 °C for 16 h. The mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as white solid. MS (ES, m/z): [M+l]⁺ = 677.1. The following compounds were synthesized by proceeding analogously as described in Example 5.

Example 8 Synthesis of 4-((5-(difhioromethoxy)pyrimidin-2-yl)amino)-N-(2-(4-(3-(2,4-dioxotetrahydro- pyrimidin- 1 (2H)-yl)- 1 -methyl- lH-indazol-6-yl)piperi din- 1 -yl)ethyl)-N-m ethylpiperidine- 1 - sulfonamide

Step 1 : tert-Butyl (l-(N-(2-hydroxyethyl)-N-methylsulfamoyl)piperidin-4-yl)carbamate

To a solution of 2-(methylamino)ethan-l-ol (161 mg, 2.14 mmol) and TEA (542 mg, 5.36 mmol) in DCM (5.0 mL) was added tert-butyl (l-(chlorosulfonyl)piperidin-4-yl)carbamate (400 mg, 1.34 mmol) at 0 °C, and the mixture was stirred at rt under nitrogen for 1 h. The mixture was diluted with water and extracted with DCM and the combined organic layers were washed with brine and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep TLC (DCM : MeOH = 15 : 1) to afford the title compound as brown oil.

Step 2: tert-Butyl (l-(N-methyl-N-(2-oxoethyl)sulfamoyl)piperidin-4-yl)carbamate

To a solution of tert-butyl (l-(N-(2-hydroxyethyl)-N-methylsulfamoyl)piperidin-4- yl)carbamate (310 mg, 0.92 mmol) in DCM (6.0 mL) was added Dess-Martin periodinane (780 mg, 1.84 mmol), and the mixture was stirred at 0 °C for 2 h. The mixture was filtrated and concentrated to afford the title compound as yellow solid.

Step 3: tert-Butyl (l-(N-(2-(4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6- yl)piperidin-l-yl)ethyl)-N-methylsulfamoyl)piperidin-4-yl)carbamate

To a solution of l-(l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine- 2,4(lH,3H)-dione (206 mg, 0.63 mmol) in DMA (4.0 mL) was added TEA (191 mg, 1.89 mmol) and tert-butyl (l-(N-methyl-N-(2-oxoethyl)sulfamoyl)piperidin-4-yl)carbamate (210 mg, 0.63 mmol). Then sodium triacetoxyborohydride (320 mg, 1.51 mmol) was added to the mixture at 0 °C, and the resulting mixture was stirred for 3 h. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep TLC (DCM:MeOH = 20 : 1) to afford the title compound.

Step 4: 4-Amino-N-(2-(4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6- yl)piperidin- 1 -yl)ethyl)-N-methylpiperidine- 1 -sulfonamide hydrochloride To a solution of tert-butyl (l-(N-(2-(4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l- methyl-lH-indazol-6-yl)piperidin-l-yl)ethyl)-N-methylsulfamoyl)piperidin-4-yl)carbamate (90 mg, 0.14 mmol) in ethyl acetate (2.0 mL) was added 4 M HC1 solution in ethyl acetate (2.0 mL), and the resulting mixture was stirred at rt for 2 h. The mixture was concentrated to afford the title compound as yellow solid.

Step 5: 4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)-N-(2-(4-(3-(2,4-dioxotetrahydropyrimidin- l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)ethyl)-N-methylpiperidine-l-sulfonamide

To a solution of 4-amino-N-(2-(4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl- lH-indazol-6-yl)piperidin-l-yl)ethyl)-N-methylpiperidine-l-sulfonamide hydrochloride (72 mg, 0.12 mmol) in DMSO (2.0 mL) was added DIEA (62 mg, 0.48 mmol), CsF (91 mg, 0.60 mmol) and 2-chloro-5-(difluoromethoxy)pyrimidine (43 mg, 0.24 mmol). The mixture was stirred at 50 °C under nitrogen for 16 h. After cooling to rt, the reaction mixture was quenched with water and extracted with EtOAc and the combined organic layers were washed with brine and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by /c -HPLC (ACN : H2O = 5 : 95 ~ 95 : 5) (0.1% TFA) to afford the title compound as light yellow solid. MS (ES, m/z): [M+l]⁺ = 691.2.

Example 9

Synthesis of 3-(6-(l-(2-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)- ethyl)piperidin-4-yl)-l -methyl- lH-indazol-3-yl)piperidine-2, 6-dione Step 1 : N-(l-((2-Chloroethyl)sulfonyl)piperidin-4-yl)-5-(difluoromethoxy)pyrimidin-2-amine

To a stirred solution of 5-(difluoromethoxy)-N-(piperidin-4-yl)pyrimidin-2-amine (220 mg, 0.90 mmol) and TEA (273 mg, 2.70 mmol) in DCM (4.0 mL) was added 2-chloroethane-l- sulfonyl chloride (189 mg, 1.17 mmol) at 0°C, and the resulting mixture was stirred for 2 h. The reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a yellow solid.

Step 2: 3-(6-(l-(2-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)ethyl)- piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

A mixture of N-(l-((2-chloroethyl)sulfonyl)piperidin-4-yl)-5-(difluoromethoxy)pyrimidin- 2-amine (230 mg, 0.62 mmol), 3-(l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)piperidine-2,6- dione hydrochloride (247 mg, 0.68 mmol), KI (206 mg, 1.24 mmol) and TEA (188 mg, 1.86 mmol) in ACN (4.0 mL) was stirred at 70°C for 16 h. After cooling to rt, the reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by / c -HPLC to afford the title compound as an off-white solid. MS (ES, m/z): [M+l]⁺ = 661.2. The following compounds were synthesized by proceeding analogously as described in Example 9.

Example 16

Synthesis of 3-(l-cyclopropyl-6-(l-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin- l-yl)sulfonyl)propyl)piperidin-4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione

To a mixture of 3-(l-cyclopropyl-6-(piperidin-4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2-trifluoroacetaldehyde (Reference 24; 90 mg, 0.20 mmol) in MeCN (3.0 mL) was added N- (l-((3-chloropropyl)sulfonyl)piperidin-4-yl)-5-(difluoromethoxy)pyrimidin-2-amine (Reference compound 56; 77 mg, 0.20 mmol), DIEA (77 mg, 0.60 mmol) and KI (53 mg, 0.20 mmol), and the resulting mixture was stirred at 80 °C under N2 for 16 h. After cooling to rt, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by /c -HPLC to afford the title compound as white solid. MS (ES, m/z): [M+l] ⁺ = 701.2.

The following compounds were synthesized by proceeding analogously as described in Example 16.

Example 88

Synthesis of 3-(l-methyl-6-(l-(3-((6-((5-(trifluoromethyl)pyrimidin-2-yl)amino)-2- azaspiro[3.3]heptan-2-yl)sulfonyl)propyl)piperidin-4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione

A mixture of tert-butyl (2-azaspiro[3.3]heptan-6-yl)carbamate (1.00 g, 4.71 mmol), 3- chloropropane-1 -sulfonyl chloride (0.91 g, 5.18 mmol), TEA (1.43 g, 14.13 mmol) in DCM (30 mL) was stirred at rt for 2 h. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE:ethyl acetate = 6: 1 to afford the title compound as a yellow solid. Step 2: tert-Butyl (2-((3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l- yl)propyl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)carbamate

A mixture of tert-butyl (2-((3-chloropropyl)sulfonyl)-2-azaspiro[3.3]heptan-6- yl)carbamate (900 mg, 2.55 mmol), 3-(l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)piperidine- 2, 6-dione (831.3 mg, 2.55 mmol), KI (423.3 mg, 2.55 mmol), DIEA (986.8 mg, 7.65 mmol) in MeCN (30.0 mL) was stirred at 80 °C for 16 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with DCM/MeOH = 20: 1 to afford the title compound as a yellow solid. Step 3: 3-(6-(l-(3-((6-Amino-2-azaspiro[3.3]heptan-2-yl)sulfonyl)propyl)piperidin-4-yl)-l- methyl-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2-trifluoroacetate

A mixture of tert-butyl (2-((3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6- yl)piperidin-l-yl)propyl)sulfonyl)-2-azaspiro[3.3]heptan-6-yl)carbamate (100 mg, 0.15 mmol) in DCM/TFA (5: 1) (5.0 mL) was stirred at rt for 16 h. The mixture was concentrated under reduced pressure to afford the title compound as a yellow solid.

Step 4: tert-Butyl 4-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l-methyl-lH-pyrazolo[4,3-c]pyridin-6- yl)-3 ,6-dihydropyridine- 1 (2H)-carboxylate A mixture of 3-(6-(l-(3-((6-amino-2-azaspiro[3.3]heptan-2-yl)sulfonyl)propyl)piperidin-4- yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione (92 mg, 0.14 mmol), CsF (79.0 mg, 0.52 mmol), 2-chloro-5-(trifluoromethyl)pyrimidine (25.5 mg, 0.14 mmol), DIEA (67.0 mg, 0.52 mmol) in DMSO (5.0 mL) was stirred at 65 °C for 16 h. After cooling to rt, the mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by / c -HPLC to afford the title compound as a white solid. MS (ES, m/z): [M+l]⁺ = 689.3

Example 89

Synthesis of 4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)-N-(3-(4-(l-(2,6-dioxopiperidin-3-yl)- 3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)piperidin-l-yl)propyl)-N- methylpiperidine-1 -sulfonamide

Step 1 : 4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidine-l-sulfonyl chloride

To a mixture of 5-(difluoromethoxy)-N-(piperidin-4-yl)pyrimidin-2-amine (1.00 g, 4.10 mmol) in DCM (10.0 mL) was added thionyl chloride (1.24 g, 12.30 mmol) and TEA (0.59 g, 4.92 mmol), and the mixture was stirred at 0 °C for 3 h under N2. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford the title compound. Step 2: N-(3 -chi oropropyl)-4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)-N-methylpiperi dine- 1- sulfonamide

To a mixture of 4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidine-l-sulfonyl chloride (500 mg, 1.46 mmol) in DCM (10.0 mL) was added (3-chloropropyl)(methyl)amine hydrochloride (420 mg, 2.92 mmol) and TEA (738 mg, 7.29 mmol), and the mixture was stirred at 0 °C for 3 h under N2. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated, and the residue was purified by flash column chromatography (ethyl acetate:PE=0~100%) to afford the title compound. Step 3 : 4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)-N-(3-(4-(l-(2,6-dioxopiperidin-3-yl)-3- methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)piperidin-l-yl)propyl)-N-methylpiperidine- 1 -sulfonamide

To a mixture of N-(3-chloropropyl)-4-{[5-(difluoromethoxy)pyrimidin-2-yl]amino}-N- methylpiperidine- 1 -sulfonamide (200 mg, 0.48 mmol) in MeCN (5.0mL) was added 3-[3-methyl- 2-oxo-4-(piperidin-4-yl)- 1,3 -benzodiazol- l-yl]piperidine-2, 6-dione hydrochloride (183 mg, 0.48 mmol), KI (160 mg, 0.97 mmol), TEA (146 mg, 1.45 mmol). The mixture was stirred at 80 °C for 16 h. After cooling to rt, the reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated and the residue was purified by /c -HPLC to afford the title compound. MS (ES, m/z): [M+l]⁺ = 720.2. The following compounds were synthesized by proceeding analogously as described in

Example 89.

Example 94 Synthesis of l-(l-methyl-6-(l-(4-((4-((5-(trifluoromethyl)pyrimidin-2-yl)amino)piperidin-l- yl)sulfonyl)butan-2-yl)piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione

Step 1 : 3 -Hydroxybutyl carbamimidothioate A mixture of 4-bromobutan-2-ol (500 mg, 3.27 mmol) in EtOH (5.0 mL) was added thiourea (274 mg, 3.60 mmol), and the mixture was stirred at 80 °C for 12 h. The mixture was concentrated to afford the title compound. Step 2: 3 -Chlorobutane- 1 -sulfonyl chloride

A mixture of 2 M HC1 solution (1.14 mL, 2.29 mmol) in CH3CN (5.0 mL) was added NCS (873 mg, 6.54 mmol) at 0 °C. 3 -Hydroxybutyl carbamimidothioate (485 mg, 3.27 mmol) was added at 0 °C, and the mixture was stirred at 0 °C for 2 h. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated to afford the title compound as a pale-yellow oil.

Step 3 : N-(l-((3-Chlorobutyl)sulfonyl)piperidin-4-yl)-5-(trifluoromethyl)pyrimidin-2-amine

To a mixture of N-(piperidin-4-yl)-5-(trifluoromethyl)pyrimidin-2-amine hydrochloride (297 mg, 1.05 mmol) in DCM (6.0 mL) was added TEA (319 mg, 3.15 mmol) at 0 °C. Then a solution of 3 -chlorobutane- 1 -sulfonyl chloride (300 mg, 1.57 mmol) in DCM (2.0 mL) was added, and this mixture was stirred at 0 °C for 3 h. The mixture was diluted with water and extracted with

DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE: ethyl acetate =2: 1) to afford the title compound as a white solid.

Step 4 : 1 -(1 -Methyl-6-( 1 -(4-((4-((5-(trifluoromethyl)pyrimidin-2-yl)amino)piperidin- 1 - yl)sulfonyl)butan-2-yl)piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione

A mixture of l-(l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine- 2,4(lH,3H)-dione (49 mg, 0.15 mmol) in CEECN (2.0 mL) was added N-(l-((3- chlorobutyl)sulfonyl)piperidin-4-yl)-5-(trifluoromethyl)pyrimidin-2-amine (60 mg, 0.15 mmol), KI (75 mg, 0.45 mmol) and K2CO3 (62 mg, 0.45 mmol). This mixture was stirred at 100 °C for 30 h under microwave irradiation. The mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated. The residue was purified by prep-HPLC to afford the title compound as a white solid. LCMS (ES, m/z): [M+l]⁺ =692.1.

Example 95

Synthesis of 3-(6-(l-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)- 2-hydroxypropyl)piperidin-4-yl)-l -methyl- lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2- tri fluoroacetate

Step 1 : tert-Butyl (l-(allylsulfonyl)piperidin-4-yl)carbamate

To a stirred solution of tert-butyl piperidin-4-ylcarbamate (15 g, 106.7 mmol) and TEA (54 g, 533 mmol) in DCM (150 mL) was added prop-2-ene-l -sulfonyl chloride (25.6 g, 128 mmol) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature for 1 h. The resulting mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate/PE (0-100%) to afford the title compound as a yellow solid.

Step 2: tert-Butyl (l-((oxiran-2-ylmethyl)sulfonyl)piperidin-4-yl)carbamate

To a stirred solution of tert-butyl (l-(allylsulfonyl)piperidin-4-yl)carbamate (8 g, 26.3 mmol) in DCM (80 mL) was added m-CPBA (13.6 g, 79 mmol) in portions at 0 °C. The resulting mixture was stirred at 40 °C for 30 h. After cooling to rt, the reaction mixture was quenched with sat. NaHSCh aq. solution. The mixture was then diluted with water and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over anhydrous

Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-60%) to afford the title compound as a light yellow oil.

Step 3: tert-Butyl (l-((3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l-yl)- 2-hydroxypropyl)sulfonyl)piperidin-4-yl)carbamate

To a stirred solution of tert-butyl (l-((oxiran-2-ylmethyl)sulfonyl)piperidin-4-yl)carbamate (2.3 g, 7.2 mmol) and 3-(l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione (2.34 g, 7.2 mmol) in EtOH (23 mL) were added TEA (2.2 g, 21.5 mmol) at room temperature, and the resulting mixture was stirred at 80 °C for 24 h. After cooling to rt, the reaction mixture was diluted with water, and extracted with DCM. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-80%) to afford the title compound as a light yellow solid.

Step 4: 3-(6-(l-(3-((4-Aminopiperidin-l-yl)sulfonyl)-2-hydroxypropyl)piperidin-4-yl)-l-methyl- lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride

To a stirred solution of tert-butyl (l-((3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH- indazol-6-yl)piperidin-l-yl)-2-hydroxypropyl)sulfonyl)piperidin-4-yl)carbamate (120 mg, 0.186 mmol) in DCM (1.2 mL) was added 4 M HC1 in dioxane (1.2 mL) dropwise at 0 °C, and the resulting mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure to afford the title compound as a light yellow solid. Step 5: 3-(6-(l-(3-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2- hydroxypropyl) piperidin-4-yl)-l -methyl- lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2- tri fluoroacetate

To a stirred solution of 3-(6-(l-(3-((4-aminopiperidin-l-yl)sulfonyl)-2-hydroxypropyl)- piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (105 mg, 0.18 mmol) in DMSO (1 mL) was added DIEA (140 mg, 1.1 mmol) at room temperature, and the resulting mixture was stirred at room temperature for 10 min. To the above mixture was added 2- chloro-5-(difluoromethoxy)pyrimidine (33 mg, 0.18 mmol) and CsF (55 mg, 0.4 mmol), and the resulting mixture was stirred at 80 °C for 16 h. After cooling to rt, the reaction mixture was diluted with water, and extracted with DCM. The combined organic layers were washed with water and brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as a white solid. LCMS (ES, m/z): [M+l]⁺ =691.5.

Example 96

Synthesis of 4-((5-chloropyrimi din-2 -yl)amino)-N-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-l -methyl- lH-indazol-6-yl)piperidin-l-yl)ethyl)-N-methylpiperidine-l-sulfonamide

Step 1 : tert-Butyl (l-(N-(2-chloroethyl)-N-m ethyl sulfamoyl)piperidin-4-yl)carbamate

A mixture of tert-butyl (l-(chlorosulfonyl)piperidin-4-yl)carbamate (1.00 g, 3.36 mmol), 2-chloro-N-methylethan-l -amine (480 mg, 3.69 mmol) and TEA (1.02 g, 10.06 mmol) in DCM (10.0 ml) was stirred at rt for 2 h. The reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford the title compound as a yellow oil.

Step 2: tert-Butyl (l-(N-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l- yl)ethyl)-N-methylsulfamoyl)piperidin-4-yl)carbamate

To a stirred solution of tert-butyl (l-(N-(2-chloroethyl)-N-methylsulfamoyl)piperidin-4- yl)carbamate (500 mg, 1.41 mmol) in MeCN (6.0 mL) was added 3-(l-methyl-6-(piperidin-4-yl)- lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (614 mg, 1.69 mmol), DIEA (900 mg, 7.05 mmol) and KI (1.12 g, 7.05 mmol), and the mixture was stirred at 100 °C for 3 h. After cooling to rt, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM:MeOH=15: 1) to afford the title compound as a white solid. Step 3: 4-Amino-N-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin-l- yl)ethyl)-N-m ethylpiperidine- 1 -sulfonamide hydrochloride

To a stirred solution of tert-butyl (l-(N-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH- indazol-6-yl)piperidin-l-yl)ethyl)-N-methylsulfamoyl)piperidin-4-yl)carbamate (261 mg, 0.40 mmol) in ethyl acetate (2.0 mL) was added 2 M HC1 in ethyl acetate (2.0 mL) at rt, and the resulting mixture was stirred for 2 h. The reaction mixture was concentrated under reduced pressure to afford the title compound as a yellow oil. Step 4: 4-((5-Chloropyrimidin-2-yl)amino)-N-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH- indazol-6-yl)piperidin- 1 -yl)ethyl)-N-m ethylpiperidine- 1 -sulfonamide

To a stirred solution of 4-amino-N-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH- indazol-6-yl)piperidin-l-yl)ethyl)-N-methylpiperidine-l -sulfonamide hydrochloride (87 mg, 0.15 mmol) in DMSO (4.0 mL) was added 2,5-dichloropyrimidine (24 mg, 0.16 mmol), DIEA (95 mg, 0.73 mmol) and CsF (112 mg, 0.73 mmol), and the resulting mixture was stirred at 60 °C for 16 h. After cooling to rt, the reaction mixture was diluted with water and extracted with EtOAc. The combined organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as a white solid. MS (ES, m/z): [M+l]⁺ = 658.1.

The following compounds were synthesized by proceeding analogously as described in Example 96.

Example 98

Synthesis of 4-((5-chloropyrimi din-2 -yl)amino)-N-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-l -methyl- lH-indazol-6-yl)piperidin-l-yl)ethyl)piperidine-l -sulfonamide Step 1 : N-(2-Chloroethyl)-4-((5-chloropyrimidin-2-yl)amino)piperidine-l -sulfonamide

To a stirred solution of 5-chloro-N-(piperidin-4-yl)pyrimidin-2-amine (140 mg, 0.56 mmol), TEA (57 mg, 1.68 mmol) in DCM (4.0 mL) was added (2-chloroethyl)sulfamoyl chloride (100 mg, 0.56 mmol) at 0 °C, and the resulting mixture was stirred for 2 h. The reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to afford the title compound as a yellow solid.

Step 2: 4-((5-Chloropyrimidin-2-yl)amino)-N-(2-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH- indazol-6-yl)piperi din- l-yl)ethyl)piperi dine- 1 -sulfonamide

A mixture of N-(2-chloroethyl)-4-((5 -chi oropyrimidin-2-yl)amino)piperi dine- 1- sulfonamide (80 mg, 0.23 mmol), 3-(l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)piperidine-2,6- dione hydrochloride (91 mg, 0.25 mmol), KI (76 mg, 0.46 mmol) and DIEA (89 mg, 0.69 mmol) in MeCN (4.0 mL) was stirred at 60°C for 16 h. After cooling to rt, the reaction mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water, brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by / c -HPLC to afford the title compound as a white solid. MS (ES, m/z): [M+l]⁺ = 644.2.

The following compounds were synthesized by proceeding analogously as described in Example 98.

Example 100

Synthesis of 3-(6-(l-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-

2-hydroxy-2-methylpropyl)piperidin-4-yl)-l -methyl- lH-indazol-3-yl)piperidine-2, 6-dione

Step 1 : 2-Methylprop-2-ene-l -sulfonyl chloride

To a stirred solution of sodium 2-methylprop-2-ene-l -sulfonate (15.8 g 0.1 mol) in DCM (160 mL) was added PCh (25 g, 0.12 mol) at rt under nitrogen atmosphere. To the above mixture was added DMF (730 mg), and the resulting mixture was stirred at rt for 16 h. The reaction mixture was diluted with H2O and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure to afford the title compound as a yellow solid.

Step 2: 3-(6-(l-(3-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-2- hydroxy-2-methylpropyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

The title compound was synthesized by proceeding analogously as described in Example 95, Steps 1-5. Example 101

Synthesi s of 3 -(6-( 1 -(3 -((4-((5 -(difluoromethoxy )pyrimidin-2-yl)amino)cy cl ohexyl)- sulfonyl)propyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

Step 1 : 4-((tert-Butoxycarbonyl)amino)cyclohexyl 4-methylbenzenesulfonate

To a solution of tert-butyl (4-hydroxycyclohexyl)carbamate (6.00 g, 27.87 mmol), TEA (8.46 g, 83.61 mmol), DMAP (341 mg, 2.79 mmol) in DCM (100.0 mL) was added TsCl (7.97 g, 41.81 mmol) in portion at 0 °C, and the resulting mixture was stirred at rt for 16 h. Then the reaction mixture was quenched with water and extracted with DCM. The combined organic layers were washed with brine and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (PE:ethyl acetate = 5: 1) to afford the title compound as white solid. Step 2: S-(4-((tert-Butoxycarbonyl)amino)cyclohexyl) ethanethioate

To a solution of 4-((tert-butoxycarbonyl)amino)cyclohexyl 4-methylbenzenesulfonate

(1.00 g, 2.70 mmol) in DMF (10.0 mL) was added potassium ethanethioate (616 mg, 5.40 mmol) in portion at 0 °C, and the mixture was stirred at 60 °C for 16 h. Then the reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE: ethyl acetate = 30:1) to afford the title compound as brown oil.

Step 3: S-(4-Aminocyclohexyl) ethanethioate hydrogen chloride To a solution of S-(4-((tert-butoxycarbonyl)amino)cyclohexyl)ethanethioate (320 mg, 1.2 mmol) in ethyl acetate (2.0 mL) was added 2 M HC1 in ethyl acetate (1.0 mL), and the resulting mixture was stirred at rt for 3 h. The reaction mixture was concentrated to afford the title compound as yellow solid.

Step 4: S-(4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)cyclohexyl) ethanethioate

To a solution of S-(4-aminocyclohexyl) ethanethioate hydrogen chloride (250 mg, 1.2 mmol) in DMSO (10.0 mL) was added 2-chloro-5-(difluoromethoxy)pyrimidine (421 mg, 2.4 mmol), DIEA (755 mg, 5.9 mmol) and CsF (889 mg, 5.9 mmol), and the mixture was stirred at 50 °C under N2 for 16 h. After cooling to rt, the reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (PE:ethyl acetate = 10: 1) to afford the title compound as yellow solid.

Step 5: 4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)cyclohexane-l -thiol sodium salt

To a solution of S-(4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)cyclohexyl) ethanethioate (300 mg, 0.95 mmol) in MeOH (10.0 mL) was added MeONa (30% in MeOH, 684 mg, 3.8 mmol) in portion at 0 °C, and the resulting mixture was stirred at rt for 3 h. The reaction mixture was concentration to afford the title compound as yellow solid.

Step 6: N-(4-((3-chloropropyl)thio)cyclohexyl)-5-(difluoromethoxy)pyrimidin-2-amine

A mixture of 4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)cyclohexane-l -thiol sodium salt (260 mg, 0.95 mmol) and l-bromo-3 -chloropropane (297 mg, 1.90 mmol) in MeCN (5.0 mL) was stirred at rt for 16 h. Then the mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (PE:ethyl acetate = 10:1) to afford the title compound as yellow oil.

Step 7 : N-(4-((3-chloropropyl)sulfonyl)cyclohexyl)-5-(difluoromethoxy)pyrimidin-2-amine

To a mixture of N-(4-((3-chloropropyl)thio)cyclohexyl)-5-(difluoromethoxy)pyrimidin-2- amine (130 mg, 0.37 mmol) in MeOEl/TElF/EEO (2.0 mL/2.0 mL/2.0 mL) was added oxone (341 mg, 0.56 mmol) in portion at 0 °C, and the resulting mixture was stirred at 0 °C for 2 h. The reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (PE: ethyl acetate = 2: 1) to afford the title compound as white solid.

Step 8: 3-(6-(l-(3-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)cyclohexyl)sulfonyl)- propyl)piperidin-4-yl)- 1 -methyl- lH-indazol-3 -yl)piperidine-2, 6-dione

To a mixture of N-(4-((3-chloropropyl)sulfonyl)cyclohexyl)-5-(difluoromethoxy)- pyrimidin-2-amine (142 mg, 0.37 mmol) in MeCN (5.0 mL) was added 3-(l-methyl-6-(piperidin- 4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione hydrogen chloride (134 mg, 0.37 mmol), DIEA (143 mg, 1.11 mmol) and KI (61 mg, 0.37 mmol), and the mixture was stirred at 80 °C under N2 for 16 h. After cooling to rt, the reaction mixture was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and the organic layer was dried over anhydrous ISfeSC The residue was purified by / c -HPLC to afford the title compound as white solid. MS (ES, m/z): [M+l] ⁺ = 674.1. Example 102

Synthesis of 3-(6-(l-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)- 3, 3-difluoropropyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2- trifluoroacetate

Step 1 : 5-(Difluoromethoxy)-N-(l-((difluoromethyl)sulfonyl)piperidin-4-yl)pyrimidin-2-amine

To a stirred solution of 5-(difluoromethoxy)-N-(piperidin-4-yl)pyrimidin-2-amine hydrochloride (3 g, 12.3 mmol) and TEA (6.2 g, 61.4 mmol) in DCM (30 mL) was added difluoromethanesulfonyl chloride (2.2 g, 14.7 mmol) dropwise at room temperature, and the resulting mixture was stirred for 1 h. The reaction mixture was diluted with DCM, washed with H2O and brine, dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (1 : 1) to afford the title compound as a yellow solid.

Step 2 : 3 -((4-((5 -(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin- 1 -yl)sulfonyl)-3 ,3 - difluoropropan- 1 -ol

To a stirred solution of 5-(difluoromethoxy)-N-(l-((difluoromethyl)sulfonyl)piperidin-4- yl)pyrimidin-2-amine (300 mg, 0.84 mmol) and 1, 3, 2-di oxathiolane 2,2-dioxide (104 mg, 0.84 mmol) in THF (3 mL) were added IM LiHMDS in THF (1 mL) dropwise at - 78°C under nitrogen atmosphere, and the resulting mixture was stirred at -30°C for 4 h. Then 20% H2SO4 aq. solution (3 mL) was added to the mixture at -30°C, and the mixture was stirred overnight at room temperature. The reaction mixture was diluted with DCM and washed with H2O and brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse-phase column chromatography to afford the title compound as a yellow solid.

Step 3 : 3 -((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperi din- l-yl)sulfonyl)-3, 3 -difluoro- propanal

To a stirred solution of 3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l- yl)sulfonyl)-3,3-difhioropropan-l-ol (100 mg, 0.25 mmol) in DCM (1 mL) was added Dess- Martin periodate (264 mg, 0.62 mmol) at 0 °C, and the resulting mixture was stirred at room temperature for 1 h. The mixture was diluted with DCM, washed with Na2S20s (aq.), NaHCO3(aq.) and brine. The organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-10%) to afford the title compound as a white solid.

Step 4: 3-(6-(l-(3-((4-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)-3,3- difluoropropyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2- tri fluoroacetate

To a stirred solution of 3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l- yl)sulfonyl)-3,3-difhioropropanal (53 mg, 0.13 mmol) and 3-(l-methyl-6-(piperidin-4-yl)-lH- indazol-3-yl)piperidine-2, 6-dione hydrochloride (48 mg, 0.13 mmol) in DMAc (1 mL) were added EtsN (40 mg, 0.4 mmol) and AcOH (0.3 mL) at rt under nitrogen atmosphere, and the resulting mixture was stirred at 40 °C for 2 h. To the above mixture was added NaBH(OAc)3 (112 mg, 0.53 mmol) in portions, and the resulting mixture was stirred at 40 °C for 2 h. After cooling to rt, the mixture was diluted with ethyl acetate and washed with water and brine, and dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as a yellow solid. MS (ES, m/z): [M+l] ⁺ = 711.2.

Example 103

Synthesis of 3-(6-(l-(3-((4-((5-ethynylpyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)propyl)- piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

Step 1 : tert-Butyl (l-((3-chloropropyl)sulfonyl)piperidin-4-yl)carbamate

To a solution of tert-butyl piperidin-4-ylcarbamate (5.00 g, 25.00 mmol) and TEA (7.59 g, 75.00 mmol) in DCM (100.0 mL) was added 3 -chloropropane- 1 -sulfonyl chloride (4.43 g, 25.00 mmol) slowly at 0 °C, and the resulting mixture was stirred at rt for 2 h. Then the mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine and the organic layer was dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:ethyl acetate = 3 : 1) to afford the title compound as a white solid.

Step 2: tert-Butyl (l-((3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6-yl)piperidin- l-yl)propyl)sulfonyl)piperidin-4-yl)carbamate

A mixture of 3-(l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (2.13 g, 5.87 mmol), tert-butyl (l-((3-chloropropyl)sulfonyl)piperidin-4- yl)carbamate (2.00 g, 5.87 mmol), KI (0.97 g, 0.34 mmol), DIEA (2.27 g, 17.60 mmol) in MeCN (20.0 mL) was stirred at 80 °C for 16 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was purified by flash column to afford the title compound as a white solid.

Step 3 : 3 -(6-(l -(3 -((4-Aminopiperidin- 1 -yl)sulfonyl)propyl)piperidin-4-yl)- 1 -methyl-lH- indazol-3-yl)piperidine-2, 6-dione hydrochloride

A mixture of tert-butyl (l-((3-(4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-indazol-6- yl)piperidin-l-yl)propyl)sulfonyl)piperidin-4-yl)carbamate (1.00 g, 1.59 mmol) in 2 M HC1 in ethyl acetate (20.0 mL) was stirred at rt for 3 h. The mixture was concentrated to afford the title compound as a pale yellow solid.

Step 4: 3-(6-(l-(3-((4-((5-Ethynylpyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)propyl)- piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

To a stirred solution of 3-(6-(l-(3-((4-aminopiperidin-l-yl)sulfonyl)propyl)piperidin-4-yl)- l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (102 mg, 0.18 mmol) in DMSO (2.5 mL) was added 2-chloro-5-ethynylpyrimidine (28 mg, 0.20 mmol), DIEA (122 mg, 0.88 mmol), and CsF (134 mg, 0.88 mmol) at 60 °C, and the mixture was stirred for 16 h under N2. The mixture was diluted with water and extracted with EtOAc. The combined organic layer was washed with brine, dried over anhydrous ISfeSCL After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by /c -HPLC to afford the title compound. MS (ES, m/z): [M+l]⁺ = 633.1. The following compounds were synthesized by proceeding analogously as described in Example 103.

Example 110

Synthesis of 3-(6-(4-(3-((4-((5-(difluoromethoxy)pyrimidin-2-yl)amino)piperidin-l-yl)sulfonyl)- propyl)piperidin-l-yl)-l,5-dimethyl-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2-trifluoroacetate

Step 1 : 4-Vinylpiperidine hydrochloride

To a stirred solution of tert-butyl 4-vinylpiperidine- 1 -carboxylate (2 g, 9.5 mmol) in DCM (20 mL) was added 4 M HCI in dioxane (15 mL) dropwise at 0 °C, and the mixture was stirred at rt for 1 h. The mixture was concentrated under reduced pressure to afford the title compound as a white solid.

Step 2: 3-(2,6-Bis(benzyloxy)pyridin-3-yl)-l,5-dimethyl-6-(4-vinylpiperidin-l-yl)-lH-indazole

To a stirred solution of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-6-bromo-l,5-dimethyl-lH- indazole (1.1 g, 2.14 mmol) and 4-vinylpiperidine hydrochloride (316 mg, 2.14 mmol) in dioxane

(11 mL) were added Pd2(dba)s (392 mg, 0.43 mmol) and XantPhos (247 mg, 0.43 mmol) and CS2CO3 (2.1 g, 6.4 mmol), and the mixture was stirred at 100 °C for 4 h under

N2. After cooling to rt, the resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-30%) to afford the title compound as a yellow solid.

Step 3: tert-Butyl (E)-(l-((3-(l-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l,5-dimethyl-lH-indazol-6- yl)piperidin-4-yl)allyl)sulfonyl)piperidin-4-yl)carbamate

To a stirred solution of 3-(2,6-bis(benzyloxy)pyridin-3-yl)-l,5-dimethyl-6-(4- vinylpiperidin-l-yl)-lH-indazole (1 g, 1.84 mmol) and tert-butyl (l-(allylsulfonyl)piperidin-4- yl)carbamate (0.8 g, 2.75 mmol) in DCM (10 mL) was added Grubbs catalyst 2nd Generation (0.3 g, 0.37 mmol), and the resulting mixture was stirred at 40°C for 48 h under N2. After cooling to rt, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-50%) to afford the title compound as a grey solid.

Step 4: tert-Butyl (l-((3-(l-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH-indazol-6-yl)piperidin-4- yl)propyl)sulfonyl)piperidin-4-yl)carbamate

To a stirred solution of tert-butyl (E)-(l-((3-(l-(3-(2,6-bis(benzyloxy)pyridin-3-yl)-l,5- dimethyl-lH-indazol-6-yl)piperidin-4-yl)allyl)sulfonyl)piperidin-4-yl)carbamate (160 mg, 0.20 mmol) in dioxane (2 mL) was added 20% w/w Pd(OH)2/C (80 mg), and the resulting mixture was stirred at room temperature for 16 h under 1 atm hydrogen atmosphere. The reaction mixture was filtered, and the filter cake was washed with THF. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with ethyl acetate / PE (0-90%) to afford the title compound as a yellow solid. Step 5 : 3 -(6-(4-(3 -((4- Aminopiperidin- 1 -yl)sulfonyl)propyl)piperidin- 1 -yl)- 1 ,5-dimethyl- 1H- indazol-3-yl)piperidine-2, 6-dione hydrochloride

To a stirred solution of tert-butyl (l-((3-(l-(3-(2,6-dioxopiperidin-3-yl)-l,5-dimethyl-lH- indazol-6-yl)piperidin-4-yl)propyl)sulfonyl)piperidin-4-yl)carbamate (71 mg, 0.11 mmol) in DCM (1 mL) was added 4 M HC1 in dioxane (0.5 mL) at rt, and the resulting mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure to afford the title compound as a yellow solid.

Step 6: 3 -(6-(4-(3-((4-((5-(Difluorom ethoxy )pyrimidin-2-yl)amino)piperi din- l-yl)sulfonyl)- propyl)piperidin-l-yl)-l,5-dimethyl-lH-indazol-3-yl)piperidine-2, 6-dione 2,2,2-trifluoroacetate

To a stirred solution of 3-(6-(4-(3-((4-aminopiperidin-l-yl)sulfonyl)propyl)piperidin-l-yl)- l,5-dimethyl-lH-indazol-3-yl)piperidine-2, 6-dione hydrochloride (70 mg, 0.13 mmol) and DIEA (100 mg, 0.77 mmol) in DMSO (1 mL) were added 2-chloro-5-(difluoromethoxy)pyrimidine (35 mg, 0.19 mmol) and CsF (39 mg, 0.26 mmol), and the mixture was stirred at 60 °C for 16 h under N2. After cooling to rt, the mixture was diluted with water and extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford the title compound as a white solid. MS (ES, m/z): [M+l]⁺ = 689.3.

Biological Examples

Biological Example 1

Inhibition of CDK2 and CDK4: Phospho-Rb Measurement in Cells

Phosphorylation of RB protein at S807/811 were measured using HTRF phospho-RB cellular kits (Cat# 64RBS807PEG) from Cisbio. On Day 1, OVCAR3 (CDK2-dependent cell line) and T47D (CDK4-dependent) cells were seeded into 96-well tissue-culture treated plates at 20,000 cells/well in 200 pL and incubated overnight at 37 °C in CO2 atmosphere. On Day 2, the cells were treated with test compounds at concentrations from 0.3 to 3,000 nM using HP D300 digital dispenser. Twenty-four hours after compound treatment, cell culture media was removed by flicking the plate and tapping the plate against clean paper towel. 30 pL IX lysis buffer was supplemented from the kit was added to each well and the plates were then incubated at room temperature on shaker for 30 min. After homogenization by pipetting up and down, 8 pL cell lysate from 96-well cell culture plate was transferred to 384-well small volume white detection plate. 2 pL premixed detection solution was added and the plate was covered with sealer. To prepare the detection solution, d2 conjugated- phospho-RB antibody and Eu-cryptate conjugated phosphor-RB antibody were diluted into detection buffer following manufacturer’s instruction. Detection plates were incubated for 4 h at room temperature and read on ClarioStar (BMG Labtech) in TR-FRET mode (665 nM and 620 nM). The TR-FRET ratio (665 nM/620 nM) was plotted against the compound concentration and normalized to DMSO controls. Half maximal inhibition concentration (IC50) values were calculated with a four-parameter logistic fit using GraphPad Prism (version 9; La Jolla, CA).

In the table below, AA indicates an IC50 of less than 1 nM; A indicates an IC50 of greater than or equal to 1 nM but less than or equal to 100 nM; B indicates an IC50 of greater than 100 nM but less than or equal to 500 nM; C indicates an IC50 of greater than 500 nM but less than or equal to 2.5 pM; D indicates an IC50 of greater than 2.5 pM but less than or equal to 5.0 pM; E indicates an IC50 of greater than 3 pM; NT is not determined.

* Except for synthetic example 9 which is 3-(6-(l-(2-((4-((5-(difluoromethoxy)pyrimidin-2- yl)amino)piperidin-l-yl)sulfonyl)-ethyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2,6- di one

Biological Example 2

High-throughput Measurement of Cellular Endogenous CDK1/2/4/6

Effects of compounds on cellular CDK levels were monitored by a high-throughput HTRF assay.

To determine half maximal degradation concentration (DCso) and maximum degradation level (Dmax) values of compounds, cellular CDK level was measured in 96-well format using HTRF total CDK cellular kit (CDK1, Cat# 64CDK1TPEG; CDK2 Cat# 64CDK2TPEG; CDK4 Cat# 64CDK4TPEG; CDK6, Cat# 64CDK6TPEG) from Cisbio/Revvity.

On Day 1, cells were seeded into 96-well tissue-culture treated plates at 20,000 cells/well in 200 pL and incubated overnight at 37°C in CO2 atmosphere. On Day 2 cells were treated with compounds at concentration ranging from 0.1 to 1,000 nM using Tecan D300edigital dispenser (HP Inc., CA, USA). 6 or 24 hours after compound treatment, cell culture media was removed by flicking the plate and tapping the plate against clean paper towel. Immediately 30 pL IX lysis buffer was supplemented from the kit and added to each well and the plate is incubated at room temperature on shaker for 30 min. After homogenization by pipetting up and down, 8 pL cell lysate from 96-well cell culture plate was transferred to 384-well small volume white detection plate. 2 pL premixed detection solution was added and the plate is covered with sealer. To prepare the detection solution, d2 conjugated-CDK antibody and Eu-cryptate conjugated CDK antibody were diluted into detection buffer following manufacturer’s instruction. Detection plates were incubated overnight at room temperature and read on ClarioStar (BMG Labtech) in TR-FRET mode (665 nM and 620 nM). The TR-FRET ratio (665 nM/620 nM) was normalized to DMSO controls (0% degradation) and lysis buffer controls (100% degradation) to calculate the relative CDK level (%CDK relative to DMSO) which was then plotted against the compound concentration. Half maximal degradation concentration (DCso) and maximal degradation (D_max) values were calculated with a four-parameter logistic fit using GraphPad Prism (version 9; La Jolla, CA).

In the table below, A indicates a DCso of less than or equal to 0.1 nM but less than or equal to 10 nM; B indicates a DCso of greater than 10 nM but less than or equal to 100 nM; C indicates a DCso of greater than 100 nM but less than or equal to 1 pM; and D indicates a DC50 of greater than 1 pM nM but less than or equal to 5 pM. NT means not tested.

Formulation Examples

The following are representative pharmaceutical formulations containing a compound of the present disclosure.

Tablet Formulation

The following ingredients are mixed intimately and pressed into single scored tablets.

Ingredient Quantity per tablet (mg) compound Formula (I) 400 cornstarch 50 croscarmellose sodium 25 lactose 120 magnesium stearate 5

Capsule Formulation

The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule.

Ingredient Quantity per capsule (mg)

Compound Formula (I) 200 lactose spray dried 148 magnesium stearate 2

Injectable Formulation

Compound of Formula (I) in 2% HPMC, 1% Tween 80 in DI water, pH 2.2 with MSA, q.s. to at least 20 mg/mL

Inhalation Composition

To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound of Formula (I) is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery unit, such as a nebulizer, which is suitable for inhalation administration.

Topical Gel Composition

To prepare a pharmaceutical topical gel composition, 100 mg of a compound of Formula (I) is mixed with 1.75 g of hydroxypropyl cellulose, 10 mL of propylene glycol, 10 mL of isopropyl myristate and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into containers, such as tubes, which are suitable for topical administration.

Ophthalmic Solution Composition To prepare a pharmaceutical ophthalmic solution composition, 100 mg of a compound of

Formula (I) is mixed with 0.9 g of NaCl in 100 mL of purified water and filtered using a 0.2 micron filter. The resulting isotonic solution is then incorporated into ophthalmic delivery units, such as eye drop containers, which are suitable for ophthalmic administration. Nasal spray solution

To prepare a pharmaceutical nasal spray solution, 10 g of a compound of Formula (I) is mixed with 30 mL of a 0.05M phosphate buffer solution (pH 4.4). The solution is placed in a nasal administrator designed to deliver 100 pL of spray for each application.

Claims

What is Claimed:

1. The compound of Formula (I): wherein:

R¹ is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyloxy (wherein cycloalkyl, either alone or as part of cycloalkoxy, is substituted with one to three halo), halo, haloalkyl, haloalkoxy, alkoxy, aryloxy, or cyano;

R² and R^2a are independently hydrogen or deuterium;

Hy is cycloalkylene, arylene, heteroarylene, heterocyclylene, bicyclic heterocyclylene, spiro heterocyclylene, bridged heterocyclylene, or fused heterocyclylene, where each of the aforementioned rings is substituted with R^a, R^b, and R^c independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano;

Degron is an E3 ubiquitin ligase ligand selected from:

(a) a group of formula (i):

(b) a group of formula (ii):

Y^a is CH or N;

Z^a is a bond, -CH2-, -NH-, -O-, or -NHC(O)- where NH of -NHC(O)- is attached to Y^a; ring A is a group of formula (a) or (b): where:

R^aa, R^bb, R^cc, and R^dd are independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano;

R⁴ and R⁵ are independently hydrogen or alkyl; or R⁴ and R⁵ together with the carbon to which they are attached form >C=O;

M is -O- or -NR⁶-; and

R⁶ is hydrogen or alkyl; ring B is phenylene, cyclylaminylene, a 5- or 6-membered monocyclic heteroarylene, or a 9- or 10-membered fused bicyclic heteroarylene, wherein in each heteroarylene one to three ring atoms are heteroatomsindependently selected from nitrogen and oxygen, or sulfur and further wherein the phenylene, cyclylaminylene, and each heteroarylene are independently substituted with R^ee and R^ff independently selected from hydrogen, alkyl, cycloalkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano; and

Z is -O-, -NR³- (where R³ is hydrogen or alkyl), cycloalkylene, phenylene, monocyclic heteroarylene, unsaturated heterocyclylene, heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene and where each of the aforementioned ring is substituted with R^d and R^e independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano; alk is C3 to Ce alkenylene substituted with R^f selected from hydrogen, fluoro, and cyano; C3 to Ce alkylene, C3 to Ce heteroalkylene (wherein the C3 to Ce alkylene and C3 to Ce heteroalkylene are substituted with R^g, R^h, and R¹ where R^g is hydrogen, deuterium or halo, R^h is hydrogen, deuterium, cycloalkyl, cycloalkyloxy, bridged cycloalkyl, halo, haloalkoxy, alkoxy, hydroxy, cyano, cyanoalkyl, cyanoalkyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, phenyl, heteroaryl, heterocyclyl, heterocyclyloxy, heterocyclylcarbonyl, or bridged heterocyclyl (where cycloalkyl, either by itself or as part of cycloalkyloxy, bridged cycloalkyl, phenyl, heteroaryl, heterocyclyl, either by itself or as part of heterocyclyloxy or heterocyclylcarbonyl, and bridged heterocyclyl are substituted with R⁷ and R⁸ independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, alkyl carbonyl, alkyloxycarbonyl, amino, alkylamino, dialkylamino, and cyano) and R¹ is hydrogen or halo; or when R^h and R¹ are attached to the same carbon atom or to adjacent carbon atoms of the linear portion of the C3 to Ce alkylene or C3 to Ce heteroalkylene, R^h and R¹ together with the carbon atom(s) to which they are attached can form cycloalkylene or heterocyclylene (where the cycloalkylene and heterocyclylene formed by R^h and R¹ are substituted with R⁹ and R¹⁰ independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, hydroxy, alkyl carbonyl, alkyloxycarbonyl, amino, alkylamino, dialkylamino, and cyano)); or C3 to Ce alkynylene substituted with R¹ and R^k independently selected from hydrogen, halo, haloalkyl, alkoxy, hydroxy, and cyano; or when R> and R^k are attached to the same carbon atom of the alkynylene, they can combine with the carbon atom to which they are attached to form cycloalkylene or heterocyclylene wherein the cycloalkylene and heterocyclylene are substituted with R¹¹ and R¹² independently selected from hydrogen, alkyl, and halo; and the linear portion of C3 to Ce alkenylene, C3 to Ce alkylene, C3 to Ce heteroalkylene, and C3 to Ce alkynylene attaching -SO2- and Z, contains at least three atoms; or or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^g, R^h, and R¹ are hydrogen.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein alk is C3 to Ce alkylene substituted with R^g, R^h, and R¹ where R^h is other than hydrogen and R¹ is hydrogen.

4. The compound claim 2 or 3, or a pharmaceutically acceptable salt thereof, wherein the C3 to Ce alkylene of alk is linear alkylene substituted with R^g, R^h, and R¹.

5. The compound of any one of claims 2 to 4, or a pharmaceutically acceptable salt thereof, wherein the linear alkylene of C3 to Ce alkylene of alk is -CH2CH(R^h)CH2-, -CH2CH₂CH(R^h)-, -CH₂C(R^g)(R^h)CH₂-, or -CH2CH₂C(R^g)(R^h)-.

6. The compound of any one of claims 2 to 5, or a pharmaceutically acceptable salt thereof, wherein the linear C3 to Ce alkylene of alk is -CH2CH(R^h)CH2- where R^g and R¹ are hydrogen.

7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein alk is 1,3 -propylene.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R¹ is halo.

9. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R¹ is haloalkyl or haloalkoxy.

10. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R¹ is chloro, bromo, fluoro, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, difluoromethoxy, trifluoromethoxy, difluoroethoxy, or trifluoroethoxy.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R² and R^2a are hydrogen.

12. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein Hy is: where the N atom of the piperidin-l,4-diyl ring is attached to -SO2-.

13. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein the Degron is an E3 ubiquitin ligase ligand of formula (i):

(i).

14. The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein the Degron is an E3 ubiquitin ligase ligand of formula (ii):

(ii).

15. The compound of any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein Z is

16. The compound of any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein Degron is the E3 ligase ligand selected from:

17. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein

Degron is the E3 ubiquitin ligase ligand i each R^ee is hydrogen, methyl, ethyl, cyclopropyl, or 2,2,2-trifluoroethyl.

18. A pharmaceutical composition comprising a compound of any one of claims 1 to

17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

19. A method of treating cancer mediated by CDK2 and/or CDK4 in a patient which method comprises administering to the patient in need thereof, a therapeutically effective amount a compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 18.